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INTRODuCTION
1.	 	Liver	function	and	liver	disease
The liver is the largest internal organ in the body, weighing about 1.5 kg, and is situated 
under the rib cage on the right side of the abdomen. It is divided into right and left lobes 
by the middle hepatic vein (1). In the liver, nutrients that are absorbed in the digestive 
tract are processed and stored for use in other parts of the body. It is thus an interface 
between the digestive system and the blood. Most of its blood (about 70%) comes from 
the intestine via the portal vein; the hepatic artery supplies the remaining percentage 
(Figure 1). The position of the liver in the circulatory system is optimal for two of its 
main functions: 1) gathering, processing, and storage of metabolites and 2) neutralization 
and elimination of toxic substances. Elimination occurs in the bile, an exocrine secretion 
product of the liver that is important for lipid digestion in the gut. The third important 
function of the liver is production of carrier proteins, such as albumin; production of 
factors involved in blood clotting, synthesis of factors important in systemic immunity, 
and production of hormones (2).
Since the liver is essential for maintaining body homeostasis, disease of the liver can 
be life threatening. Over time, damage to the liver due to disease may result in scarring 
(cirrhosis) which can lead to liver failure, a life-threatening condition. Possible causes 
of liver failure are: inherited/genetic disorders (such as hemochromatosis or Wilson’s 
disease); immune system abnormalities (such as autoimmune hepatitis, primary biliary 
cirrhosis, primary sclerosing cholangitis); infections (such as viral infections with hepati-
tis A, B, or C); cancer (such as hepatocellular carcinoma or cholangiocarcinoma); chronic 
Figure	1.	Anatomy of a healthy liver
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alcohol abuse, or obesity leading to non-alcoholic fatty liver disease; and intoxication, for 
example with toxic drugs (3).
2.	 	Complications	in	patients	with	end-stage	liver	disease
As described above, liver disease can result in cirrhosis. Cirrhosis is an advanced stage 
of liver fibrosis that is accompanied by distortion of the hepatic vasculature. It leads to 
shunting of the portal and arterial blood supply directly into the hepatic outflow (central 
veins), which compromises exchange of nutrients and oxygen between hepatic sinusoids 
and the adjacent liver parenchyma (hepatocytes) (4). When cirrhosis progresses and 
becomes irreversible, it results in a state of end-stage liver disease (ESLD), with liver 
transplantation (LTx) as the only life-saving treatment option (described in next para-
graph). Because of the shortage of donor organs, ESLD patients are waitlisted for liver 
transplantation, and during their time on the waiting list they may suffer from severe 
complications of their disease and even die before they can become transplanted. 
Important complications of cirrhosis are bleeding of esophageal varices, ascites, en-
cephalopathy, renal failure, spontaneous bacterial peritonitis (SBP) and other severe 
infections (4). Severe bacterial infections (SBIs) represent the second leading cause of 
death in patients with ESLD waitlisted for LTx (5, 6), with mortality approaching 10% in 
Europe (7) and 23% in the US (8). Liver dysfunction leads to several abnormalities of the 
defense mechanisms against pathogens, as both humoral and cell-mediated immunity 
are suppressed, and bacterial translocation from the intestine increases susceptibility to 
infection, particularly SBP. Due to infection, a systemic inflammatory response syndrome 
may occur resulting in sepsis, renal failure, encephalopathy, and death (6).
3.	 	Liver	transplantation
Because ESLD may lead to liver failure and life-threatening complications, the diseased 
liver in patients with ESLD needs to be removed and replaced by a healthy liver coming 
from another person (most commonly a deceased organ donor). This treatment is called 
liver transplantation (LTx). Thomas Starzl performed the first successful human LTx in 
Denver, USA in 1967 (9). Before that, human LTx was an experimental procedure with 
short patient survival, due to surgical complications and failure to obtain good immedi-
ate liver function or the inability to subsequently maintain such function (9). Since the 
outcome of LTx was not mainly driven by surgical complications or primary non-function 
anymore, the two most important complications that needed attention became: 1) rejec-
tion of the donor liver, also called allograft rejection (“allo-“ means non-self or foreign; 
“graft” is another word for transplant); and 2) infections early after LTx.
11
Introduction and outline
1
4.	 	Innate	immunity	and	the	occurrence	of	infections	in	patients	before	and	
after liver transplantation
Cirrhotic patients are prone to develop SBIs because of compromised antimicrobial de-
fense caused by several complications of cirrhosis. The liver produces factors important 
in systemic immunity, which is impaired in patients with cirrhosis, leading to a higher 
susceptibility to infections. Other reasons for the susceptibility to SBIs are portal hyper-
tension, bacterial translocation from the gut (5, 6, 10, 11), in combination with dysfunction 
of immune cells (12, 13). Also after LTx, infections are an important complication, being 
the leading cause of death in the first year after LTx (14, 15). One of the major reasons 
for this is that patients use immunosuppressive drugs after LTx, which leads to a higher 
susceptibility to infections. To identify patients before and after LTx who are at high risk 
for development of infections, insight into the mechanisms of the increased susceptibil-
ity for infections is needed. In this paragraph, an introduction is given on the role of 
the immune system, especially of innate immunity receptors, in the response against 
infections. In addition, genetic variants in innate immunity receptors will be introduced.
Innate and adaptive immune system
The function of the immune system is to protect the body against invading microorgan-
isms. This system is divided into innate immunity and adaptive immunity. The innate 
immune system is a relatively non-specific system that in general detects pathogens 
rapidly (within a few minutes) by recognition of molecular structures, such as certain 
carbohydrate patterns, that are present on a broad variety of microorganisms, but not 
on human cells. These structures are called pathogen-associated molecular patterns 
(PAMPs), and they are detected by pattern recognition receptors (PRRs). One type of 
PRRs are signaling receptors, which are expressed by cells of the innate immune system 
and, upon ligation to PAMPs, activate them to attack the invading pathogen. The Toll-
like receptor (TLR)-family is the best-characterized class of signaling PRRs in mammalian 
species. Other types of PRRs are: endocytic receptors (such as DC-SIGN and mannose 
receptor), and secreted opsonizing receptors (such as Mannose Binding Lectin (MBL) and 
complement factors). Signaling and secreted PRRs activate the cells of the innate immune 
system, such as macrophages, dendritic cells (DCs), granulocytes, and Natural Killer (NK) 
cells, to kill the invading microorganisms or the host cells infected by pathogens (16).
The adaptive immune system is a specific system that responds very specific to 
antigens and generates long-lasting memory of the specific antigen, thereby providing 
antigen-specific protection. Though, this response takes longer (3-5 days) than the re-
sponse of the innate immune system. However, by induction of memory cells, the adap-
tive immune system can generate more rapid and effective responses to subsequent 
exposures to the antigen. The adaptive immune system is mediated by T cells and B 
cells. Adaptive immune responses are initiated and regulated by innate immune cells. 
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Antigen-presenting cells (APCs), such as DCs and macrophages, activate antigen-specific 
T-cells; and neutrophils and NK-cells regulate T-cell and B-cell migration. Thus, whereas 
the innate immune response generates fast but relatively non-specific responses, it 
activates the adaptive immune system to provide more specific and persistent immune 
responses (16, 17).
Toll-like receptors and other innate immunity receptors
Humans have 10 TLRs and these are expressed on macrophages, neutrophils, NK cells 
and DCs and detect multiple PAMPs. An overview of TLRs is provided in Table 1. After 
detecting PAMPs, most TLRs use myeloid differentiation primary response protein 
(MyD88) as the signal adapter, while TLR3 uses Toll/interleukin 1 receptor (TIR)-domain-
containing adapter-inducing IFN-β (TRIF) (18-20). This initiates a signaling, leading 
to translocation of the transcription factor NF-κB. In APCs this signaling initiates a 
maturation program consisting of increased expression of co-stimulatory molecules, 
and release of pro-inflammatory cytokines and chemokines, which together improve 
their capacity to activate T cells. Thus, signaling PRRs not only activate innate immune 
cell defense mechanisms such as phagocytosis or direct cytotoxic killing, but also shape 
adaptive immune responses. Especially DCs play an important role in bridging the innate 
and adaptive immune system. DCs take up antigens, become activated and migrate to 
local lymphoid tissues where they present antigens to T cells and activate them. TLRs 
expressed by DCs play an important role in recognition of pathogens, and thereby 
activation of T cells (17, 21). Chemokines secreted by innate immune cells activated via 
TLRs bind to the luminal surface of the vascular endothelium and trigger immigration of 
Table	1.	Toll-like receptors (TLRs) and the pathogen-associated molecular patterns (PAMPs) that each receptor 
recognizes
TLR PAMP
TLR1 Microbial lipopeptides present in many bacteria, fungi, parasites and viruses
TLR2 Lipoteichoic acid, peptidoglycan, and lipoproteins of Gram-positive bacteria, 
lipoarabinomannan of Mycobacteria, and zymosan of Candida, among others
TLR3 Double-stranded RNA of viral origin
TLR4 Gram-negative bacterial lipopolysaccharide (LPS), fungal mannans, and 
certain viral glycoproteins
TLR5 Flagellin of flagellated bacteria
TLR6 Bacterial lipoprotein
TLR7 Single-stranded RNA
TLR8 Single-stranded RNA
TLR9 Bacterial and viral nucleic acids containing CpG motifs
TLR10 Unknown
Based on Sanclemente et al. World Journal of Gastroenterology 2014
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other immune cells including B cells and T cells. To provide maximum surveillance for 
infectious agents, in addition to the inflammation-induced cell recruitment, most tissues 
of the body are interlaced with resident innate leukocytes such as DCs, macrophages 
and mast cells. Pathogen recognition through TLRs on these innate leukocytes regulates 
the recruitment of other leukocytes to the site of infection by activating tissue stromal 
cells, tissue-resident innate cells and circulating leukocytes. For some TLRs, accessory 
molecules are required to initiate signal transduction upon ligand binding. For example, 
TLR4 is activated by the binding of bacterial Lipopolysaccharide (LPS), but it needs three 
accessory proteins for signaling to be initiated. LPS is bound by the soluble LPS-binding 
protein (LBP) and transported to a receptor complex on the cellular membrane, con-
sisting of CD14, TLR4 and MD2. Upon association, this complex triggers TLR4 to signal, 
thereby activating NF-κB translocation to the nucleus, which in turn activates genes 
involved in defense against infection (Figure 2).
Secreted PRRs function as opsonins by binding to microbial cell walls and tagging them 
for recognition by the complement system and phagocytes. One of the best character-
ized secreted PRRs is MBL. MBL not only binds to microbial carbohydrates (mannose) 
to initiate the lectin pathway of complement activation, but also binds phospholipids, 
nucleic acids and non-glycosylated proteins. These properties may be relevant to the 
clearance of apoptotic cells and avoidance of autoimmunity (22).
Endocytic PRRs promote the attachment and destruction of microorganisms by 
phagocytes, without relaying an intracellular signal. These PRRs recognize carbohydrates 
 
Figure	 2.	 Toll-like receptor 4 (TLR4) pathway. Bacterial lipopolysaccharide (LPS) is bound by LPS binding 
protein (LBP) and transferred to a receptor complex consisting of CD14, TLR4, and the adapter molecule 
MD2. The Toll/interleukin 1 receptor (TIR) domain of TLR4 interacts with myeloid differentiation primary re-
sponse protein (MyD88), initiating a signal transduction cascade leading to the release of pro-inflammatory 
cytokines—e.g., tumour necrosis factor (TNF)-α via the transcription factor nuclear factor (NF)κB. A second, 
MyD88-independent, pathway involving TIR domain-containing adapter inducing interferon beta (TRIF) and 
TRIF-related adaptor molecule (TRAM) leads to the induction of type 1 interferons (IFN) via interferon regula-
tory factor (IRF) 3. Adapted from the original figure of Schroder and Schumann, The Lancet infectious diseases, 
2005
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and include mannose receptors present on macrophages, glucan receptors present on 
all phagocytes and scavenger receptors that recognize charged ligands. They are found 
on all phagocytes and mediate removal of apoptotic cells (16).
Genetic polymorphisms in innate immunity receptors
Genetic polymorphisms - for the most part, single nucleotide polymorphisms (SNPs) - are 
common variants within a population that are found at a frequency of over 1%. SNPs in 
coding regions may alter the amino acid sequence (non-synonymous) or alter nucleotides 
without affecting the encoded amino acid (synonymous), or can induce stop codons and 
thereby result in synthesis of truncated proteins. SNPs in non-coding regions may affect 
protein expression, e.g. SNPs in promotor regions may affect promoter functions. Muta-
tions do not occur randomly within the genome, but rather depend on the particular ge-
nomic region, as well as on selective pressure. Several SNPs have been described within 
the genes involved in immune recognition, including genes encoding pattern recognition 
molecules (23). As described above, infections represent an important complication in 
waitlisted patients and patients after LTx. SNPs in innate immunity receptors have been 
identified as risk factors for infections in critically ill patients (20, 23-26). In addition, SNPs 
in the TLR4 pathway have been described to affect levels of pro-inflammatory cytokines 
such as IL-1 and TNF-alpha, and increase the risk of infections in non-cirrhotic patients 
(27-30). However, the role of these SNPs in the occurrence of infections in patients be-
fore and after liver transplantation has not been established yet. The adaptive immune 
system is suppressed by immunosuppressive drugs used in patients after LTx. Genetic 
variants in the innate immune system may therefore lead to a higher risk of infections in 
these patients. Aim	1 of this thesis is therefore to assess whether genetic polymorphisms 
in innate immunity receptor pathways are associated with infections in patients before 
and after LTx.
5.	 	Liver	allograft	rejection	and	T-cell	alloresponses
Besides the occurrence of infections, acute rejection of the liver allograft is another 
important complication after LTx. Rejection is caused by an immune response of re-
cipient immune cells, primarily T cells, to alloantigens in the graft. These alloantigens 
are proteins that vary from individual to individual and are perceived as foreign by the 
recipient, also called polymorphic proteins (16). Between 0.1% and 10% of an individual’s 
T-cell repertoire react with alloantigens (31-35) while only <1/100 000 T cells react to 
nominal peptide antigens (36). The enormous strength of alloreactive T-cell responses 
has led to many theories regarding how and why T cells respond to foreign tissues (37, 
38), but it was the discovery of the T cell receptor (TCR) (39) and the description of the 
crystal structure of major histocompatibility complex (MHC) molecules (40) in the 1980s 
that provided the important structural clues to deciphering allorecognition on a mo-
15
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lecular level. In contrast to a T-cell response to a pathogen in which pathogen-derived 
peptides are presented on self-MHC molecules to T cells, an allograft expresses its own 
set of intact allogeneic MHC molecules, which are recognized by recipient T cells on the 
surface of donor APCs. This is called the ‘direct pathway’ of allorecognition, and it is 
caused by cross-reactivity of TCRs that recognize pathogenic peptides presented by self-
MHC molecules to allogeneic MHC molecules (41, 42). The large numbers of circulating 
T cells that cross-react to alloantigens mediate the strong acute rejection responses to 
allografts in the absence of adequate immunosuppressive therapy. Recipient T cells can 
also indirectly recognize peptides derived from polymorphic donor proteins presented 
on recipient MHC molecules. This is called the ‘indirect pathway’ of allorecognition. In 
the indirect pathway, recipient APCs that traffic through the allograft phagocytose al-
logeneic proteins shed by donor cells (the most important allogeneic peptides are those 
derived from allogeneic MHC molecules) and present them on recipient MHC molecules 
to recipient T cells (42). In Figure 3 the direct and indirect pathway of allorecognition are 
shown schematically.
Factors that regulate T-cell alloresponses
T-cells that mediate allograft rejection (through “T-cell alloresponses”) require 3 signals 
to become activated (16). This is shown schematically in Figure 4. The first signal is trig-
gering of the TCR by alloantigen, either directly or indirectly, as described above. The 
Figure	3.	Two non-mutually exclusive pathways of allorecognition: the direct and indirect pathway. (A) In the 
direct pathway, recipient T cells recognize intact allogeneic MHC molecules on the surface of donor antigen 
presenting cells (APCs). The direct pathway is responsible for the large proportion of T cells that have reactiv-
ity against alloantigens due to cross-reactivity of the T-cell receptors (TCR) recognizing pathogenic peptides 
presented in self MHC to intact foreign MHC molecules. (B) In the indirect pathway, recipient APCs trafficking 
through the allograft phagocytose allogeneic polymorphic proteins shed by donor cells (the most important 
peptides are those derived from allogeneic MHC molecules) and present them on recipient MHC molecules to 
recipient T cells. Adapted from the original figure of Sanchez-Fueyo, Gastroenterology 2011.
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second signal is the balance between co-stimulatory and co-inhibitory receptors on T 
cells that regulates T-cell function. The discovery of CD28 as a prototype co-stimulatory 
receptor provided evidence in the 1970s and ’80s for the two-signal model of T-cell 
activation, according to which both TCR and co-stimulatory signaling are required for 
full T-cell activation (43-45). Since then, T cell co-signaling receptors have been broadly 
defined as cell-surface molecules that can either activate (co-stimulatory receptors) or 
inhibit (co-inhibitory receptors) T-cell responses (46). Other examples of co-stimulatory 
receptors that can provide signal 2 for T-cell activation are Inducible T-cell co-stimulator 
(ICOS), which is also a member of the CD28-superfamily, and members of the TNF recep-
tor family (16). The role of co-inhibitory receptors in T-cell responses is described below 
in more detail. The third signal of T-cell activation is the production of pro-inflammatory 
cytokines (Interleukin-12 (IL-12), IL-23 and Tumor Necrosis Factor-alpha (TNF-α)) and anti-
inflammatory cytokines (IL-10 and Transforming Growth Factor-beta (TGF-β)) by APCs. 
These cytokines determine differentiation of naïve T cells to pro-inflammatory Th1 or 
Th17 cells or to anti-inflammatory regulatory T cells, thereby critically contributing to 
transplant rejection (47). After activation of T cells, antigen-specific T cells proliferate 
and differentiate into effector T cells that attack the allogeneic tissue. The majority of 
Signal 1 Signal 2 Signal 3
Figure	4.	Within	 the immune synapse formed between antigen presenting cells (APCs) and T cells, three 
signals are required for antigen-specific T-cell activation. Signal 1 comprises the presentation of antigen (Ag) 
peptide, in the context of MHC class II molecules, which is recognized by the antigen-specific T-cell receptor 
(TCR). Signal 2 involves the stabilization of the synapse through adhesion molecules and the generation of sig-
nals via costimulatory molecules present on the surface of APCs and T cells. CD80/CD86 on APCs interact with 
their receptor, CD28, on T cells to generate activating signals, while interaction between Programmed Death 
1 (PD1) and its ligand PD-L1 generates inhibitory signals. Signal 3 is produced by the secretion of cytokines by 
APCs, which signal via cytokine receptors on T cells in order to polarize them towards an effector phenotype. 
Adapted from the original figure of Gutcher et al. J Clin Invest. 2007
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effector T cells undergoes apoptosis, but a minority survives and becomes long-lived 
memory T cells. Memory T cells have been called “a hurdle to immunologic tolerance” in 
the field of transplantation (48).
Co-inhibitory receptors
As described above, the balance between co-stimulatory and co-inhibitory receptors 
regulate the outcome of T-cell activation. After solid organ transplantation, blocking of 
co-stimulatory receptors, for example blocking CD28 with Belatacept, has been shown 
to inhibit allogeneic T-cell responses and prevent acute and chronic rejection (49-53). 
Also co-inhibitory receptors expressed on T cells affect T-cell activation and they have 
been described to inhibit T-cell responses in patients with chronic viral infections (54). 
Co-inhibitory receptors that have been described to be important in inhibiting T-cell 
responses are: Programmed Death 1 (PD1), Lymphocyte-Activation Gene 3 (LAG3), T cell 
immunoglobulin mucin 3 (TIM3), CD160 and CD244 (54, 55). PD1 is a member of the 
Immunoglobulin superfamily (IgSF) and has two ligands: PD-L1 and PD-L2 (56, 57). PD-L1 
is expressed on both hematopoietic cells (T cells, B cells, dendritic cells (DC), macro-
phages, regulatory T cells (Treg)) and nonhematopoietic cells (parenchymal cells of many 
organs including liver; and endothelial cells). PD-L2 expression is restricted to DC and 
macrophages. Binding of PD1 to its ligand(s) negatively regulates T-cell responses (57, 
58). LAG3 is a protein closely related to CD4, and mediates negative regulation through 
interactions with its ligand MHC class II, to which it binds with higher affinity than CD4 
(59, 60). TIM3 is expressed on virus-specific T cells of patients with chronic viral infec-
tions and inhibits CD8+ T-cell responses in these patients by interaction of TIM3 with 
its ligand galectin 9 (61, 62). CD160 is a glycosylphosphatidylinositol-anchored receptor 
that inhibits T-cell responses upon binding with its ligand herpes virus entry mediator 
(HVEM) that is expressed on both hematopoietic (T cells, B cells, DC, Tregs, monocytes, 
neutrophils and natural killer (NK) cells) and non-hematopoietic cells (parenchymal cells) 
(63). CD244, also called 2B4, is a transmembrane receptor of the IgSF primarily expressed 
by NK cells and antigen-experienced CD8+ T cells that can mediate both activating and 
inhibitory signals upon binding with its ligand CD48. High levels of CD244 expression 
are associated with inhibitory receptor function (64-66). Various experimental studies in 
organ transplanted mice have shown enhanced rejection and/or decreased graft survival 
after blockade of co-inhibitory receptors. This implies that co-inhibitory receptors are 
involved in suppressing allograft rejection in mice (67-70). However, the role of co-
inhibitory receptor-ligand interactions in human solid organ transplantation has not yet 
been widely studied (69). Aim	2	of this thesis is therefore to assess whether co-inhibitory 
receptors are induced after LTx and whether they inhibit allogeneic T-cell responses in 
humans. In Table 2 an overview is provided of co-inhibitory receptors and their ligands 
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that have been described to inhibit T-cell responses during chronic viral infections, and 
that we studied in this thesis.
Cytomegalovirus infection (CMV)
Besides expression of co-inhibitory receptors, virus infections after LTx may also affect 
the outcome of T-cell alloresponses, and thereby influence the risk of rejection after LTx. 
Cytomegalovirus (CMV) is a prevalent β-herpesvirus that resides in the human body as a 
latent virus. After LTx and other solid organ transplantations, CMV is the most common 
viral infection (71), especially in patients who did not experience a CMV infection before 
LTx and were transplanted with a CMV-seropositive liver transplant donor. This is called 
“CMV-mismatch” between donor and recipient. T-cell responses to viruses, including 
CMV, have been proposed as one of the main barriers to achieve transplant tolerance 
(72), as shown in experimental animal models (73-75). As reviewed by D’Orsogna et al (76), 
large amounts of virus-specific T cells cross-react against allogeneic HLA, which causes 
T-cell responses against the donor organ. However, associations between CMV infection 
and graft rejection in humans vary between different types of organ transplants and 
show conflicting results (77). Importantly, it is unknown how CMV infection affects T-cell 
alloresponses after LTx. Aim	3	of this thesis investigate this possible relation.
Table	2.	Co-inhibitory receptors and their ligands
Receptor Ligand(s) Remarks
Programmed Death 1 (PD1) PD-L1 and PD-L2 PD-L1 is expressed on both hematopoietic 
cells (T cells, B cells, dendritic cells (DCs), 
macrophages, regulatory T cells (Treg)) and 
nonhematopoietic cells (parenchymal cells of 
many organs including liver; and endothelial 
cells). PD-L2 expression is restricted to DCs and 
macrophages
Lymphocyte-Activation Gene 3 
(LAG3)
MHC class II LAG3 binds to MHC class II with higher affinity 
than CD4
T cell immunoglobulin mucin 3 
(TIM3)
Galectin 9
CD160 Herpes virus entry 
mediator (HVEM)
HVEM is expressed on both hematopoietic (T 
cells, B cells, DC, Tregs, monocytes, neutrophils 
and natural killer (NK) cells) and non-
hematopoietic cells (parenchymal cells)
CD244, also called 2B4 CD48 CD244 can mediate both activating and 
inhibitory signals upon binding with its ligand 
CD48. High levels of CD244 expression are 
associated with inhibitory receptor function
Based on Wherry EJ. T cell exhaustion. Nat Immunol. 2011
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6.	 	Immunosuppression	after	liver	transplantation
To prevent allograft rejection, the majority of liver transplant recipients needs to use 
immunosuppressive drugs life-long. Strikingly however, while almost all patients after 
other solid organ transplantations need immunosuppressive drugs, in a small percentage 
of patients after LTx immunosuppressive drugs can be weaned without losing their graft 
due to rejection. Moreover, HLA –matching between donor and recipient is not neces-
sary and chronic rejection is less frequent after liver transplantation than after other 
solid organ transplantations, such as kidney and heart transplantation (78). The liver is 
therefore considered an immune privileged organ (79-81). This so called tolerogenic en-
vironment of the liver means that intra-hepatic immune responses are strictly regulated. 
From a physiological perspective this is beneficial in order to avoid unnecessary inflam-
mation in response to the great amount of bacterial and food antigens derived from the 
intestines that enter the liver. However, as a consequence, the tolerogenic environment 
of the liver also negatively impacts immunological responses to hepatotrophic viruses. 
Likely, the tolerogenic environment of the liver may also dampen the severity of the 
alloresponse to the liver graft after transplantation.
Several studies in almost 900 patients have shown that approximately 20% of liver 
transplant recipients can be safely weaned from immunosuppressive drugs and maintain 
good liver graft function without rejection (82-92). This phenomenon is called ‘opera-
tional tolerance’. The mechanisms underlying this phenomenon are however not well 
understood, and it is therefore not possible yet to identify patients in which immunosup-
pressive drugs can safely be withdrawn (93). Until reliable diagnostic tests are available 
to predict operational tolerance in liver transplant patients, most patients need to use 
immunosuppressive drugs life-long.
The currently most used immunosuppressive drug regimen after LTx consists of the 
Calcineurin Inhibitor (CNI) tacrolimus, combined with prednisolone, and in some centers 
an induction therapy with IL-2 antagonist basiliximab or dacluzimab. A detailed historic 
and mechanistic overview of the use of immunosuppressive drugs after LTx is provided 
in Chapter	7 of this thesis.
7.	 	Complications	of	the	use	of	immunosuppressive	drugs	after	liver	
transplantation
The use of CNIs may have serious side effects, such as infections, nephrotoxicity, 
diabetes mellitus, hypertension and cancer. Firstly, nephrotoxicity is one of the most 
serious complications of the use of CNIs (94, 95). Apart from intestinal transplants, liver 
transplant recipients have the highest five-year incidence of chronic renal failure (CRF) 
of any non-renal solid organ transplant recipient; additionally, the risk of death is at least 
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fourfold higher in patients who develop CRF (96). Secondly, CNIs are related with new-
onset diabetes mellitus after transplantation, which may lead to severe co-morbidities 
such as cardiovascular diseases (97, 98). Thirdly, the long-term use of immunosuppres-
sive agents has been associated with an increased risk of developing de novo cancer. A 
recent study in 385 patients transplanted at the Erasmus MC, Rotterdam demonstrated 
a 2.2-fold higher incidence of de novo cancer in LTx patients than in the general popula-
tion. The cumulative incidences at 1, 5, 10 and 15 years after liver transplantation were 
2.9%, 10.5%, 19.4% and 33.6% respectively (99). Finally, infections represent an important 
complication of the use of immunosuppressive drugs after LTx, which has been discussed 
in paragraph 4 of this Chapter. Besides recurrence of liver disease, the most common 
reasons of mortality long after liver transplantation are infection, malignancy, renal 
failure and cardiovascular events (100).
Despite its potential adverse effects, treatment with tacrolimus still remains the corner-
stone of preventing rejection after LTx. The occurrence of these adverse effects has led 
to a shift in focus from acute cellular rejection and short-term post-transplant survival 
to long-term management of complications. However, treatment of these complications 
is often challenging, because in many patients these complications are irreversible and 
may lead to death (101). It is therefore needed to optimize the use of immunosuppression 
after LTx. Aim	4 of this thesis is to describe strategies to optimize currently used immuno-
suppressive drugs and experimental cell-based immunosuppressive treatment options.
8.	 	Alternative	options	for	immunosuppressive	treatment	after	liver	
transplantation
Because the currently used immunosuppressive drugs have serious side effects, alterna-
tive immunosuppressive treatment strategies are being developed. These include use of 
intravenous immunoglobulins (102-104) and cell-based immunosuppressive therapies, 
such as the use of plasmacytoid dendritic cells (105) or Mesenchymal Stem/Stromal Cells 
(MSCs) (106). The development of these alternative treatment strategies is however still 
in an experimental phase. Chapter	8 of this thesis focuses on the immunosuppressive 
properties of MSCs that are present in liver grafts. MSCs are rare, non-hematopoietic 
cells that reside in the bone marrow (BM) cavity. They are characterized by their ability to 
produce colony forming unit-fibroblasts (CFU-F); to support the hematopoietic microen-
vironment; to promote bone formation and to adhere to plastic in vitro (107-109). Besides 
their presence in the BM, MSC-like cells are present throughout the body at perivascular 
locations (110, 111) and are critically involved in maintaining tissue homeostasis via anti-
apoptotic and tissue-supporting properties (112-114). Importantly, MSCs can suppress 
T-cell responses (115-117). Bone marrow MSCs (BM-MSCs) can suppress recipient allore-
active T-cell responses and thereby prevent graft rejection (106). Hence, administration 
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of MSCs seems to be suitable for clinical application in human organ transplantation due 
to the anti-inflammatory nature of MSCs. Interestingly, human liver grafts also contain 
MSCs (L-MSCs) (118, 119) and these cells become mobilized from the liver graft during the 
transplantation procedure. In Chapter	8	we compare the immunosuppressive proper-
ties of BM-MSCs and L-MSCs to assess whether L-MSC in the future may be clinically 
applicable as an alternative immunosuppressive therapy after LTx.
AIM AND OuTLINE OF ThE ThESIS
Most liver transplant patients develop one or more complications such as infections, 
de novo malignancies or renal failure related to the immunosuppressive therapy. These 
complications strongly affect survival and quality of life in these patients. It is therefore 
urgently needed to develop strategies to predict the risk of these complications and op-
timize immunosuppression after LTx in order to prevent complications or to treat them in 
an early stage. Moreover, patients with end-stage liver disease awaiting a liver transplant 
frequently develop severe infections, sometimes causing death before a donor liver is 
offered.
The aim of this thesis is to identify risk factors for the occurrence of complications in 
liver transplant patients, both before and after LTx, and develop strategies to optimize 
immunosuppression after LTx. The thesis is divided into four parts (I-IV), from which the 
first two parts focus on genetic and viral risk factors for complications before and after 
LTx; the third part describes different strategies to optimize immunosuppression after 
LTx, and in the fourth part the findings of this thesis will be summarized and discussed.
Part I (Chapters	2-4) focuses on genetic factors, specifically on genetic polymorphisms 
in innate immunity receptors that affect acute rejection after LTx and susceptibility to 
infections in patients before and after LTx. In Chapter	2 we examined the association 
between polymorphisms in TLR4 signaling pathway genes and severe bacterial infections 
in two independent cohorts of patients enlisted for LTx. In Chapter	3 we investigated the 
association between genetic variants in MBL genes and the risk of infections in patients 
after LTx. In Chapter	4 we determined the association between genetic variants in a 
broad range of innate immunity receptors and the risk of bacterial and fungal infections 
and acute rejection in two cohorts of patients post-LTx.
Part II (Chapter	5-6) describes the influence of viral factors, especially CMV, on T-cell 
alloresponses after LTx. In Chapter	5	we compared distributions of circulating T-cell sub-
sets and determined T-cell alloresponses in CMV-infected and non-infected LTx patients, 
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and in addition, the association between CMV and acute rejection after LTx. In Chapter 
6	we studied whether co-inhibitory receptors expressed on CD8+ T cells affect allogeneic 
responses of these T cells. We also determined which factors induced the expression of 
co-inhibitory receptors that affect CD8+ T-cell alloresponses, and found an important 
contribution of CMV infection.
Part III of the thesis (Chapter	7-8) describes strategies to optimize immunosuppression 
in patients after LTx, in order to optimize outcome in these patients. In Chapter	7, an 
overview is given of immunosuppressive drugs that are administered after LTx to prevent 
acute rejection. In this review, we describe clinical strategies to optimize immunosup-
pressive drug usage in patients after LTx, in order to avoid adverse effects of these drugs. 
Chapter	 8 highlights the immunosuppressive properties of liver graft-derived MSCs. 
We compare BM-MSCs and L-MSCs with regard to their suppressive capacity on T-cell 
alloresponses and describe how these findings in the future may lead to development of 
cell-based immunosuppressive therapies, as alternative for the currently used immuno-
suppressive drugs that involve serious side effects.
Finally, in part IV (Chapter	9-10), we summarize the findings of our studies on risk factors 
that are associated with the occurrence of complications in liver transplant patients and 
strategies to optimize the use of immunosuppression after LTx. We will address which 
questions have been answered, put them into perspective, and formulate new research 
questions to be pursued.
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ABSTRACT
Augmented susceptibility to infections increases mortality in patients with end-stage 
liver disease (ESLD). We sought to determine the contribution of selected genetic vari-
ants involved in inflammatory signalling downstream of the Toll-like receptor 4 (TLR4) 
to severe bacterial infections (SBIs) in patients with ESLD. We retrospectively assessed 
incidence of SBIs in 336 adult ESLD patients enlisted for orthotopic liver transplantation 
(OLT) and genotyped them for TLR4 c.+1196C/T, CD14 c.159C/T, TNFA c.238G/A, TNFA 
c.863C/A, IL1B c.31C/T and IL1RN variable number of tandem repeats allelic variants. 
Principal findings were validated in an independent cohort of 332 ESLD patients. Thirty-
four percent of patients from the identification cohort and 40% of patients from the 
validation cohort presented with SBI while enlisted for OLT. The presence of the variant 
allele TNFA c.238A (rs361525) was associated with lower serum levels of TNF-α, and with 
significantly decreased risk of SBI in both cohorts. Multivariate analysis showed that the 
relative protection from SBI associated with this allele almost completely negated the 
increased susceptibility to SBI owed to advanced ESLD. Although not predictive of overall 
mortality, the presence of the TNFA c.238A allele was associated with a complete pre-
vention of SBI-related pre-transplant deaths. Our results suggest that genetic variability 
in inflammatory signalling is associated with the development of SBI in patients with 
ESLD. Specifically, we identified the importance of the TNFA c.238A allele as a strong 
predictor of protection from SBI, and as a genetic marker associated with significantly 
improved pre-transplant survival in patients with SBI.
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INTRODuCTION
Severe bacterial infections (SBIs) represent the second leading cause of death in patients 
with end-stage liver disease (ESLD) waitlisted for orthotopic liver transplantation (OLT) 
(1,2), with mortality approaching 10% in European registries (3) and 23% in the US (4). 
The high mortality attributed to SBIs in this patient category is driven by the impaired 
antimicrobial response associated with ESLD (5,6), and by progression of liver failure 
that is accelerated by severe infection (1,2). Cirrhotic patients are prone to develop SBIs 
because of compromised antimicrobial defence caused by liver synthetic failure, portal 
hypertension and bacterial translocation from the gut (1,2,5,7,8), in conjunction with al-
tered function of immune cells, including impaired opsonizing and neutrophil phagocytic 
capacity (9,10). Therefore, early identification of patients with ESLD at risk for SBIs is of 
paramount importance, but indicators predicting the development of SBIs are missing. 
Toll-like receptors (TLRs) play a key role in innate immune responses by recognition of 
a broad range of microbial components and triggering signals critical for antimicrobial 
defences (11–13). Although substantially conserved across species, TLRs show a genetic 
variability that modulates their downstream signalling, potentially determining indi-
vidual susceptibility to infections (14). It has been shown that the variant p.399Ile of TLR4 
corresponding to the nucleotide substitution TLR4 c.+1196C/T (rs4986791) changes the 
ligand-binding site of the receptor (15) and, in one study with limited sample size, pre-
disposed cirrhotic patients to infections (16). Plasma concentration of CD14 is affected 
by the promoter polymorphism c.159C/T (rs2569190) (17), which influences expression 
of the protein (18) and the risk of death in patients with sepsis (19). SNPs at the positions 
c.863 (rs1800630) and c.238 (rs361525) of the TNFA promoter independently influence 
transcription of this gene (20–22). The Interleukin 1 gene cluster on chromosome 2 
contains genes IL1B and IL1RN encoding the pro-inflammatory IL-1β and the anti-inflam-
matory IL-1 receptor antagonist (IL-1RA) (23). The variant c.31T (rs1143627) in the IL1B 
promoter increases the transcriptional activity of this gene (24). The second intron of 
IL1RN contains a variable number of tandem repeats (VNTR) 86-bp long. Allele 2 (IL1RN2) 
increases the concentration of IL-1β in vitro (25) and increases mortality in septic patients 
(26). The above mentioned studies (16,19,26,27) demonstrated significant associations 
between genetic variants and susceptibility to bacterial infections. However, these 
studies were performed mainly on limited numbers of non-cirrhotic patients and were 
not validated. Therefore, we decided to evaluate the contribution of genetic variants in 
the TLR4 pathway to the development of SBI in large, well characterised independent 
cohorts of cirrhotic patients with ESLD enlisted for OLT in two centres.
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PATIENTS AND METhODS
Patients and definition of severe bacterial infections
Identification cohort
Three hundred and thirty-six patients with liver cirrhosis with Child-Pugh class B and C 
were enrolled and retrospectively screened for the occurrence of one or more episodes 
of extrahepatic SBIs during their time on the waiting list and 270 days before enlistment 
to include also patients with a recent episode of SBI. These patients were sorted out of 
708 adult cirrhotic patients who were enlisted for OLT in Prague between February 1995 
and June 2010. Patients with Child-Pugh class A and patients with acute liver failure were 
excluded. Patients with Caroli disease and primary and secondary sclerosing cholangitis 
were excluded as well, since intrahepatic bacterial complications are characteristic for 
the natural course of these diseases. SBIs were defined as the following bacterial infec-
tions requiring hospitalization and treatment with intravenous antibiotics:
(a) Spontaneous bacterial peritonitis (SBP), diagnosis of which was based on neutrophil 
cell count exceeding 250/mm3 and/or positive culture of ascitic fluid if secondary 
causes of peritonitis were excluded (EASL guidelines (28)).
(b) Urinary tract infections diagnosed on the basis of clinical findings (dysuria, fever), 
pyuria (leukocytes >10/mm3) and positive urine culture (29).
(c) Pneumonia, diagnosis of which was determined by clinical symptoms (cough, ex-
pectoration, and fever), positive chest X-ray and positive bacteriological finding in 
sputum (30).
(d) Skin and soft tissue infection, diagnosis of which was established by local cutaneous 
findings (blush, tumefaction, and pain) and leukocytosis (31).
(e) Bacterial infection of unknown origin defined as a positive blood culture with serum 
C-reactive protein (CRP) level ≥70 mg/L.
All clinical data were collected from hospitalisation and outpatient medical records 
archived at our centre.
Validation cohort
The validation cohort (n = 332 cirrhotic patients enlisted for OLT) was selected from the 
522 adult patients evaluated for OLT between September 1995 and April 2011 in Erasmus 
MC-University Medical Centre, Rotterdam, The Netherlands. The selection process was 
based on the same criteria as in the identification cohort. In 332 selected patients, SBIs 
were defined according to the same definitions as used in the identification cohort from 
Prague. A higher rate of Child-Pugh B patients was observed in the validation cohort be-
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cause of the Dutch policy to enlist patients for OLT when they had Child-Pugh score 8 (B) 
or higher. Another reason to enlist patients with cirrhosis staged as Child-Pugh B was the 
presence of hepatocellular carcinoma. Due to progression of liver disease on the waiting 
list, most patients had Child-Pugh score C at the moment they were transplanted.
Genotyping
Patients were genotyped for TLR4 c.+1196C/T, CD14 c._159C/T, TNFA c._238G/A, TNFA 
c._863C/A, IL1B c._31C/T and IL1RN VNTR (UniSTS:156109) allelic variants, as described in 
(32), using specific primers and PCR conditions shown in Supplementary Table 1. In order 
to minimise genotyping errors, blank control wells were left on the PCR plates and two 
operators, unaware of the status of the samples, performed the genotype assignment 
independently. After testing for Hardy-Weinberg equilibrium (HWE), allele frequencies 
were checked for consistency with data from the population of European ancestry (Utah 
Residents with Northern and Western European Ancestry) from the HapMap database 
(33).
Primary assessment of associations between allelic frequencies and SBIs was performed 
in the identification cohort from Prague, and positive associations were confirmed in the 
validation cohort from Rotterdam. The study was approved by the institutional Research 
Ethics Committee of both participating centres. Written informed consent with DNA 
sampling was obtained from all patients and the study conformed to the declaration of 
Helsinki EthicalGuidelines.
Determination	of	serum	levels	of	TNF-α
Serum levels of TNF-α were determined in blood samples taken from patients at the 
moment of liver transplantation, i.e., in patients with no physical and laboratory signs 
of infection. The samples were frozen immediately after serum separation and stored at 
-80ᵒC. In the identification cohort, TNF-α was assessed in serum samples of 199 patients, 
out of which 179 patients were homozygotes for the TNFA c._238G allele and 20 patients 
were heterozygotes. Additional 36 samples (12 samples of patients carrying the TNFA 
c._238GA genotype and 24 samples of homozygotes for TNFA c._238G) came from the 
validation cohort. Quantitative determination of TNF- α was performed with the Quan-
tikine HS ELISA human TNF-α immunoassay (R&D Systems, Abingdon, UK). All standards, 
controls and samples were analysed in duplicates and the duplicate readings were aver-
aged. Duplicates with coefficient variability (CV) higher than 50% (5 heterozygotes and 
25 homozygotes) were excluded and the remaining 27 heterozygotes were then matched 
in age, sex, and underlying diseases with 81 of the 188 non-excluded heterozygotes.
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Statistical analysis
Data are presented as mean and standard deviation, as median and range, or as frequen-
cies, as appropriate. HWE and differences in genotype frequencies between patients 
with SBI and controls were analysed using two-sided χ2 testing. Using standard formulas 
based on two-by-two tables (34), we calculated basic epidemiology statistics and evalu-
ated the preventable fractions among the population and among the exposed. t tests or 
Mann-Whitney tests were used for comparisons of the means. Due to the testing of mul-
tiple statistical hypotheses, Bonferroni correction was used in the identification cohort. 
Cox regression analysis was used to calculate hazard ratio and 95% confidence interval 
(CI). Significant risk factors from univariate analysis were entered into the multivariate 
Cox regression analysis, which was performed with a forward stepwise approach. Wald 
statistics was employed in the regression module to evaluate the relative contribution 
of significant variables to SBI. Kaplan-Meier analysis with log-rank test was performed 
to evaluate survival. A p value <0.05 was considered statistically significant throughout 
the study. Statistical analysis was performed using JMP 9.0.0. and SPSS 13.0 programs.
RESuLTS
Demographic, clinical and survival data
Demographic and clinical data of OLT candidates included in the study are shown in 
Table 1. The median time to develop SBI while on the waiting list, or the median time to 
OLT in patients who did not develop SBI, was shorter in the identification cohort com-
pared to the validation cohort (337 vs. 479 days, p <0.001) and a higher proportion of 
patients with Child-Pugh B classification were present in the validation cohort (59.9% vs. 
50.6%, p = 0.015). Both cohorts contained similar spectra of liver diseases (Table 1). The 
group of cholestatic liver diseases included primary biliary cirrhosis, secondary biliary 
cirrhosis, PBC/AIH overlap syndrome and benign recurrent intrahepatic cholestasis/By-
ler’s disease. Metabolic liver diseases group comprised Wilson’s disease, α1-antitrypsin 
deficiency, haemochromatosis, and erythropoietic protoporphyria, and liver cirrhosis of 
other aetiologies involved cryptogenic cirrhosis, Budd-Chiari syndrome and non-alcohol-
ic steatohepatitis. Significantly more patients with liver cirrhosis due to chronic hepatitis 
B were present in the validation cohort compared with the identification cohort (15.4% 
vs. 8.6%). Out of all patients evaluated for OLT, 32.1% patients in the identification cohort 
and 51.5% in the validation cohort died; 10.7% and 28.6% of patients died pre-transplant 
at a median of 84 and 206 days after enlistment for OLT, and 21.4% and 22.9% of patients 
died at a median of 1109 and 969 days after OLT, respectively (Table 1, bottom sections). 
Approximately 42% pretransplant and 31% post-transplant deaths were attributable to 
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SBI in the identification cohort. In the validation cohort, SBI were responsible for 38% 
deaths in the pre-transplant period and for 28% deaths post-transplant.
Table	1. Demographic, clinical and survival data of patients listed for OLT
Identification	cohort Validation	cohort P value
N 336 332
Age at OLT (years, mean ± SD) 53 ± 9.5 52 ± 10.2 NS
Male/Female (%) 194/142 (57.7/42.3) 216/116 (65.1/34.9) NS
Interval between enlistment and SBI or 
OLT (days, median - range)
337 (270-1335) 479 (272-2979) <0.001
Survival after enlistment  
(days, median - range)
2770 (271-6079) 2994 (274-6834) NS
Child-Pugh B/C (%) 170/166 (50.6/49.4) 199/133 (59.9/40.1) 0.015
MELD (points, median - range) 15.8 (6-40) 15.6 (1-40) NS
Aetiology	of	cirrhosis N (%) N (%) P value
ALD 119 (35.4) 97 (29.2) NS
HCV 65 (19.3) 70 (21.1) NS
HBV 29 (8.6) 51 (15.4) 0.003
Cholestatic 49 (14.6) 29 (8.7) NS
Metabolic 15 (4.5) 13 (3.9) NS
AIH 23 (6.8) 17 (5.1) NS
Other 36 (10.7) 55 (16.6) NS
Mortality N (%) N (%) P value
No death 228 (67.9) 161 (48.5) <0.001
Death prior to OLT 36 (10.7) 95 (28.6)
Death after OLT 72 (21.4) 76 (22.9)
Pre-transplant deaths
Survival (median days, IQR) 84 (38-200) 206 (37-477) 0.002
SBI-related deaths (N, %) 15 (41.7) 36 (37.9) NS
SBI-unrelated deaths (N, %)* 21 (58.3) 59 (62.1)
Post-transplant deaths
Survival (median days, IQR) 1109 (200-2322) 969 (68-2073) NS
SBI-related deaths(N, %) 22 (30.6) 28 (36.8) NS
SBI-unrelated deaths (N, %)** 50 (69.4) 48 (63.2)
Child-Pugh and MELD score at the time of enlistment for liver transplantation; ALD – alcoholic liver disease; 
HCV – hepatitis C virus; HBV – hepatitis B virus; AIH – autoimmune hepatitis. IQR – interquartile range; 
NS – not significant
*) causes of SBI-unrelated pre-transplant deaths: Liver failure 9 (42.9%); cardiovascular 7 (33.3%); GIT bleed-
ing related to portal hypertension 3 (14.3%); other 2 (9.5%) in identification cohort and liver failure 24 (40.7%); 
cardiovascular 4 (6.8%); GIT bleeding related to portal hypertension 6 (10.2%); other and unknown 25 (42.4%) 
in validation cohort
**) causes of SBI-unrelated post-transplant deaths: Malignancy 22 (44%); cardiovascular 19 (38%); graft fail-
ure 7 (14%); other 2 (4%) in identification cohort and malignancy 10 (20.8%); cardiovascular 15 (31.3%); graft 
failure 18 (37.5%); other 5 (10.4%) in validation cohort
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Severe bacterial infections
Thirty-four percent of patients with advanced liver cirrhosis in the identification cohort 
and 40% of patients in the validation cohort presented with SBI during the observation 
period (Table 2). In the identification cohort, the risk of SBI was significantly associated 
with female gender and the degree of liver dysfunction evaluated by MELD score or Child-
Pugh score. Both MELD score and Child-Pugh score but not female gender remained 
significantly associated with SBI in the validation cohort. Patients in the validation cohort 
suffering from SBI had a significantly shorter observation period than patients without 
SBI (409 vs. 499 days, p = 0.037). Age and aetiology of liver cirrhosis were not associ-
ated with susceptibility to SBI (Table 2). A total of 130 episodes of SBI were diagnosed in 
115 patients in the identification cohort compared with 170 episodes of SBI diagnosed 
in 133 patients in the validation cohort. The frequencies of most SBIs were similar in 
identification and validation cohorts: pneumonia 10/130 vs. 20/170, p = 0.244, urinary 
tract infection 21/130 vs. 25/170, p = 0.730, and infection of skin and soft tissues 8/130 
vs. 10/170, p = 0.922. However, SBP was significantly more frequent in the identification 
cohort (84/130 vs. 90/170, p = 0.042) whereas patients with bacterial infections of un-
known origin were more prevalent in the validation cohort (7/130 vs. 25/170, p = 0.001).
Table	2.	Demographic and clinical data of patients with and without severe bacterial infection
Identification	cohort Validation	cohort
with	SBI without	SBI P value with	SBI without	SBI P value
N (%) 115 (34.2) 221 (65.8) 133 (40.1) 199 (59.9)
Age at OLT (years, mean ± SD) 52 ± 10.6 53 ± 8.9 NS 52 ± 10.4 52 ± 10.1 NS
Male/Female (%) 53/62 
(46.1/53.9)
141/80
(63.8/36.2)
0.002 84/49
(63.2/36.8)
132/67
(66.3/33.7)
NS
Interval between enlistment and 
SBI or OLT (days, median - range)
 333
(271-1335)
338
(270-709)
NS 409
(274-2979)
499
(272-2644)
0.037
Child-Pugh B/C (%) 46/69
(40/60)
124/97
(56.1/43.9)
0.005 60/73
(45.1/54.9)
139/60
(69.8/30.2)
<0.001
MELD (points, median - range) 16 (6-36) 15 (7-40) 0.004 17 (7-40) 14 (1-34) <0.001
Aetiology	of	cirrhosis N (%) N (%) P value N (%) N (%) P value
ALD 41 (35.7) 78 (35.3) NS 46 (34.6) 51 (25.6) NS
HCV 21 (18.3) 44 (19.9) NS 23 (17.3) 47 (23.6) NS
HBV 8 (7.0) 21 (9.5) NS 25 (18.8) 26 (13.1) NS
Cholestatic 16 (13.9) 33 (14.9) NS 10 (7.5) 19 (9.6) NS
Metabolic 5 (4.3) 10 (4.5) NS 6 (4.5) 7 (3.5) NS
AIH 9 (7.8) 14 (6.3) NS 6 (4.5) 11 (5.5) NS
Other 15 (13.0) 21 (9.5) NS 17 (12.8) 38 (19.1) NS
Child-Pugh and MELD score at the time of enlistment for liver transplantation; ALD – alcoholic liver disease; 
HCV – hepatitis C virus; HBV – hepatitis B virus; AIH – autoimmune hepatitis. NS – not significant
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Genetic	associations	with	severe	bacterial	infections
The identification cohort was genotyped for the 6 annotated SNP loci. Genotype frequen-
cies at the individual loci were in HWE except for the TNFA c._863C/A locus, which was 
excluded from further evaluations. Single locus analysis performed in the identification 
cohort (n = 336, Table 3 and Fig. 1) revealed a strong association of the TNFA c._238 locus 
with SBIs. Subjects carrying the minor TNFA c._238A allele showed significantly reduced 
risk of SBI (OR 0.22, 95% CI 0.07–0.75, pnon-adjusted = 0.008, padjusted (Bonferroni) = 0.042) 
compared with homozygotes for the major TNFA allele c._238G. Among the genetic loci 
under study, only this allele was associated with SBI; neither of the other investigated 
genes showed any differences in the distribution of genotype frequencies between cases 
and controls (Table 3 and Fig. 1). Similar to the identification cohort, presence of the TNFA 
c._238A allele conferred a significantly decreased risk of SBI in the validation cohort (OR 
0.37, 95% CI 0.14–1.02, p = 0.046, Table 3) and the association was independent of aetiol-
Table	3.	Genotype distributions in the identification and validation cohort
Locus Genotype
Identification	cohort Validation	cohort
Patients	with	
SBI
(n=115)
Patients	
without	SBI
(n=221)
P Patients	with	
SBI
(n=133)
Patients	
without	SBI
(n=199)
P
N (%) N (%) N (%) N (%)
CD14
c.-159 
CC 32 (27.8) 62 (28.1) NS
CT 62 (53.9) 111 (50.2)     
TT 21 (18.3) 48 (21.7)     
TLR4
c.1196 
CC 101 (87.8) 196 (88.7) NS
CT 14 (12.2) 25 (11.3)     
TT 0 0     
TNFA
c.-238 
GG 112 (97.4) 197 (89.1) 0.008 128 (96.2) 180 (90.5) 0.046
GA 3 (2.6) 24 (10.9)  5 (3.8) 19 (9.5)  
AA 0 0  0 0  
TNFA
c.-863 
CC 91 (79.1) 184 (83.3) n/a*
CA 18 (15.7) 26 (11.8)     
AA 6 (5.2) 11 (5.0)     
IL1B
c.-31 
CC 13 (11.3) 33 (14.9) NS
CT 58 (50.4) 103 (46.6)     
TT 44 (38.3) 85 (38.5)     
IL1RN
VNTR 
11 47 (40.9) 103 (46.6) NS
12 51 (44.3) 91 (41.2)     
22 13 (11.3) 14 (6.3)     
14, 31, 32 4 (3.5) 13 (5.9)     
*) As TNFA c.-863 genotypes were not in HWE, no further calculations were performed. NS – not significant
Chapter 2
42
ogy of SBI in both cohorts (data not shown). The presence of minor TNFA c._238A allele 
has been previously shown to decrease the transcriptional activity of TNFA resulting in 
lower production of TNF-α protein (21). Consistent with this report, we found that 27 car-
riers of the variant TNFA c._238A allele showed significantly lower levels of serum TNF-α, 
compared with 81 age-, sex- and diagnosis-matched homozygotes for the major allele 
TNFA c._238G (2.13 ± 2.11 pg/ml vs. 3.11 ± 2.52 pg/ml, p = 0.022) (Fig. 2). The difference 
between the 27 heterozygotes and all 188 homozygotes was even more pronounced (2.13 
± 2.11 pg/ml vs. 3.52 ± 3.27 pg/ml, p = 0.006).
Figure	1.
Association of the investigated variants with SBI in the identification cohort. Bars represent OR with 95% 
confidence interval. Source data are shown in Table 3.
Figure	2.
Decreased serum levels of TNF-α in carriers of the TNFA c._238A variant. The data from 81 homozygotes 
(c._238GG) and 27 heterozygotes (c._238GA) are shown as individual dots. Horizontal bars indicate mean 
(thick line) and standard deviations (thin lines). Mann-Whitney was used for comparison of the means.
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Determinants of severe bacterial infection and mortality
The potential role of TNFA c._238A as an independent predictor of SBI was evaluated by 
Cox regression analysis. Due to the low frequency of the TNFA c._238A allele (about 4% in 
both groups), we pooled both cohorts to achieve a sufficient power to detect moderate 
and small effect sizes. Calculations of hazard ratios in the univariate mode showed that 
SBIs were significantly associated with MELD, Child-Pugh class C vs. B) and TNFA c._238 
Table	4.	Risk factors of SBI or death
I.	 Outcome:	Severe	bacterial	infection
A.	 Univariate	analysis
Variables Wald hR 95% CI P value
MELD per 1 point increment 21.918 1.072 1.041-1.104 <0.001
Child-Pugh class C vs B 6.89 1.550 1.117-2.150 0.009
TNFA c.-238A 4.869 0.427 0.200-0.914 0.028
Gender (female vs male) 2.879 1.293 0.961-1.741 0.09
Cohort (identification vs validation cohort) 0.803 1.149 0.448-1.557 NS
Age per 1 year increment 0.580 1.006 0.991-1.020 NS
B.	 Multivariate	analysis
Variables Wald hR 95% CI P value
MELD per 1 point increment 19.964 1.067 1.037-1.098 <0.001
Child-Pugh class C vs B 6.61 1.531 1.107-2.119 0.01
TNFA c.-238A 5.044 0.421 0.197-0.896 0.025
II.	 Outcome:	Pre-transplant	death	(all	causes)
A.	 Univariate	analysis
Variables Wald hR 95% CI P value
SBI 32.343 2.36 1.755-3.173 <0.001
Age per 1 year increment 17.609 1.033 1.018-1.049 <0.001
MELD per 1 point increment 11.431 1.056 1.023-1.09 <0.001
Gender (female vs male) 10.647 0.606 0.448-0.819 0.001
Child-Pugh class C vs B 0.972 1.169 0.857-1.595 NS
Cohort (identification vs validation cohort) 0.959 1.161 0.861-1.565 NS
TNFA c.-238A 0.004 1.017 0.606-1.707 NS
B.	 Multivariate	analysis
Variables Wald hR 95% CI P value
SBI 38.58 2.476 1.860-3.296 <0.001
Age per 1 year increment 17.509 1.033 1.017-1.049 <0.001
MELD per 1 point increment 16.259 1.062 1.031-1.093 <0.001
Gender (female vs male) 14.296 0.572 0.428-0.764 <0.001
HR, hazard ratio; CI, confidence interval; Wald, measurement of influence statistics
Analyses were performed in pooled patient cohorts (n=668) using Cox regression. NS – not significant
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status, but not with age and gender. Multivariate analysis confirmed that MELD, Child-
Pugh score and the TNFA c._238 genotype represent independent predictors of SBIs 
(Table 4). Specifically, advanced liver disease (Child-Pugh class C vs. B) increased the risk 
of SBI 1.5-fold and each one-point increment in MELD score increased the risk of SBI by 
approximately 7%, whereas presence of the variant TNFA c._238A allele decreased risk 
of SBI by almost 2.5-fold (Table 4, multivariate analysis). Using Wald statistics to evaluate 
the relative contributions of these determinants to SBI, we found that the presence of 
the variant TNFA c._238A allele mitigated the odds of SBI developing as a consequence 
of Child-Pugh C class liver dysfunction by 76% (5.044/6.61) (Table 4, part I.B). Further cal-
culations demonstrated that presence of the minor TNFA c._238A allele prevented 7.2% 
(95% CI 3.7–8.8%) of SBIs in the whole cohort (preventable fraction among the popula-
tion), and that among the patients who developed SBIs, 70.6% (95% CI 36.7–86.4%) of 
these cases would hypothetically be preventable by the presence of the minor TNFA 
c._238A allele (preventable fraction among the exposed). The presence of TNFA c._238A 
Figure	3.
The presence of the TNFA c._238A variant is associated with significantly decreased risk of SBI-related pre-
transplant mortality. The impact of SBI (A) and TNFA c._238GA genotype (B) on overall pre-transplant mortal-
ity and the association of TNFA c._238GA genotype with mortality attributable to SBI (C) or non-infectious 
causes (D) were analyzed in pooled patient cohorts (n = 668). Kaplan-Meier analysis with Log-rank test was 
used for statistical evaluation.
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predicted protection from SBIs in the pooled cohort with a high positive predictive value 
(84.4%; 95% CI 72.4–98.0%) and specificity (89.8%; 95% CI 86.0–92.5%), whereas sensi-
tivity and negative predictive value were low (9.3% and 38.9%, respectively). Collectively, 
these findings demonstrate that possession of the variant TNFA c._238A allele provides 
strong protection against SBI in patients with advanced end-stage liver disease. Finally, 
we evaluated TNFA c._238A allele as a predictor of mortality. Multivariate Cox regres-
sion analysis identified SBI, age, female gender and MELD score as significant predictors 
of overall pre-transplant mortality (Table 4, part II and Fig. 3A). In contrast, the TNFA 
c._238 genotype was associated with all-cause mortality neither in regression modelling 
(Table 4, part II), nor in Kaplan-Meier analysis (Fig. 3B). However, as our previous data 
demonstrated significant association of TNFA c._238 genotype with SBI (Table 3, Fig. 1), 
and SBI was strongly associated with mortality (Table 4, part II and Fig. 3A), we hypoth-
esized that TNFA c._238 genotype could be a conditional predictor of mortality based on 
infection status of the host. Therefore, we performed a subgroup analysis and found that 
patients carrying the TNFA c._238A allele had a significantly decreased risk of succumb-
ing to SBI compared with homozygotes for the major GG genotype (Fig. 3C). Specifically, 
none of the carriers of the TNFA c._238A allele who developed SBI in the pre-transplant 
period died, whereas SBI-related mortality in homozygotes for the major allele TNFA 
c._238G reached 12% (Fig. 3C). As expected, there was no association between TNFA 
c._238 and pre-transplant death from non-infectious causes (Fig. 3D).
DISCuSSION
Our study provides several lines of evidence suggesting that the TNFA c._238 status 
is a significant predictor of reduced susceptibility to SBIs. First, the variant allele was 
associated with SBIs in two independent cohorts of patients with ESLD. Second, its 
association with SBI was independent of other variables in multivariate Cox regression 
analysis. Third, the relative significance of the TNFA c._238 allelic status in predicting 
SBIs was in close succession to MELD score and Child-Pugh C class of liver dysfunction, 
the strongest determinants of SBIs identified in this study. Given the low prevalence of 
the TNFA c._238A allele, the potential clinical utility of our finding would be in ruling out 
the potential risk of SBIs in a minor group of patients with ESLD. Considering that the 
TNFA c._238A allele is a marker of protection from SBIs, the presence of this allele in 
any given individual with ESLD will predict significant protection from SBIs (84% positive 
predictive value for the protection from SBIs in carriers of the variant A allele). Moreover, 
presence of this allele in patients with SBI awaiting OLT predicts a substantial survival 
benefit. The findings are consistent with the relevant contribution of the TNFA c._238 
allelic status to the risk of SBI in multivariate Cox regression analysis and indicate that 
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the presence of the TNFA c._238A allele may be truly significant in the clinical scenario. 
However, although the allelic status aids in ruling out SBI, it has a very low ruling-in 
characteristic, since the major allele G is abundantly represented in both SBI and non-SBI 
groups. Although several allelic variants were investigated in this study, only the TNFA 
c._238 allele, but not variants in TLR4, CD14, IL1B, and IL1RN, were associated with SBIs. 
This is consistent with the hierarchical pattern of TLR signaling. Although TLR2, 4, 5, and 
9 recognize distinct microbial components (peptidoglycan from G+ bacteria, LPS from G- 
bacteria, flagellin from G+ and G- bacteria, and unmethylated CpG sequences in bacterial 
DNA, respectively), they all utilize the common adaptor MyD88 and the nuclear factor 
kappa-B to induce inflammatory cytokines TNF-α and IL-1β (13). Therefore, as SBIs are 
caused by a wide spectrum of pathogens (1,35), it is possible that the major signal for 
induction of MyD88-dependent inflammatory cytokines in SBIs comes from a source 
other than LPS, which could explain the lack of association of TLR4 and CD14 with SBIs 
in our study. This notion is further supported by our data that multiple microbial classes 
determined SBIs in our study.
The lack of association between the IL1B gene cluster and SBIs could be attributed to 
differential roles of TNF-α vs. IL-1β in immune responses. Whereas TNF-α is triggered 
by bacterial ligands and is indispensable for antimicrobial defence, IL-1β serves as an 
amplifier of inflammatory responses and requires co-activation by host-derived factors 
released from tissues upon damage (36), which may not always be present in the context 
of bacterial infection. The TNFA c._238A allele determines low transcriptional activity 
of the TNFA gene and lower production of TNF-α in vitro (21,22) as well as in vivo (our 
study, Fig. 2). This seemingly paradoxical finding is consistent with desensitisation of 
innate immune cells to bacterial components and significant neutrophilic dysfunction 
found in patients with liver cirrhosis. Tritto et al. (9) reported that severity of liver disease 
positively correlates with serum levels of TNF-α and negatively correlates with neutrophil 
phagocytic dysfunction. This suggests that chronic elevation of TNF-α level causes ex-
haustion of neutrophil opsonizing and phagocytic capacity (9). The hypothesis is further 
supported by Ono et al. (10), who found desensitisation of neutrophils to TNF-α and LPS 
stimulation resulting in opsonophagocytic dysfunction in patients with liver cirrhosis. 
Finally, Stadlbauer et al. (37) demonstrated the neutrophil phagocytic dysfunction in pa-
tients with alcoholic cirrhosis was restored by treatment with probiotics, which resulted 
in decreased endotoxemia and TNF-α production. Our finding that the low-producer 
genotype in the TNFA c._238 locus negatively affects the risk of SBIs is therefore fully 
consistent with the aforementioned studies; it furthermore supports the biological con-
cept of immune cell desensitization by overzealous activation of inflammatory signalling 
in patients with liver cirrhosis, and implies that the low-producing variant TNFA c._238A 
allele in patients with ESLD may reset the sensitivity of innate immune cells to microbial 
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ligands. The concept of neutrophil exhaustion is also strongly supported by their lower 
serum levels of TNF-α. Low TNF-α production might have unfavourable consequences 
in cirrhotic patients manifested as higher occurrence of hepatocellular carcinoma as 
described by Teixeira et al. (38). This observation might be explained by deficient anti-
tumour immunity in individuals with decreased levels of TNF-α. Nonetheless, the ben-
eficial effect consisting of lower incidence of SBI and significantly decreased mortality 
owing to SBIs in patients awaiting OLT predominates over the risk of tumour growth. The 
main limitation of our study resides in its retrospective design. For this reason we were 
not able to validate the published data (21,22) on the decreased transcriptional activity 
of TNFA in heterozygotes for the c._238A allele. On the other hand, we assessed serum 
levels of TNF-α in a representative subset of enrolled patients and provided indirect 
evidence supporting such hypothesis.
In conclusion, we have shown that presence of the TNFA c._238A allele in ESLD patients 
virtually excludes the probability of developing SBIs or dying of SBI in patients awaiting 
OLT. The strong effect of this allele supports the biological concept that TNF-mediated 
desensitisation of innate immune cells drives increased susceptibility to bacterial infec-
tions in patients with ESLD. Our findings indicate potential utility of TNFA rs361525 geno-
typing in assessment of individual risk of SBIs in patients waitlisted for OLT and warrant 
further mechanistic studies.
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Supplementary	table.	Genotyped loci in CD14, TLR4, TNFA, IL1B and IL1RN
Variation
Ref.	SNPa ID
Forward	primer
Reverse primer
Tm, °C
Time [s]
Restriction	enzyme
Fragment length (bp)
CD14 5’-TTGGTGCCAACAGATGAGGTTCAC-3’ 60°C HaeIII
c.-159C/T 5’-TTCTTTCCTACACAGCGGCACCC-3’ 30 s 204, 201, 156 
rs2569190 
TLR4 c.+1196C/T 5’-GGTTGCTGTTCTCAAAGTGATTTTGGGAGAA-3’ 55°C HinfI
rs4986791 5’-ACCTGAAGACTGGAGAGTGAGTTAAATGCT-3’ 40 s 378, 29 
TNFA c.-238G/A 5’-GCCCCTCCCAGTTCTAGTTC-3’ 62°C BamHI
rs361525 5’-CTCACACTCCCCATCCTCCCGGATC-3’ 30 s 185, 26 
TNFA c.-863C/A 5’- GGCTCTGAGGAATGGGTTAC-3’ 63°C TaiI
rs1800630 5’- CTACATGGCCCTGTCTTCGTTACG-3’ 30s 125, 104, 21 
IL1B 5’-CCCTTCCATGAACCAGAGAA-3’ 60°C AluI
c.-31C/T 5’-GCTGAAGAGAATCCCAGAGC-3’ 30 s 97, 87, 54 
rs1143627 
IL1RN VNTR 5’-CCCCTCAGCAACACTCC-3’ 64°C -
156109b 5’-GGTCAGAAGGGCAGAGA-3’ 30 s 442, 270, 528, 356, 614 
aSNP database of genetic variation, www.ncbi.nlm.nih.gov/SNP. bSTS database of unified sequence tagged 
sites, www.ncbi.nih.gov/genome/STS, VNTR, variable number of tandem repeats; Tm, melting temperature.
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Based	on	letter	to	the	editor.
With great interest, we read the recent article by De Rooij et al (1) and the accompany-
ing editorial (2). The authors showed that functional single-nucleotide polymorphisms 
within donor genes involved in the lectin complement pathway [mannose-binding lectin 
2 (MBL2), ficolin 2, and mannan-binding lectin-associated serine protease 2 (MASP2)] 
determine the risk of bacterial infections after liver transplantation (LT). Although this is 
the first study associating single-nucleotide polymorphisms in ficolin 2 and MASP2 with 
the risk of infection after LT, the value of the donor MBL2 genotype as a risk factor for 
infection after LT is supported by two other studies (3,4). However, a fourth study (5) 
found no difference in the overall rate of infections between patients who received liver 
transplants from donors with insufficient MBL genotypes and those who received liver 
transplants from donors with sufficient MBL genotypes; although there was a higher 
incidence of septic shock after transplantation with MBL-insufficient livers. Moreover, 
the published studies used different ways to stratify MBL genotypes into groups with 
MBL serum levels predicted to be sufficient or insufficient. Donor YA/YA and YA/XA 
genotypes result in high serum MBL2 levels, O/O and XA/O genotypes are almost MBL2-
deficient, and YA/O and XA/XA genotypes are associated with intermediate MBL2 serum 
levels after LT (4). Although De Rooij et al. used a strict definition of MBL insufficiency 
and considered only O/O and XA/O genotypes to be MBL-insufficient, Worthley et al. (4) 
also considered the intermediate XA/XA genotype to be MBL-insufficient, and the two 
other studies (3,5) also included the second intermediate genotype (YA/O) in the MBL-
insufficient group. Therefore, the value of the donor MBL genotype and the method of 
its interpretation for the early identification of LT patients at risk of infectious complica-
tions are not established yet.
We studied the predictive value of donor MBL genotyping for bacterial infections in 
our own center. The MBL genotypes of 290 donor livers used for orthotopic transplan-
tation between 1987 and 2010 were determined. Notably, this cohort represents the 
largest single-center cohort of LT patients in which associations between the donor 
MBL2 genotype and bacterial infections have been analyzed. In three different ways, we 
categorized donor livers as MBL-sufficient or MBL-insufficient according to the stratifica-
tion systems used in the cited studies, and we analyzed associations with clinically signifi-
cant and laboratory-confirmed bacterial infections occurring during the first 3 months 
after LT by chi-square analysis with Fisher’s exact test (Table 1). Thirty-eight percent of 
LT recipients experienced one or more infectious episodes, and this is comparable to 
the numbers reported by the previous studies (1,4,5). Importantly, none of the three 
stratifications resulted in a statistically significant association between the donor MBL 
genotype and clinically significant infections. In addition, when we analyzed associations 
with site-specific infections, independently of MBL genotype stratification, we observed 
no significant increases in the risk of intra-abdominal infections or bacteremia in patients 
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who underwent transplantation with MBL-insufficient livers. However, in two of the 
three types of MBL genotype stratification, significantly more pneumonia was diagnosed 
in patients who underwent transplantation with MBL-deficient livers.
In conclusion, this retrospective study indicates that in our center, the donor MBL2 
genotype is not helpful in predicting the risk of bacterial infection after LT.
Table	1.	Associations between donor MBL2 genotypes and clinically significant bacterial infections after LTx
MBL-genotype	stratification
CSI Intra-abdominal Bacteremia PneumoniaIa
Insufficient: O/O, XA/O 22/47 (47%) 15/47 (32%) 12/47 (26%) 6/47 (13%)
Sufficient: YA/YA, YA/XA, XA/XA, YA/O 88/243 (36%) 58/243 (24%) 47/243 (19%) 12/243 (5%)
p-value 0.190 0.272 0.328 0.090
IIb
Insufficient: O/O, XA/O, XA/XA 31/66 (47%) 17/66 (26%) 18/66 (27%) 9/66 (14%)
Sufficient: YA/YA, YA/XA, YA/O 79/224 (35%) 56/224 (25%) 41/224 (18%) 9/224 (4%)
p-value 0.112 0.873 0.120 0.008
IIIc
Insufficient: O/O, XA/O, XA/XA, YA/O 51/131 (39%) 28/131 (21%) 30/131 (23%) 13/131 (10%)
Sufficient: YA/YA, YA/XA 59/159 (37%) 45/159 (28%) 29/159 (18%) 5/159 (3%)
p-value 0.808 0.221 0.380 0.026
aMBL-genotypes stratified according to the combinations of promoter -221 and exon 1 SNPs used by De Rooij 
et al (1). bMBL-genotypes stratified according to Worthley et al (4). cMBL-genotypes stratified according to 
Bouwman et al (3) and Cervera et al (5).
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ABSTRACT
We studied the influence of a broad range of genetic variants in recipient and donor 
innate immunity receptors on bacterial and fungal infections and acute rejection after 
liver transplantation (LT). Seventy-six polymorphisms in TLR 1-10, NOD2, LBP, CD14, 
MD2, SIGIRR, Ficolins 1, -2, and -3, MASP 1, -2, and -3, and the complement receptor 
C1qR1 were determined in 188 LT recipients and 135 of their donors. Associations with 
clinically significant infections and acute rejection were analyzed for 50 polymorphisms. 
Significant associations were validated in an independent cohort of 181 recipients and 
167 donors. Three recipient polymorphisms and 3 donor polymorphisms were associ-
ated with infections in the identification cohort, but none of these associations were 
confirmed in the validation cohort. Three donor polymorphisms were associated with 
acute rejection in the identification cohort, but not in the validation cohort. In contrast 
to their effect in the general population, 50 common genetic variations in innate im-
munity receptors do not influence susceptibility to bacterial/fungal infections after LT. 
In addition, no reproducible associations with acute rejection after LT were observed. 
Likely, transplant-related factors play a superior role as risk factors for bacterial/fungal 
infections and acute rejection after LT.
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INTRODuCTION
Lifelong immunosuppressive medication is one of the factors that contribute to the high 
incidence of infections early after liver transplantation (LT). Currently, infections are 
the leading cause of death in the first year after LT (1-2). Despite immunosuppressive 
therapy, about 30% of LT-recipients experience one or more episodes of acute rejection. 
Apparently, these patients need more immunosuppressive medication, while among 
70% of LT-recipients who do not experience acute rejection, a considerable proportion is 
probably over-immunosuppressed. At present, no tests are available that predict the risk 
of infection and acute rejection after LT.
Adaptive immunity is inhibited by immunosuppressive therapy. However, innate im-
munity is largely unaffected by currently used immunosuppressive drugs and is therefore 
probably important in combating infections after organ transplantation. Innate immune 
cells recognize molecular structures on pathogens by Pattern Recognition Receptors 
(PRR), also called innate immunity receptors. Genetic polymorphisms in these receptors 
have been recently recognized as determinants of the ability to combat infections in 
non-transplantation patients (3-4). For instance, Toll-like receptor (TLR) 4 rs4986790 and 
CD14 rs 2569190 polymorphisms have been shown to increase the risk of gram-negative 
infections in intensive care unit populations (5-8). In a septic shock cohort, the TLR2 
rs5743708 polymorphism predisposed patients to staphylococcal infections (9). The 
same polymorphism may influence the risk of developing tuberculosis (10). In another in-
tensive care unit cohort, polymorphisms in Nucleotide-binding Oligomerization Domain 
2 (NOD2) and TLR4 were associated with bacteremia (11).
Little is known about the effects of these and other genetic polymorphisms in innate 
immunity receptors on the risk of bacterial and fungal infections after organ transplanta-
tion. In addition, the available data are often contradictory. An association between a 
recipient TLR4 single nucleotide polymorphism (SNP) and bacterial infections in kidney 
transplant recipients (12) was not confirmed in independent studies (13-15). Significant 
associations between genetic variations in donor Mannose-Binding Lectin 2 (MBL2) and 
the incidence of infections after LT were reported by two different centers (16-18), but 
were not confirmed by two other liver transplant centers, including our center (19-20). 
Apart from the cited studies on the influence of genetic polymorphisms in components 
of the lectin pathway of complement activation and a recent single-cohort study on one 
single TLR2 SNP (rs5743708), which showed that this polymorphism did not influence 
the incidence of gram-positive bacterial infections after LT (21), the relevance of genetic 
variations in innate immunity receptors for inter-individual differences in susceptibility 
to bacterial infections after LT has not been studied.
Regarding the influence of polymorphisms in innate immunity receptor genes on acute 
rejection after LT, less is known. Antigen-presenting cells (APC), which express numerous 
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PRR, are required for presentation of allo-antigens to T cells, thereby promoting acute 
rejection, and signalling via PRR in APC dictates the initiation, type, magnitude and dura-
tion of T-cell responses (22). Since inflammatory responses upon ischemia-reperfusion 
are similar to those observed when the innate immune system is activated via PRR and 
ischemia-reperfusion related injury can contribute to acute rejection, it is likely that PRR 
play a role in allograft rejection (23). Indeed, PRR can detect sterile injury upon binding 
to endogenous ligands that are released from damaged tissues (24-26), and thereby 
activate innate and adaptive immunity. In agreement with this concept, mice that are 
deficient in TLR signaling display impaired allograft rejection (27-28), and engagement of 
certain PRR is sufficient to prevent allograft acceptance in experimental animals (29-32). 
In addition, increased expression of endogenous PRR-ligands has been observed dur-
ing rejection in allografts in experimental animals (24-25) and in humans (33), and on 
circulating monocytes (34-35). Moreover, recipient TLR4 SNP have been associated with 
acute rejection after lung (13, 36) and kidney transplantation (37), although the associa-
tion in kidney transplantation was not confirmed in two other studies (13, 15). One single 
study (15) reported a significantly higher rate of acute rejection after kidney transplan-
tation in carriers of the TLR3 rs3775291 SNP T-allele. A CD14 promotor polymorphism 
was associated with earlier onset of acute rejection in lung transplant recipients (38). 
However, no studies associating polymorphisms in innate immune receptor genes with 
acute rejection after LT have been published.
The aim of the present study was to assess whether a broad range of genetic poly-
morphisms in innate immunity receptors, mostly SNPs, may influence susceptibility to 
bacterial and fungal infections or development of acute rejection after LT. To prevent 
the risk of yielding false-positive results, we repeated positive associations in a second 
cohort, as has been advocated in genetic research (39).
PATIENTS AND METhODS
Study design, patients and setting
The identification cohort consisted of primary LT-recipients who were transplanted at 
the Erasmus Medical Center, Rotterdam, between 1987 and 2006. We excluded non-
Caucasian patients and patients with graft or patient survival less than 5 days, thereby 
excluding intraoperative and direct postoperative, operation-related morbidity and 
mortality. From 188 of these patients DNA was available, and from 135 donors of this 
cohort. Since many innate immunity receptors are expressed in the liver (40) or secreted 
by the liver, we determined both recipient and donor polymorphisms. While the identifi-
cation study was performed, we collected DNA from 181 additional primary LT-recipients 
with a graft and patient survival of at least 5 days, transplanted at the Erasmus Medical 
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Center between 2001 and 2010 (validation cohort). No patient was included in both 
cohorts. Polymorphisms that were identified as a risk factor for bacterial and fungal 
infection and/or rejection after LT in the identification cohort, were subsequently stud-
ied in this second cohort, which contained 38 non-Caucasian patients (21 Asians and 17 
Black-Africans). From 167 liver donors of this cohort, frozen splenocytes were available, 
from which donor DNA could be isolated. All patients gave informed consent, and the 
study was performed according to the guidelines of the Medical Ethics Committee of the 
Erasmus MC.
Patient	follow-up
All patients in the identification and validation cohorts received standard immunosup-
pressive therapy consisting of corticosteroids and a calcineurin inhibitor (cyclosporine or 
tacrolimus), with or without mycophenolate mofetil or azathioprine and/or basiliximab. 
Patients transplanted before 2000 received selective bowel decontamination, using or-
floxacin, colistin and amfotericin B. After 2000, patients received cefazolin as antibiotic 
prophylaxis. After LT, patients were intensively monitored according to the local protocol 
for any sign of infection and acute rejection. After inclusion in either the identification 
cohort or the validation cohort, clinical information about bacterial and fungal infections 
and acute rejection was retrospectively collected from patient files. All infections were 
categorized into site-specific infections (abdominal infections, bloodstream infections, 
pneumonia). Clinically serious infections (CSI) were defined using the Center for Disease 
Control and Prevention criteria (41). Infections were only registered if the etiologic patho-
gen was identified by culture, and patients received adequate treatment. Infections 
with only coagulase-negative staphylococci were assumed to be contamination, and 
excluded. Abdominal infections included cholangitis, peritonitis, and intra-abdominal 
abscesses, but bilomas were excluded. Pneumonia had to be confirmed by chest X-ray 
or CT-scan, showing a new or progressive infiltrate. Bacterial infections were grouped 
by causative pathogen (gram negative bacteria and/or gram positive bacteria). Fungal 
infections were only included if they were invasive. In addition to bacterial and fungal 
infection, CMV infection was registrered. CMV infection was defined as positive viral 
load in blood. Follow-up time for infections was from LT to three months after LT. For 
acute rejection, the follow-up time was from LT to end of follow-up. End of follow-up 
was defined as date of acute rejection, date last seen, or date of death. Acute rejection 
was defined as: at least two-fold increase in serum liver enzymes (AST and/or ALT) or 
bilirubin, confirmed by a biopsy-proven rejection (rejection activity index (RAI)-score 5 
or higher) according to BANFF-criteria (42), and responsiveness to treatment with im-
munosuppressive medication.
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Genotyping
DNA was isolated from peripheral blood of patients or splenocytes from donors using 
the Wizard® Genomic DNA Purification Kit (Promega), according to the manufacturers’ 
protocol. Seventy-six (76) genetic polymorphisms in 21 signaling and secreted innate 
immunity receptors were determined in both patient and donor DNA of the identifica-
tion cohort. Genes studied were TLR 1 to 10, the cytosolic bacterial sensor NOD2, the 
TLR-accessory molecules LBP, CD14, MD2 and SIGIRR, the Ficolins1, -2, and -3, MASP 1, -2, 
and -3, and the complement receptor C1qR1. The polymorphism had been selected due 
to their localization in an exon, an intron (up to 30 bp before an exon; up to 10 bp after an 
exon) or in a promoter region/5’-untranslated region (UTR) up to 1,000 bp before exon 
1. DNA of the samples was amplified using PCR: five multiplex PCR reactions and one 
single PCR (for NOD2) were carried out. Polymorphisms were determined with a probe 
assay based on the reverse hybridization principle, using primers and probes developed 
by Innogenetics NV, Ghent, Belgium. For every SNP, specific probes had been designed 
both for the major and the minor allele to ensure detection of homozygotes as well as 
heterozygotes. Hybridization, wash steps, and visualization of the DNA products were 
performed in Auto-LiPA 30 devices (Innogenetics NV). For each SNP, the dots on the 
membranes were interpreted using in-house developed software (43).In the validation 
cohort, SNPs were determined by KBioscience, UK (http://www.kbioscience.co.uk) using 
the KASP SNP genotyping system, a homogeneous Fluorescent Resonance Energy Trans-
fer (FRET) based system, coupled with competitive allele specific PCR. Twelve polymor-
phisms in 7 patients and 7 donors of cohort 2 (in total168 samples) were determined by 
Innogenetics and KBiosciences, which yielded only 1 discrepant result (=0.6%), showing 
the accuracy of both techniques.
Statistical analysis
Associations between genetic variants and bacterial and fungal infections after LT 
were determined by chi-square analysis using the outcome “no infection” and “one or 
more infections” as variables. Associations with “time to first acute rejection episode” 
were determined by Kaplan-Meier survival analysis, using the Log rank test to assess 
statistical significance. Associations of baseline characteristics of the LT-patients or their 
donors with CSI or time to acute rejection were analyzed using Logistic regression and 
Cox regression, respectively. Analyses were censored for death, re-transplantation, or 
loss of follow-up. In multivariate analysis, using logistic regression or cox regression 
respectively, it was tested whether significant associations of polymorphisms with infec-
tions or acute rejection were independent of each other and independent of clinical and 
demographic parameters. Only polymorphisms with at least 10 individuals per genotype 
were included in multivariate analysis, or genotypes that both contained the risk allele 
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were combined. Statistical analysis was performed using SPSS for Windows, version 17.0 
software package. P-values of <0.05 were considered as statistically significant.
RESuLTS
Clinical characteristics and post-transplant infection and rejection
Table 1 shows the clinical and demographic characteristics of both cohorts. The identifica-
tion cohort consisted of 188 Caucasian primary LT-recipients, of which 68 (36%) had one 
or more clinically serious infections (CSI) in the first three months after LT, and 60 (32%) 
experienced one or more episodes of acute rejection. In the validation cohort, 78 (43%) of 
181 LT-recipients had one or more bacterial or fungal infections in the first three months 
after LT, and 47 (26%) experienced acute rejection. In both cohorts most infections were 
intra-abdominal. The majority of infections was caused by bacteria, in the identification 
cohort predominantly by gram-positive, but in the validation cohort equally by gram-
positive and gram-negative bacteria. None of the clinical and demographic characteristics 
that were significantly associated with bacterial and fungal infections or acute rejection 
in the identification cohort could be confirmed in the validation cohort.
Genetic polymorphisms in innate immunity receptors and post-transplant 
infections
In the identification cohort, genotypes of all 76 polymorphisms were determined in 
LT-recipients and in their donors (Table 2). Associations with total CSI as well as site-
specific CSI (abdominal, bloodstream) were first determined using univariate analysis. 
Associations with pneumonia as a separate entity were not analyzed, because the num-
ber of patients with pneumonia was low. Because many pattern recognition receptors 
recognize molecular patterns specifically expressed on either gram-negative or gram-
positive bacteria, we additionally analyzed associations between genotypes and infec-
tions caused by these two different categories of pathogens. No associations with fungal 
infections as a separate entity were performed because of the low numbers of patients 
with fungal infections. Subsequently, we included polymorphisms and clinical variables 
that showed significant association in univariate analysis in a multivariate analysis. To 
prevent accidental findings, we excluded 26 polymorphisms with less than 10 individuals 
per genotype from multivariate analysis, unless homozygous and heterozygous carriers 
of risk alleles emerging from univariate analysis could be combined to a group of at least 
10 subjects. Polymorphisms that were included in the analyses are indicated in bold in 
Table 2. In Table 3 the polymorphisms in recipient and donor innate immunity receptors 
that were significantly associated with bacterial and fungal infections in the identifica-
tion cohort in both univariate and multivariate analysis are shown.
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Table	2.	Genetic polymorphisms in innate immune receptors determined in the identification cohort
Gene rs number Region
Identification	cohort
Genotypes	donors	(no.) Genotypes	recipients	(no.)
Masp1-3 rs710474 Promoter CC/CT/TT 57/60/15 CC/CT/TT 87/85/16
Masp3 rs850312 Protease domein GG/GA/AA 56/60/16 GG/GA/AA 90/76/22
Masp1 rs3733001 Intron 15 GG/GA/AA 83/41/9 GG/GA/AA 112/66/10
Masp2 not 
submitted
Exon3 D105 AA/AG/GG 120/12/0 AA/AG/GG150/29/9
Masp2 rs2273343 Exon4 AA/AG 132/0 AA/AG 187/1
Masp2a rs6695096 Intron 8 AA/AG/GG 92/38/2 AA/AG/GG 140/42/6
Masp2 rs223346 Exon 9 TT/CT 128/3 TT/CT 183/4/1
Masp2a rs12711521 Exon 9 TT/TG/GG 88/38/6 TT/TG/GG 134/46/8
Masp2a rs1782455 Exon 11 TT/CT/CC 92/34/6 TT/CT/CC 138/44/6
FCN1 rs2989727 Promoter AA/GA/GG 52/62/18 AA/GA/GG 85/78/25
FCN1 rs1071583 Exon 9 GG/AG/AA 56/59/17 GG/AG/AA 89/75/24
FCN2 rs7865453 Promoter AA/AC/CC 101/30/1 AA/AC/CC 148/37/3
FCN2 rs17514136 Promoter AA/AG/GG 64/57/11 AA/AG/GG 85/90/13
FCN2 rs17549193 Exon 8 CC/CT/TT 62/55/15 CC/CT/TT 76/96/16
FCN2 rs7851696 Exon 8 GG/GT/TT 93/38/2 GG/GT/TT 143/42/3
FCN3 rs3813800 Intron 5 CC/CG 132/0 CC/CG 187/1
C1qR1 rs3746731 Exon 1 TT/CT/CC 46/62/24 TT/CT/CC 66/89/33
C1qR1 rs7492 Exon 2 (untranslated region) CC/CT/TT 116/16/1 CC/CT/TT 157/30/1
LBP rs2232578 Promoter AA/AG/GG 92/36/4 AA/AG/GG 115/65/8
LBP rs5744204 Exon 4 GG/AG 128/4 GG/AG 185/3
LBP rs2232607 Exon 8 AA/AG 130/2 AA/AG 186/2
LBP rs1780627 Intron 9 CC/TC/TT 28/77/27 CC/TC/TT 41/116/31
LBPa rs2232613 Exon 10 CC/CT/TT 109/19/4 CC/CT/TT 163/25/0
LBP rs2232618 Exon 13 TT/TC 117/15 TT/TC 154/34
CD14a rs3138078 Promoter GG/GT/TT 77/51/4 GG/GT/TT 112/70/6
CD14 rs2569190 Promoter CC/TC/TT 39/63/28 CC/TC/TT 38/102/48
CD14 rs2228049 Exon 2 AA 132 AA 188
CD14 rs2563298 Intron 9 GG/GT/TT 62/58/12 GG/GT/TT 109/68/11
MD2 rs1809440 Promoter AA/AG/GG 48/54/30 AA/AG/GG 65/84/39
MD2 rs6472812 Exon 2 GG/AG 117/15 GG/AG 171/17
MD2b rs11466004 Exon 5 CC/CT 130/2 CC/CT 175/13
NOD2 rs2066844 Exon 4 CC/CT 123/9 CC/CT 166/22
NOD2 rs2066845 Exon 8 GG/GC 130/2 GG/GC 185/3
NOD2 rs2066847 Exon 11 (insertion) —/-C 127/5 —/-C 180/8
Sigirr rs7482596 Promoter AA 131 AA 188
Sigirra rs3210908 Exon 9 GG/AG/AA 75/48/7 GG/AG/AA 106/64/18
Table	2.	Genetic polymorphisms in innate immune receptors determined in the identification cohort (continued)
Gene rs number Region
Identification	cohort
Genotypes	donors	(no.) Genotypes	recipients	(no.)
Sigirra rs3087588 Exon 9 GG/TG/TT 75/48/7 GG/TG/TT 106/64/18
TLR1 rs5743551 Promoter AA/AG/GG 68/57/8 AA/AG/GG 100/66/22
TLR1 rs5743611 Exon4 GG/GC/CC 111/19/3 GG/GC/CC 163/24/1
TLR1 rs4833095 Exon4 AA/AG/GG 69/57/8 AA/AG/GG 101/65/22
TLR1 rs3923647 Exon4 AA/AT/TT 123/10/1 AA/AT/TT 182/6/0
TLR2 rs1898830 Promoter AA/AG/GG 52/59/21 AA/AG/GG 77/89/22
TLR2 rs3804100 Exon 2 TT/TC/CC 111/23/0 TT/TC/CC 165/21/2
TLR2 rs5743708 Exon2 GG/GA 129/5 GG/GA 176/12
TLR2 not 
submitted
Exon2 R677W CC 134 CC 188
TLR3 rs5743305 Promoter TT/TA/AA 59/57/18 TT/TA/AA 69/91/28
TLR3 rs3775296 Intron 1 CC/CA/AA 88/40/6 CC/CA/AA 133/48/7
TLR3 rs3775291 Exon4 CC/CT/TT 62/60/12 CC/CT/TT 103/71/14
TLR4 rs1927914 Promoter AA/GA/GG 69/50/15 AA/GA/GG 83/81/24
TLR4 rs4986790 Exon4 AA/AG 117/17 AA/AG 165/23
TLR4 rs4986791 Exon4 CC/CT 116/18 CC/CT 165/23
TLR5 rs759303 Promoter GG/GA 121/13 GG/GA 170/18
TLR5 rs5744168 Exon6 CC/CT/TT 118/12/3 CC/CT/TT 170/17/1
TLR5 rs2072493 Exon6 AA/AG/GG 105/24/4 AA/AG/GG 139/45/4
TLR5 rs5744174 Exon6 TT/CT/CC 45/55/33 TT/CT/CC 56/100/32
TLR6 rs1039559 Promoter TT/CT/CC 36/69/29 TT/CT/CC 59/84/45
TLR6 rs5743810 Exon1 CC/CT/TT 43/67/24 CC/CT/TT 77/74/37
TLR6 rs3821985 Exon1 CC/CG/GG 55/65/13 CC/CG/GG 88/82/18
TLR6 rs5743815 Exon1 TT/CT 125/8 TT/CT 183/5
TLR7 rs5743712 Promoter GG/GC 134/0 GG/GC 186/2
TLR7 rs2897827 Promoter AA/AT/TT 93/27/14 AA/AT/TT 128/30/30
TLR7 rs179008 Exon3 CC/CT 131/2 CC/CT 187/1
TLR7 rs5743781 Exon3 CC/CT 130/2 CC/CT 187/1
TLR8 rs1548731 pro(var1)/IVS1 (var2) CC/CT/TT 98/20/15 CC/CT/TT 119/32/37
TLR8 rs3764880 uTR5 (var1)/Exon1(var2) AA/AG/GG 94/24/16 AA/AG/GG 125/34/29
TLR8 rs5744077 Exon3 AA/AG/GG 132/0/0 AA/AG/GG 180/4/4
TLR8 rs2159377 Exon3 CC/CT/TT 100/23/10 CC/CT/TT 138/31/19
TLR8 rs5744080 Exon3 CC/CT/TT 78/28/32 CC/CT/TT 94/39/55
TLR9 rs187084 Promoter TT/CT/CC 41/67/25 TT/CT/CC 64/96/28
TLR9 rs5743836 Promoter TT/TC/CC 98/30/5 TT/TC/CC 125/55/8
TLR9 rs352140 Exon2 AA/AG/GG 44/61/29 AA/AG/GG 58/91/39
TLR10 rs7694115 Promoter TT/CT/CC 57/61/16 TT/CT/CC 73/78/37
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Recipient polymorphisms
The T-allele of recipient TLR10 gene polymorphism rs7694115 was protective against 
abdominal infections. LT-recipients that carried the Lipopolysaccharide Binding Protein 
(LBP) gene rs2232613 T-allele were completely protected from bloodstream infections. 
Recipients carrying the C-allele of the TLR3 rs3775291 polymorphism were less suscep-
tible to infections caused by gram-negative micro-organisms.
Donor polymorphisms
Two donor polymorphisms were significantly associated with the incidence of total CSI: 
CD14 rs2569190 and TLR9 rs187084. The T-allele of the CD14 SNP was protective against 
total CSI, and was also significantly associated with a lower incidence of infections caused 
by gram-positive bacteria. Patients transplanted with livers from donors homozygous for 
the TLR9 rs187084 T-allele were protected from total CSI, bloodstream infections, and 
gram-negative infections. Patients who received a liver from a donor with an A-allele in 
the Sigirr rs3210908 gene had a higher incidence of bloodstream infections and gram-
negative infections compared to the GG-genotype.
The results of genotyping of those significantly associated polymorphisms in the 
validation cohort are shown in Table 4, while associations with infections are shown in 
Table 3. None of the associations observed in the identification cohort was confirmed in 
the second cohort. While the identification cohort consisted of Caucasian patients only, 
the validation cohort contained 38 non-Caucasian patients. Therefore, we repeated the 
analyses in Caucasians only, but again none of the polymorphisms showed significant 
association with infections.
Table	2.	Genetic polymorphisms in innate immune receptors determined in the identification cohort (continued)
Gene rs number Region
Identification	cohort
Genotypes	donors	(no.) Genotypes	recipients	(no.)
TLR10a,b rs11466645 Promoter TT/TA/AA 86/45/1 TT/TA/AA 116/50/22
TLR10a rs11096957 Exon3 AA/AC/CC 56/60/18 AA/AC/CC 75/77/36
TLR10a,b rs11096956 Exon3 GG/GT/TT 77/54/3 GG/GT/TT 107/59/22
TLR10 rs4129009 Exon3 AA/AG/GG 87/44/2 AA/AG/GG 118/57/13
a Genotypes containing minor alleles were combined, based on outcomes of univariate analysis
b Numbers of genotypes significantly different between donors and recipients (p<0.05)
Bold polymorphisms were included in analyses, based on number of subjects per genotype of at least 10 or 
when minor alleles could be combined to a group of at least 10 if significantly associated in univariate analysis.
Abbreviations of the genes: MASP: MBL-associated serine protease; FCN: ficolin; C1qR1: Complement 1 q re-
ceptor 1; LBP: lipopolysaccharide-binding protein; CD14/MD2: co-receptors; NOD: Nucleotide-binding oligo-
merization domain; TLR: Toll-like receptor
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4
Genetic polymorphisms in innate immunity receptors and acute rejection
Analyses of associations with acute rejection were performed in a similar manner as 
described for assocations with infections. In Table 5 the polymorphisms that were 
significantly associated in both univariate analysis and multivariate analysis with acute 
rejection in the identification cohort are shown.
Recipient polymorphisms
No recipient polymorphisms were associated with acute rejection after LT.
Donor polymorphisms
Three donor polymorphisms were significantly associated with acute rejection in the 
identification cohort. The minor T-allele of the donor LBP rs2232613 gene was associated 
with a higher incidence of acute rejection. In the donor TLR6 rs5743810 gene the T-allele 
was a risk allele for acute rejection with a dose-allele effect on the incidence of acute 
rejection. The donor TLR9 rs352140 G-allele was associated with a higher incidence of 
acute rejection.
The results of the replication of these associations in the validation cohort are also 
depicted in Table 5, showing that none of the associations was confirmed. Likewise, no 
significant association was obtained when the analyses were repeated for Caucasian 
patients only.
Table	4.	Genetic polymorphisms in innate immune receptors determined in the validation cohort
Gene rs number
Region /
for MBL level: donor 
genotypes
Validation	cohort
Genotypes donors 
(no.)
Genotypes recipients 
(no.)
LBP rs2232613 Exon 10 CC/CT/TT 137/29/1 CC/CT/TT 142/24/0
Sigirr rs3210908 Exon 9 GG/AG/AA 93/62/10 GG/AG/AA 113/46/5
CD14 Rs2569190 Promoter CC/CT/TT 41/81/35 CC/CT/TT 37/87/37
TLR1 rs5743551 Promoter AA/AG/GG 84/59/14 AA/AG/GG 75/69/17
TLR3 rs3775291 Exon 4 CC/CT/TT 84/61/7
TLR6 rs5743810 Exon1 CC/CT/TT 57/77/29 CC/CT/TT 76/62/23
TLR9 rs187084 Promoter TT/CT/CC 49/85/32
TLR9 rs352140 Exon2 TT/CT/CC 41/54/29
TLR10 rs7694115 Promoter AA/GA/GG 58/75/16
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DISCuSSION
To determine whether genetic variations in innate immunity receptors may influence 
susceptibility to bacterial and fungal infections and rejection after LT, we designed a 
comprehensive study to identify possible associations between genetic polymorphisms 
in all known TLRs, TLR4 accessory molecules (LBP, CD14, MD2, SIGIRR), the NOD-like re-
ceptor NOD2, and components of the lectin pathway of complement activation (Ficolins, 
MBL-associated serine proteases (MASPs), and C1q receptor 1) in both recipients and 
donors with post-transplant infections and acute rejection. To prevent the pitfall of false-
positive associations due to a type I error, we repeated the observed associations in a 
second cohort from the same liver transplant center. We did not include MBL polymor-
phisms in the present study, since we have previously observed that these are not as-
sociated with infections in LT-patients from our center (20). Several polymorphisms were 
significantly associated with the risk of bacterial or fungal infection or acute rejection 
after LT in our identification cohort, but none of these associations was confirmed in the 
validation cohort. Even the association between donor TLR9 rs 187084 with bloodstream 
infections, which after adjustment for multiple testing according to Bonferroni had a 
two-sided p-value <0.05 in the identification cohort, was not confirmed in the second 
cohort. Interestingly, donor MASP3 rs12711521 and Ficolin-2 rs17549193 SNP, which were 
recently found to be associated with post-LT bacterial infections in another center (18) 
showed in the present study no association with bacterial infections. In addition, none 
of the donor polymorphisms that were significantly associated with acute rejection in 
the identification cohort could be confirmed in the validation cohort. Our study dem-
onstrates the absolute necessity of validating genetic associations in an independent 
cohort before drawing conclusions.
Interestingly, several of the polymorphisms in innate immunity receptor genes 
analyzed in the present study have been associated with alterations in susceptibility to 
bacterial or fungal infections in critically ill non-transplant patients (3-11). None of these 
polymorphisms were associated with infections after LT in the present study. Apparently, 
the influence of genetic variations in innate immunity receptors of recipients or donors 
on the occurrence of post-transplant bacterial and fungal infections is less important 
compared to transplant-related factors. The impact of surgical trauma combined with 
the often dismal clinical condition of recipients and the use of immunosuppressive drugs 
render patients at high risk for infections early after LT. Furthermore, not much is known 
about the influence of type and intensity of immunosuppression on expression of PRR, 
although it has been shown that high dose steroid pulse therapy to treat acute rejection 
after LT reduced expression of TLR2 and TLR4 on circulating monocytes (35). Such ef-
fects of immunosuppressive drugs may influence the ability of combat infections. The 
incidence of CSI after LT is severely influenced by high volumes of blood transfusion and 
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by prolonged intensive care stay (2, 44-46). Cytomegalovirus (CMV) seropositive donor, 
prolonged operative procedure time, bilio-enteric reconstruction, and biliary stricturing 
after LT are risk factors for bacteremia (47-48). Pneumonia is more frequent after LT 
than after other transplantations (49). In addition to the usual operative risks, recipients 
of LT are at higher risk for pneumonia due to pre-existing alterations in the diaphragm 
function, pleural effusion and atelectasis related to ascites, blood product transfusions, 
immunosuppression and pulmonary involvement associated with their pre-LT underlying 
liver disease (50). Other risk factors for pneumonia after LT described in the literature are: 
piggyback anastomosis, mechanical ventilation, lactatemia, vasopressor requirements 
and lung edema (50-52). These transplant-related factors strongly increase the risk of 
post-LT infections, and may have more impact than differences in genetic susceptibility 
to infections after LT.
The present study has a few limitations. At first, the numbers of patients in our identi-
fication cohort may have been too low to detect associations with alleles with low allele 
frequencies. For this reason, we excluded polymorphisms with less than 10 individuals 
per genotype in the identification cohort from multivariate analysis, unless homozygous 
and heterozygous carriers of risk alleles emerging from univariate analysis could be 
combined to a group of at least 10 subjects. As a result, the conclusions of our study 
apply only for 50 more common polymorphisms that are indicated in bold in Table 2. 
Nevertheless, we detected in the identification cohort statistically significant associa-
tions of 3 recipient SNPs and 3 donor SNPs with infections, and of 3 donor SNPs with 
acute rejection, of which one (LBP rs2232613) had a minor allele frequency of only 0.10. 
Secondly, the use of unselected LT-patients with different underlying liver diseases may 
have introduced confounding factors that disturb penetration of the effects of genetic 
variations on outcome. However, this may also be considered as strength of the study, 
because results are representative for a general LT-population. Thirdly, LT-patients from 
which no DNA was available were excluded from the cohorts. However, since 73 of 76 
SNPs showed comparable genotype distributions in recipients and donors (Table 2), we 
believe that this limitation has not resulted in a genetic bias of the cohorts.
In conclusion, our data together with a previously published study (20) show that 
neither risk of bacterial and fungal infections nor risk of acute rejection after LT is signifi-
cantly influenced by 50 common genetic polymorphisms in innate immunity receptors. 
Transplant-related variables may play a superior role as risk factors for bacterial and 
fungal infections and acute rejection compared to the genetic polymorphisms tested.
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ABSTRACT
Viral infections, including cytomegalovirus (CMV), abrogate transplantation tolerance in 
animal models. Whether this also occurs in humans remains elusive. We investigated how 
CMV affects T cells and rejection episodes after liver transplantation (LT). Phenotype and 
alloreactivity of peripheral and allograft-infiltrating T cells from LT patients with differ-
ent CMV status were analyzed by flow cytometry. The association of CMV status with 
early and late acute rejection was retrospectively analyzed in a cohort of 639 LT patients. 
CMV-positivity was associated with expansion of peripheral effector memory T-cell 
subsets after LT. Patients with CMV primary infection showed donor-specific CD8+ T-cell 
hyporesponsiveness. While terminally differentiated effector memory cells comprised 
the majority of peripheral donor-specific CD8+ T cells in CMV primary infection patients, 
they were rarely present in liver allografts. Retrospective analysis showed that R-D+ 
serostatus was an independent protective factor for late acute rejection by multivari-
ate Cox regression analysis (hazard ratio=0.18, 95%CI=0.04-0.86, P=0.015). Additionally, 
CMV primary infection patients showed the highest Vδ1/Vδ2 γδ T-cell ratio, which has 
been shown to be associated with operational tolerance after LT. In conclusion, our data 
suggest that CMV primary infection may promote tolerance to liver allografts, and CMV 
status should be considered when tapering or withdrawing immunosuppression.
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INTRODuCTION
Cytomegalovirus (CMV) is a prevalent β-herpesvirus that establishes lifelong latency 
in humans, and a leading viral infection after solid organ transplantation (1). Immune 
responses to viruses, including CMV, have been proposed as one of the main barriers to 
the achievement of transplantation tolerance (2) as they prevent tolerance induction in 
experimental animal models (3-5). However, associations between CMV infection and 
graft rejection in humans vary between different types of organ transplants and show 
inconsistent results (6). No consensus has been made on the effect of CMV infection on 
graft rejection or tolerance after liver transplantation (LT).
Acute rejection (AR) is primarily initiated by recipient T lymphocytes (T cells) that 
recognize nonself antigens derived from donor (7). T cells can be classified into different 
subsets based on their differentiation status, reflecting distinct migration patterns and 
effector functions upon antigenic stimulation. While naive (TNaive) and central memory 
(TCM) T cells proliferate robustly in response to antigen, effector memory (TEM) and 
terminally differentiated effector memory (TEMRA) T cells produce high amounts of 
pro-inflammatory cytokines and cytolytic mediators (8, 9). In addition, TNaive and TCM 
recirculate between secondary lymphoid organs, while TEM home to inflamed periph-
eral tissues (10). On one hand, accumulation of CD8+ TEMRA is a typical characteristic of 
CMV-driven immune senescence (11), which is associated with increased susceptibility of 
the elderly to infections, and poor responses to vaccinations (12, 13). On the other hand, 
CMV-specific memory T cells are hypothesized to be detrimental to allografts as they can 
be cross-reactive to allogeneic HLA (14, 15). However, no literature is available on how 
CMV infection alters T-cell alloreactivity after LT.
To address these issues, using ex vivo isolated cells from peripheral blood and liver 
allografts explanted during re-LT, we investigated the effect of CMV infection on T-cell 
differentiation and alloreactivity, as well as on γδ T-cell subset distribution, which has 
been shown to be associated with operational tolerance after LT (16-18). In addition, we 
performed a retrospective study in a cohort of 639 LT patients, to analyze the association 
of CMV infection with both early (< 6 months) and late (> 6 months) acute rejection (EAR 
and LAR).
PATIENTS AND METhODS
Study subjects
Peripheral blood samples were collected from 75 patients that underwent primary 
orthotopic LT between 2009 and 2012 at Erasmus MC, The Netherlands (Supplemental 
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Table 1). Liver allograft biopsies were obtained from explants of 10 patients that under-
went re-LT (Supplemental Table 2), and 9 heathy donor livers prior to LT.
In the retrospective analysis to study the impact of CMV on graft rejection, 639 pa-
tients that underwent LT at Erasmus MC from 1992-2010 were included. Demographic 
details of donors and recipients are summarized in Table 1. Patients were followed up 
until graft loss, death, or the end of the study period on 31 December 2011.
Immunosuppression therapies are described in Supplemental Materials and Methods.
Written informed consent was obtained from all patients before collection of samples. 
The medical ethics committee of the Erasmus MC approved this study.
Cell	isolation	and	flow	cytometry
Protocols for cell isolation, list of antibodies, and flow cytometry details are described in 
Supplemental Materials and Methods.
Quantification of alloreactive T-cell frequencies
Alloreactive T cells were analyzed by determination of activation-induced CD137 expres-
sion after allogeneic stimulation (19, 20)(Supplemental Figure 1). Protocol is described in 
Supplemental Materials and Methods.
CMV diagnostics, treatment, and patient groups
CMV serostatus of patients and donors was determined as part of the standard diagnos-
tic routine. CMV viremia was determined by CMV-DNA polymerase chain reaction (PCR) 
assay, and 50 copies/mL was considered as the threshold for positive result. Patients 
included in the ex vivo T-cell analysis were grouped as: CMV-negative (R-D-), primary 
infection (R-D+), and R+ patients. CMV primary infection was confirmed by detection of 
viremia or IgG seroconversion after LT, and CMV-negative was defined as no detection 
of viremia nor IgG seroconversion prior to blood collection (Supplemental Table 1). No 
differences in baseline characteristics were observed between groups in all experi-
ments. Detailed CMV diagnostics and treatment strategies are available in Supplemental 
Materials and Methods.
Definition of early and late acute rejection
AR was defined as graft dysfunction accompanied by moderate or severe rejection activ-
ity (RAI≥5) detected in the liver biopsy according to Banff criteria, and responsiveness to 
additional immunosuppressive treatment. While EAR was defined as rejection occurring 
within 180 days after LT, LAR was defined as those occurring after 180 days after LT. 
Associations of CMV with EAR or LAR were analyzed separately, as EAR is most common 
during the first few weeks after LT, generally preceding CMV infection.
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Table	1.	Demographic and baseline clinical characteristics of patients included in the retrospective analysis
Variable Total n=639  R- D- n=127 R- D+ n=122 R+ n=390 P-value
Recipient age, years 50 (16-71) 47 (17-68) 48 (16-71) 51 (16-67) 0.121
Recipient, female 264 (41%) 46 (36%) 54 (44%) 164 (42%) 0.039
Recipient BMI, kg/m2 25 (16-43) 24 (17-39) 24 (17-37) 25 (16-43) 0.299
Primary liver diseases     < 0.001
AHF 119 (19%) 23 (18%) 25 (20%) 71 (18%)  
HCC 64 (10%) 10 (8%) 10 (8%) 44 (11%)  
PBC/PSC/AIH 149 (23%) 40 (31%) 37 (30%) 72 (18%)  
HBV/HCV 84 (13%) 5 (4%) 2 (2%) 77 (20%)  
Alcoholic cirrhosis 71 (11%) 14 (11%) 17 (14%) 40 (10%)  
Cryptogenic cirrhosis 41 (6%) 10 (8%) 8 (7%) 23 (6%)  
Others 111 (17%) 25 (20%) 23 (19%) 63 (16%)  
Donor age, years 46 (8-78) 43 (13-73) 45 (12-72) 46 (8-78) 0.149
Donor, female 333 (52%) 49 (39%) 61 (50%) 223 (57%) 0.001
DCD donor 49 (8%) 8 (6%) 9 (7%) 32 (8%) 0.775
Cold ischemia time, minutes 470 (114-1099) 476 (120-1099) 479 (114-988) 455 (133-913) 0.441
Warm ischemia time, minutes 36 (14-143) 34 (14-106) 35 (17-143) 37 (16-129) 0.121
Re-LT 75 (12%) 15 (12%) 9 (7%) 51 (13%) 0.233
Basiliximab as induction 
immunosuppression
375 (59%) 82 (65%) 72 (59%) 221 (57%) 0.290
Calcineurin inhibitor     0.645
Cyclosporin A 249 (39%) 55 (43%) 46 (38%) 148 (38%)  
Tacrolimus 367 (57%) 70 (55%) 68 (58%) 229 (59%)  
CMV prophylaxis  104 (16%) - 104 (85%) - < 0.001
CMV viremia 145 (23%) 4 (3%) 59 (48%) 82 (21%) < 0.001
Timing of CMV viremia detection 
after LT, days
35 (2-2502) 30 (17-35) 45 (22-288) 31 (2-2502) 0.001
Timing of first CMV viremia after 
LT < 180 days
134 (92%) 4 (100%) 54 (92%) 76 (93%) 0.703
Peak CMV-DNA copy number, 
copies/mL*
2.8 (1.8-6.8) 5.0 (4.0-6.8) 2.7 (1.8-5.3) 2.8 (1.9-6.5) 0.031
CMV IgG seroconversion** 97 (20%) 14 (14%) 83 (86%) - < 0.001
Early acute rejection 144 (23%) 26 (20%) 29 (24%) 89 (23%) 0.805
Timing of early acute rejection, 
days
9 (2-166) 8 (2-155) 9 (3-147) 8 (3-166) 0.999
Late acute rejection 41 (6%) 11 (9%) 2 (2%) 28 (7%) 0.048
Timing of late acute rejection, days 487 (186-6368) 997 (208-2967) 353 (186-521) 379 (206-6368) 0.138
* Log10 transformed
** Only patients with follow-up ≥ 180 days were taken into account (R-D- n=101, R-D+ n=97, R+ n=299; total 
n=497), and from 9 patients serology data after LT were not available (R-D- n=5, R-D+ n=4). 
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Statistical analysis
Patient baseline characteristics were summarized using median with range for continu-
ous variables and percentage for discrete variables. Differences between groups were 
compared by Pearson Chi-Square test or one-way Kruskal-Wallis test. Experimental 
data were analyzed using nonparametric Mann-Whitney U test (unpaired) or Wilcoxon 
matched pairs test (paired) when comparing two groups, and one-way Kruskal-Wallis 
test (unpaired) or Friedman test (paired) with Dunn’s multiple comparison test when 
comparing three groups. In the retrospective analysis, EAR and LAR were used as 
separate endpoints. The cumulative incidences of EAR and LAR were estimated using 
the Kaplan-Meier method with log-rank test. Analysis of risk factors for EAR and LAR was 
performed using Cox proportional-hazards regression model with likelihood ratio test. 
We first performed univariate analysis for each potential independent variable. Inde-
pendent variables with P-values less than 0.2 were included in the multivariate analysis 
together with CMV serostatus and viremia. Linearity of continuous variables and clinical 
relevant interactions were tested. Where multiple pairwise comparisons were made, a 
Bonferroni correction on the alpha level was applied. SPSS v.21 was used for statistical 
analysis, and P-values < 0.05 were considered significant.
RESuLTS
CMV-positivity	is	associated	with	the	expansion	of	effector	memory	T-cell	
subsets in peripheral blood after liver transplantation
We prospectively collected PBMC samples from 34 patients with distinct CMV status 
before, at 1 month and at 6 months after LT. Peripheral T-cell subsets were analyzed by 
flow cytometry on basis of CCR7 and CD45RO expression (Figure 1A)(10). Patients were 
grouped based on CMV status (R-D- n=7, R-D+ n=10, R+ n=17), and distribution of CD8+ 
(Figure 1B) and CD4+ (Figure 1C) T-cell subsets at three time points were compared.
The proportion of both CD4+ and CD8+ T-cell subsets remained stable in CMV-negative 
patients (R-D-). However in CMV primary infection (R-D+) and R+ patients, the propor-
tion of CD8+ TNaive and TCM decreased continuously within the first 6 months, while 
the percentages of CD8+ TEM and TEMRA increased. Particularly CD8+ T-cell subsets 
from R-D+ patients underwent the most dramatic changes, characterized by rapidly 
increasing percentage of TEMRA (pre-LT 9%, 6 months 62%; median values). When divid-
ing all patients at increased risk for CMV-replication (R-D+ and R+) by proven viremia, 
increasing percentage of CD8+ TEMRA were observed in both groups (Supplemental 
Figure 2), suggesting that the TEMRA increase was a result of CMV-positivity, rather 
than CMV-replication. However it was likely that not all viremia episodes were detected 
in R+ patients. The change in CD8+ T-cell subset distribution was a manifestation of ef-
89
CMV may promote liver transplant tolerance
5
fector memory T-cell expansion rather than a selective disappearance of naive T cells, 
as absolute numbers of TEM and TEMRA increased in R-D+ and R+ patients, while the 
absolute numbers of TNaive remained relatively stable (Supplemental Figure 3). As for 
the CD4+ compartment, the percentages of TNaive also decreased within 6 months in 
CMV primary infection and R+ patients, which was mainly compensated by an increased 
percentage of TEM. Together, these data show that CMV-positivity is associated with the 
expansion of effector memory T-cell subsets in peripheral blood after LT.
Figure	1.
Changes of circulating CD4+ and CD8+ T-cell subsets after LT in relation to patient CMV status. (A) T-cell subsets 
were defined as TNaive (CCR7+CD45RO-), TCM (CCR7+CD45RO+), TEM (CCR7-CD45RO+), and TEMRA (CCR7-CD45RO-), 
shown as representative FACS plots from one patient. Patients were grouped based on CMV status (R-D- n=7, 
R-D+ n=10, R+ n=17). Distribution of (B) CD8+ and (C) CD4+ T-cell subsets before (white), at 1 month (grey) 
and at 6 months (black) after LT were compared. Horizontal lines indicate mean values. *P<0.05, **P<0.01, 
***P<0.001.
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CD8+ T cells from CMV primary infection patients develop donor-specific 
hyporesponsiveness
We hypothesized that the expansion of effector memory T-cell subsets driven by CMV 
might increase the frequencies of alloreactive T cells, as cross-reactive viral-specific 
memory T cells are common (15). Thus we quantified the frequencies of donor-specific 
and third party-reactive T cells in 51 patients at minimum 6 months after LT by measuring 
the allogeneic activation-induced CD137 expression (Supplemental Figure 1A, B). The 
numbers of donor-recipient and third party-recipient HLA-mismatches were similar 
between groups (Supplemental Figure 4).
Overall CD8+ T cells showed donor-specific hyporesponsiveness (Figure 2A, left panel). 
We did not observe higher frequencies of alloreactive T cells in CMV primary infection 
or R+ patients than in CMV-negative patients. Unexpectedly, patients with primary infec-
tion showed prominent donor-specific hyporesponsiveness in CD8+ T cells (Figure 2B, 
left panel), which was evident in TNaive, TCM and TEM (Figure 2C). In contrast, no 
donor-specific hyporesponsiveness was observed in CMV-negative patients, while in R+ 
patients significant donor-specific hyporesponsiveness was only observed in TEM. CD4+ 
T cells did not show any significant donor-specific hyporesponsiveness (Figure 2A, right 
panel), and the frequencies of alloreactive CD4+ T cells were also similar in patients with 
distinct CMV status (Figure 2B, right panel).
When focusing on patients with proven viremia, donor-specific hyporesponsiveness 
was only seen in R-D+ patients, and the frequency of donor-specific CD8+ T cells in R-D+ 
patients were lower than that in R+ patients (Supplemental Figure 5), indicating that the 
donor-specific hyporesponsiveness was not due to CMV-replication as such. However, 
the peak CMV-DNA copy number tended to be negatively associated with the frequency 
of donor-specific CD8+ T cells (P=0.06), but not with third-party reactive CD8+ T cells or 
alloreactive CD4+ T cells (Supplemental Figure 6).
Furthermore, we assessed the subset composition of alloreactive CD8+ T cells 
(CD8+CD137+ T cells) (Supplemental Figure 1B). Compared to CMV-negative and R+ 
patients, donor-specific T cells from patients with CMV primary infection were predomi-
nantly TEMRA (R-D- 29.7%, R-D+ 57.7%, R+ 33.1%; mean values) (Figure 2D, E), which is 
possibly due to the robust donor-specific hyporesponsiveness in other subsets except 
for TEMRA.
CD8+ TEMRA are a minor T-cell population infiltrating liver allografts
As TEMRA were the major CD8+ T-cell subset present in peripheral blood after LT and 
comprised the majority of residual donor-specific CD8+ T cells in patients with CMV 
primary infection, we wondered whether CD8+ TEMRA are abundantly present in liver 
allografts and thereby contribute to allograft rejection. To investigate this, we isolated 
intrahepatic lymphocytes (IHLs) from liver allografts which were explanted during re-LT 
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Figure	2.
CMV primary infection is associated with the development of donor-specific CD8+ T-cell hyporesponsiveness 
after LT. The frequencies of peripheral alloreactive CD8+ and CD4+ T cells were analyzed by flow cytometric 
determination of CD137 expression on T cells after allogeneic stimulation. (A) Overall frequencies of donor-
specific and third party-reactive CD8+ (left panel) and CD4+ (right panel) T cells were compared (n=51). Al-
loreactive T-cell frequencies of (B) total CD8+ (left panel) and CD4+ (right panel) T cells, and of each (C) CD8+ 
T-cell subset were compared between patients with different CMV status (R-D- n=18, R-D+ n=15, R+ n=18). 
Horizontal lines indicate median values. Subset composition of alloreactive CD8+ T cells was assessed by 
measuring CD45RO and CCR7 expression on CD137+CD8+ T cells. (D) Proportions of each T-cell subset within 
donor-specific and third party-reactive CD8+ T cells are shown as median values and interquartile ranges, (E) 
and summarized as pie charts presenting mean proportions. *P<0.05, **P<0.01, ***P<0.001.
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(n=10; Supplemental Table 2). IHLs isolated from heathy donor livers prior to LT were 
used as healthy control. IHLs contained mainly CD4+ and CD8+ TEM and hardly any TNaive 
and TCM (Figure 3A, B). CD8+ TEMRA were present in the liver allografts but accounted 
for a significantly smaller proportion than in paired PBMC samples and IHLs of healthy 
donor livers (Figure 3B). The ratio of CD8+ TEM and TEMRA in liver allografts was 5-fold 
Figure	3.
CD8+ TEMRA are a minor T-cell population infiltrating liver allografts. Intrahepatic lymphocytes (IHLs) were 
isolated from explant liver allografts to study the subset composition of graft infiltrating T cells. CD8+ and CD4+ 
T-cell subsets of IHLs of explant allografts (n=10) were compared to those of paired PBMCs, and IHLs of healthy 
donor livers (n=9), and are shown (A) as representative FACS plots (PBMCs and paired explant IHLs) from one 
patient and (B) are summarized. (C) Ratios CD8+ TEM and TEMRA were also compared between groups. Large 
amounts of IHLs were isolated from two explant allografts and were co-cultured with donor and third-party 
splenocytes. Donor-specific and third party-reactive T cells were identified by CD137 upregulation. (D) Results 
are shown by FACS plots and percentages of CD137+ T cells for each subset are depicted in the plots for both 
allografts. *P<0.05, **P<0.01.
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higher than that in peripheral blood, and 1.7-fold higher than that in healthy donor livers 
(median values, Figure 3C). Explant allografts with AR activity tended to have lower per-
centages of CD8+ TEMRA and a higher CD8+TEM/TEMRA ratio (Supplemental Figure 7). 
Sufficient amounts of IHLs were isolated from two of the liver explants to measure their 
allogeneic responses (Figure 3D). CD8+ TEM were enriched for donor-specific T cells, as 
20% and 33.9% of CD8+ TEM from these two IHLs samples, respectively, were reactive 
to donor splenocytes, while 8.8% and 7.5% of them responded to third-party stimulation 
(CD137 expression in conditions without stimulation were subtracted). In contrast, CD8+ 
TEMRA contained less alloreactive cells than TEM. Altogether, these data indicate that 
TEM preferentially infiltrate liver allografts, while CD8+ TEMRA largely remain in the 
circulation.
CMV	R-D+	status	is	associated	with	the	protection	against	late	acute	rejection
To study whether the donor-specific T-cell hyporesponsiveness that we observed in CMV 
primary infection patients has any clinical impact, we performed a retrospective study 
on 639 patients that underwent LT in our center between 1992 and 2010 to investigate 
the impact of CMV infection on EAR and LAR. One, 3 or 6 months have been variably 
used in literature as the cut-off to define EAR and LAR (21). The first episodes of CMV 
viremia were detected at median 35 days after LT, 92% of which were within the first 6 
Figure	4.
CMV R-D+ status is associated with the protection against late acute rejection. Patients were grouped based 
on CMV serostatus before LT as follows: Group 1: R-D-; Group 2: R-D+; Group 3: R+. The cumulative incidences 
of (A) early acute rejection (EAR) and (B) late acute rejection (LAR) were estimated using the Kaplan-Meier 
method and differences between curves were analyzed using the log-rank test. The number of patients at risk 
are depicted below the graphs.
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months (Table 1). Thus we choose 6 months as the cut-off to define LAR in order to focus 
on the effect of CMV infection on graft rejection and not the other way around. Of the 
639 patients, 144 (22.5%) developed EAR (median 9 days; range 2-166 days), and 41 (6.4%) 
developed LAR (median 487 days; range 186-6368 days) (Table 1).
EAR and LAR were set as separate endpoints for risk factor analysis. CMV serostatus 
was not associated with the cumulative incidence of EAR (P=0.77) (Figure 4A), while the 
incidence of LAR in R-D+ patients was lower than in R-D- patients (P=0.014) and R+ pa-
tients (P=0.017) (Figure 4B). In univariate Cox regression analysis, recipient age (P=0.007), 
recipient BMI (P=0.026), female donor (P=0.034), warm ischemia time (P<0.001), basilix-
imab induction (P<0.001), tacrolimus as CNI (P<0.001), and CMV viremia (P=0.008) were 
Table	2.	Risk factor analysis for late acute rejection following liver transplantation
 
Variable
univariate analysis Multivariate	analysis
hR 95% CI P Value hR 95% CI P Value
Recipient age, year 0.99 (0.97-1.02) 0.455    
Recipient, female 1.29 (0.70-2.39) 0.416    
Recipient BMI, kg/m2 1.04 (0.97-1.12) 0.309    
Primary liver disease   0.189   0.217
HBV/HCV (Ref) 1.00   1.00   
AHF 1.45 (0.49-4.34)  1.75 (0.57-5.44)  
HCC 0.29 (0.03-2.50)  0.35 (0.04-2.99)  
PBC/PSC/AIH 1.54 (0.56-4.29)  1.90 (0.67-5.43)  
Alcoholic cirrhosis 0.49 (0.10-2.54)  0.61 (0.12-3.16)  
Cryptogenic cirrhosis 2.04 (0.59-7.07)  2.22 (0.63-7.87)  
Others 0.81 (0.24-2.81)  1.05 (0.30-3.72)  
Donor age, year 0.99 (0.97-1.01) 0.239    
Donor, female 1.35 (0.72-2.51) 0.342    
DCD donor 1.43 (0.44-4.65) 0.575    
Cold ischemia time, 10 min 0.99 (0.97-1.01) 0.344    
Warm ischemia time, 10 min 1.01 (0.89-1.15) 0.877    
Re-LT 0.94 (0.33-2.63) 0.900    
Basiliximab induction 0.97 (0.51-1.85) 0.920    
Calcineurin inhibitor, Tacrolimus 0.63 (0.34-1.19) 0.154 0.69 (0.36-1.31) 0.258
Early acute rejection 0.90 (0.44-1.86) 0.781    
CMV serostatus   0.015   0.015
R- D- (Ref) 1.00   1.00   
R- D+ 0.18 (0.04-0.81)  0.18 (0.04-0.86)  
R+ 0.87 (0.43-1.76)  0.99 (0.47-2.05)  
CMV viremia 0.87 (0.42-1.83) 0.711 1.10 (0.50-2.43) 0.813
Peak copy number during viremia 1.07 (0.55-2.09) 0.846
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significantly associated with EAR (Supplemental Table 3). Meanwhile, CMV serostatus 
(P=0.015) was the only factor associated with LAR (Table 2).
In the multivariate Cox regression analysis, recipient age (P=0.046, hazard ratio 
[HR]=0.99), female donor (P=0.020, HR=0.67), basiliximab induction (P=0.015, HR=0.59), 
tacrolimus as CNI (P<0.001, HR=0.47), and CMV viremia (P=0.018, HR=1.62) were con-
sidered as independent factors associated with EAR (Supplemental Table 3). In contrast, 
CMV serostatus was the only independent factor associated with LAR (P=0.015; HR for 
R-D+=0.18; HR for R+=0.99) (Table 2). CMV seroconversion and the use of CMV prophy-
laxis were not included in the analysis as they largely overlapped with R-D+ status, and 
yielded the same association as R-D+ status (data not shown). Altogether, these data 
indicate that CMV primary infection after LT protects patients against the occurrence of 
LAR, corroborating the ex vivo data on donor-specific T-cell hyporesponsiveness that we 
observed in CMV primary infection patients.
CMV	primary	infection	patients	show	the	highest	Vδ1/Vδ2	γδ	T-cell	ratio	after	LT
To further investigate whether patients with CMV primary infection show signs of toler-
ance, we measured peripheral Vδ1 and Vδ2 γδ T-cell subsets in patients at minimum 6 
months after LT, and calculated the Vδ1/Vδ2 γδ T-cell ratio, which has been shown to be 
associated with operational tolerance after LT (16-18). CMV primary infection patients 
contained the highest percentage of Vδ1 γδ T cells within peripheral CD3+ cells, while 
CMV-negative patients contained the lowest (R-D- 0.73%, R-D+ 5.36%, R+ 2.29%; median 
values) (Figure 5A). In contrast, the percentages of Vδ2 γδ T cells were similar (R-D- 0.56%, 
R-D+ 0.27%, R+ 0.39%; median values) (Figure 5B). As a result, patients with CMV primary 
infection showed higher Vδ1/Vδ2 γδ T-cell ratio than the other two groups (R-D- 1.39, 
R-D+ 10.81, R+ 6.31; median values) (Figure 5C).
Figure	5.
CMV primary infection patients show the highest peripheral Vδ1/ Vδ2 γδ T cell ratio after LT. Peripheral blood 
Vδ1 and Vδ2 γδ T-cell subsets were analyzed by flow cytometry in LT patients. The percentages of (A) Vδ1 and 
(B) Vδ2 γδ T cells within total CD3+ T cells, and (C) the subsequent Vδ1/ Vδ2 γδ T-cell ratio were compared 
between patients with different CMV status (R-D- n=20, R-D+ n=20, R+ n=27). Horizontal lines indicate median 
values. ***P<0.001.
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DISCuSSION
Immune responses resulting from viral infections are proposed to promote allograft 
rejection and prevent the establishment of tolerance (14). Cross-reactive viral-specific 
memory T cells are common in humans. Approximately 45% of viral-specific, including 
CMV-specific, T-cell clones are cross-reactive to at least one allogeneic HLA molecule 
(15). Unexpectedly, and contrary to our initial hypothesis, we did not find higher frequen-
cies of alloreactive T cells in either R+ patients or patients who developed CMV primary 
infection. In contrast, we found a robust donor-specific CD8+ T-cell hyporesponsiveness 
in patients with CMV primary infection. In accordance with the donor-specific hypore-
sponsiveness, retrospective analysis showed that LT patients with R-D+ serostatus had 
a significantly lower risk to develop LAR. Moreover, CMV primary infection patients 
showed the highest ratio of peripheral Vδ1/Vδ2 γδ T cells, which has shown to be as-
sociated with operational tolerance after LT. This is the first study showing that CMV 
primary infection remarkably reduces donor-specific T-cell reactivity and is a protective 
factor against the occurrence of LAR, suggesting a prominent role for CMV infection in 
transplant tolerance to liver allografts in humans.
We first found that CMV-positivity, particularly CMV primary infection, is associated 
with the expansion of CD8+ effector memory T-cell subsets in peripheral blood after LT. 
Since TEM and TEMRA subsets can mount rapid effector responses upon allostimulation 
(8), they are hypothesized to be detrimental to allografts (22). Nonetheless we do not 
support a detrimental role of CD8+ TEMRA for LT patients, as our data suggest that CD8+ 
TEMRA rarely infiltrate liver allograft but largely remain in circulation. A recent study 
shows that increased numbers of circulating CD8+ TEMRA before kidney transplantation 
are associated with a reduced incidence of AR (23). Similarly, few CD8+ TEMRA were 
found in rejecting kidney allografts (24). However we cannot rule out the possibility that 
TEMRA may change their phenotype into TEM upon infiltration.
An intriguing question is how CMV infection induces donor-specific T-cell hypore-
sponsiveness. CMV infection is known to drive immunosenescence, which has been 
suggested to promote kidney allograft acceptance in elderly recipients (25). Immunose-
nescence driven by CMV is manifested by inflation of CMV-specific effector memory T 
cells. It has been postulated that the massively expanded CMV-specific effector memory 
T-cell pool competes with newly generated T cells for niches and survival factors, and 
as a consequence T-cell diversity and responses to other pathogens are restricted (26, 
27). Indeed both in humans and mice CMV infection causes impaired T-cell immunity to 
other pathogens (28, 29), and CMV infection after organ transplantation is associated 
with a higher incidence of opportunistic infections (30). This is supported by previous 
findings showing that high numbers of CMV-IE-1-specific memory T cells are associated 
with lower numbers of alloreactive T cells and improved renal allograft function after 
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kidney transplantation (31), and that high CMV-specific CD4+ T-cell responses correlate 
with protection from cardiac allograft rejection (32). We hypothesize that the donor-
specific T-cell hyporesponsiveness observed in CMV primary infection patients might be 
related to the multifaceted immune evasion capacity used by CMV to establish latency, 
in particular its capacity to modulate antigen presentation (33). Alexander et al. reported 
the development of hematopoietic chimerism and donor-specific hyporesponsiveness in 
a patient with severe CMV disease early after LT (34). We also reported three cases of 
long-term hematopoietic chimerism within liver allografts (35), and interestingly all three 
patients were R+D+ with detection of viremia in two of them (unpublished data). The 
immune-modifying effects of CMV may have contributed to the engraftment of donor 
cells, leading to subsequent donor-specific hyporesponsiveness. Moreover, dendritic 
cells present in liver graft are the main instigators of T-cell immunity against the graft 
(36, 37), but CMV infected dendritic cells are impaired in their ability to stimulate al-
logeneic lymphocytes (38). The immunomodulatory effect of primary infection has also 
been suggested, shown by higher bacterial and fungal infection-related mortality in R-D+ 
patients after allogeneic hematopoietic stem cell transplantation, which is independent 
from CMV-replication, diseases and treatments (39). We hypothesize that the rapidly 
inflated anti-CMV immunity following primary infection in an immunocompromised en-
vironment, may contribute to its immunomodulatory effect. The exact mechanisms 
attributing to this phenomenon remain to be investigated.
In the retrospective analysis, we found that CMV viremia was positively associated 
with EAR. However, EAR occurred on median 9 days after LT, preceding the detection 
of CMV viremia in general. This finding is in line with the hypothesis that alloimmune 
stimulation triggers CMV-replication from latency (40). Heavy immunosuppression 
during EAR treatment may also increase the risk of CMV viremia. In the multivariate 
analysis older patient age decreased the risk of EAR, which could be explained by the 
senescence of immune system (25, 41). The use of basiliximab induction and tacrolimus 
both decreased the risk of EAR, which is in line with previous findings (42, 43). Patients 
with female donors had a decreased incidence of EAR. However this could be a finding by 
chance, as previous studies showed that donor gender does not influence AR incidences. 
In contrast, we found that CMV R-D+ serostatus was an independent protective factor 
against LAR. Despite antiviral prophylaxis, the rate of seroconversion in R-D+ patients 
was 86%, in agreement with previous study (44), indicating that almost all R-D+ patients 
get primarily infected eventually. LAR was not associated with viremia or peak CMV-DNA 
copy number, suggesting that the lower incidence of LAR was not due to CMV-replication 
as such. We cannot exclude an effect of prophylaxis, however it is unlikely since higher 
dosages of valGCV or GCV were administrated in case of CMV viremia, but viremia was 
not associated with lower incidence of LAR. As there is no indication that in R-D- or R+ 
patients immunosuppression was prescribed differently hence affecting the occurrence 
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of LAR, the lower incidence of LAR is probably a reflection of the pro-tolerogeneic status 
of the patients with CMV primary infection. The discrepancy of EAR and LAR in relation 
to CMV infection indicates that CMV during active replication or in a quiescent state may 
have differential effects on graft rejection. Careful distinguishing CMV primary infection 
from non-primary infection, and between EAR and LAR in our analysis, may be possible 
reasons why this association has never been reported before.
Immunosuppression can be completely discontinued in more than 40% of stable, 
adult LT patients (45, 46). Whether CMV infection plays a role in achieving operational 
tolerance has yet not been investigated. However, studies sought to identify biomark-
ers for operational tolerance have found expansion of peripheral Vδ1 γδ T cells, and an 
increased Vδ1/Vδ2 ratio in tolerant LT patients. Vδ1/Vδ2 ratio has even been used as 
a surrogate marker to predict operational tolerance (16-18). Interestingly, expansion of 
Vδ1 γδ T cells is also a feature that is observed upon CMV infection (47, 48), arguing in 
favour of a potential association between CMV infection and liver graft tolerance. In ad-
dition to previous findings, we found that patients with CMV primary infection showed 
the highest Vδ1/Vδ2 ratio. This finding corroborates the lower incidence of LAR in our 
retrospective analysis and suggests that these patients may have the highest chance to 
achieve operational tolerance after immunosuppression discontinuance. Since we do 
not minimize immunosuppression routinely, we are not able to demonstrate a direct link 
between CMV infection and operational tolerance.
There are limitations of this study that need to be acknowledged. First, we focused on 
allogeneic T-cell responses in LT patients with different CMV status, however anti-CMV 
responses were not studied, which could help understanding the interplay between al-
logeneic and anti-viral immune responses (31). Second, we were not able to demonstrate 
the direct link between the donor-specific T-cell hyporesponsiveness and the lower inci-
dence of LAR in primary infection patients, as the overall incidence of LAR was low and 
we did not have enough PBMC samples available from LAR patients. A case-control study 
comparing LAR cases to patients with stable graft function, or a large-scale prospective 
study with long follow-up, may reveal the direct relationship between T-cell responses 
and LAR.
To conclude, the primary findings of this study are that patients with CMV primary in-
fection after LT show donor-specific CD8+ T-cell hyporesponsiveness, are protected from 
the occurrence of LAR, and show signs of operational tolerance. Further investigation 
into the role of CMV infection in the development of operational tolerance is necessary. 
Since CMV status is easily measured without additional effects or costs, this parameter 
can be taken into account by physicians when selecting patients for tapering or with-
drawing immunosuppressive therapy in LT patients. Altogether, for the first time to our 
knowledge, we show evidences that CMV primary infection may promote immunological 
tolerance towards allogeneic liver graft in humans.
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Supplemental	Table	1.	Characteristics of patients included for peripheral blood T-cell analysis
Total:	75	patients R- D- (n=20)
 
R- D+	(n=20)
 
R+	(n=35)
 
P value
 Recipient
 Age (median, range), years 54 (33-65) 48 (21-64) 54 (19-68) 0.190
 Sex, female 7 (35%) 10 (50%) 14 (40%) 0.614
Donor     
 Age (median, range), years 48 (16-64) 58 (22-73) 51 (13-78) 0.118
 Sex, female 8 (40%) 13 (65%) 15 (43%) 0.202
Primary liver disease*    0.831
 AHF 1 (5%) 4 (20%) 4 (11%)  
 HBV/HCV 1 (5%) 1 (5%) 3 (9%)  
 HCC 3 (15%) 3 (15%) 9 (26%)  
 Metabolic diseases 2 (10%) 1 (5%) 3 (9%)  
 PSC/PBC/AIH 9 (45%) 6 (30%) 8 (23%)  
 other 4 (20%) 5 (25%) 8 (23%)  
Initial immunosuppressive regimen     
 Basiliximab 16 (80%) 19 (95%) 29 (83%) 0.347
 Tacrolimus 20 (100%) 20 (100%) 33 (94%) 0.309
 Mycophenolate mofetyl 16 (80%) 13 (65%) 25 (71%) 0.569
Early acute rejection 4 (20%) 3 (15%) 6 (17%) 0.916
Late acute rejection 1 (5%) 1 (5%) 1 (3%) 0.894
CMV viremia 0 (0%) 17 (85%) 10 (29%) 0.000
Timing of viremia (median, range), days - 79 (23-288) 27 (12-60) 0.003
Peak CMV-DNA copy number, copies/mL** - 2.9 (1.9-5.0) 2.5 (2.1-5.5) 0.628
CMV IgG seroconversion 0 (0%) 20 (100%) - 0.000
*AHF, acute hepatic failure; HCC, hepatocellular carcinoma; HBV, hepatitis B virus infection; HCV, hepatitis C 
virus infection; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis.
**Log10 transformed
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Supplemental	Table	2.	Characteristics of patients studied for liver allograft infiltrating T cells
Patient	
no. Age Sex
Time since 
first	LT Re-LT	indication RAI score
CMV 
status
1 66 M 7 months Hepatic artery thrombosis and HCV 
recurrence
7 R+ D-
2 40 M 6 years PSC recurrence 4 R- D-
3 67 M 3 years Chronic rejection 3-4 R+ D+
4 59 M 8 years HCV recurrence - R+ D-
5* 56 M 1 year Chronic rejection - R+ D+
6 56 F 1 year Ischemic cholangiopathy - R- D+
7 38 M 24 years Chronic rejection 4 R- D-
8* 29 M 6 years Chronic rejection - R+ D+
9 56 M 2 years Chronic rejection 3-4 R+ D-
10 50 M 2 years PSC recurrence - R+ D-
* Large amount of IHLs were isolated for functional experiments
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Supplemental	Table	3.	Risk factor analysis for early acute rejection following liver transplantation
 
Variable
univariate analysis Multivariate	analysis
hR 95% CI P Value hR 95% CI P Value
Recipient age, year 0.98 (0.97-0.99) 0.007 0.99 (0.97-1.00) 0.046
Recipient, female 1.26 (0.91-1.76) 0.164 1.14 (0.81-1.60) 0.448
Recipient BMI, kg/m2 0.96 (0.92-1.00) 0.026 0.98 (0.94-1.02) 0.375
Primary liver disease   0.415    
HBV/HCV (Ref) 1.00      
AHF 1.40 (0.78-2.53)     
HCC 0.95 (0.46-1.96)     
PBC/PSC/AIH 1.27 (0.72-2.24)     
Alcoholic cirrhosis 0.82 (0.39-1.72)     
Cryptogenic cirrhosis 0.64 (0.25-1.63)     
Others 1.10 (0.60-2.03)     
Donor age, year 0.99 (0.98-1.00) 0.192 1.00 (0.99-1.01) 0.904
Donor, female 0.70 (0.50-0.98) 0.034 0.67 (0.47-0.94) 0.020
DCD donor 0.50 (0.22-1.14) 0.065 0.91 (0.39-2.11) 0.820
Cold ischemia time, 10 min 1.01 (1.00-1.02) 0.067 1.00 (0.99-1.01) 0.354
Warm ischemia time, 10 min 1.19 (1.12-1.26) 0.000 1.05 (0.97-1.15) 0.249
Re-LT 0.85 (0.50-1.45) 0.535    
Basiliximab induction 0.39 (0.28-0.55) 0.000 0.59 (0.39-0.90) 0.015
Calcineurin inhibitor, Tacrolimus 0.36 (0.26-0.50) 0.000 0.47 (0.32-0.71) 0.000
CMV serostatus   0.773   0.856
R-/D- (Ref) 1.00   1.00   
R-/D+ 1.20 (0.71-2.04)  0.92 (0.51-1.67)  
R+ 1.14 (0.74-1.76)  1.05 (0.66-1.66)  
CMV viremia 1.62 (1.14-2.28) 0.008 1.62 (1.09-2.39) 0.018
Peak CMV-DNA copy number 1.17 (0.85-1.63) 0.352
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Supplemental	Figure	1.
Determination of allogeneic activation-induced CD137 expression on CD4+ and CD8+ T cells to study the fre-
quencies and subset composition of alloreactive T cells by flow cytometry. (A) AQUA staining was used to 
exclude dead cells, and stimulatory splenocytes were labeled by PKH26 and were excluded from the analysis. 
(B) Alloreactive CD4+ and CD8+ T cells were identified by the up-regulation of CD137 after 24 hours of co-
culture. Subset composition of alloreactive T cells was analyzed by measuring the expression of CCR7 and 
CD45RO on CD137+ T cells, and was defined as follows: TNaive (CCR7+CD45RO-), TCM (CCR7+CD45RO+), TEM 
(CCR7-CD45RO+), and TEMRA (CCR7-CD45RO-). All events in culture were recorded to ensure the detection 
of alloreactive T cells. Background expression of CD137 in conditions without allogeneic stimulation was sub-
tracted during analysis.
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Supplemental	Figure	2.
Comparison of CD8+ TEMRA changes in CMV-positive patients with or without proven viremia. Viremia was 
detected in 16 of 27 CMV-positive patients (R-D+ and R+). We compared the percentages of CD8+ TEMRA be-
fore (Pre), at 1 month (1M) and at 6 months (6M) after LT (one-way Friedman test) in both groups. Horizontal 
lines indicate median values. *P<0.05, **P<0.01, ***P<0.001.
Supplemental	Figure	3.
Changes in absolute numbers of CD8+ T-cell subsets after LT in relation to CMV status. Absolute numbers of 
CD8+ T-cell subsets were measured longitudinally in 11 patients (R-D- n=3, R-D+ n=4, R+ n=4) before (Pre), at 1 
month (1M) and at 6 months (6M) after LT. Black dots represent patients without detected viremia, and black 
triangles represent patients with detected CMV viremia after LT. Absolute numbers are shown on the Y-axis.
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Supplemental	Figure	4.
Numbers of HLA-mismatches between donor-recipient and third party-recipient in ex vivo allogeneic stimula-
tions. The total numbers of HLA-mismatches at HLA-A, B, DR loci between donor-recipient and third party-
recipient in the ex vivo allogeneic stimulation experiments are shown as mean with standard deviation, and 
were compared between the three experimental groups. No statistically significant difference was observed.
Supplemental	Figure	5.
Alloreactive CD8+ T-cell frequencies in patients with proven viremia. The frequencies of donor-reactive and 
third party-reactive CD8+ T cells were compared between R-D+ patients with viremia and R+ patients with 
viremia. Horizontal lines indicate median values. *P<0.05, **P<0.01.
Supplemental	Figure	6.
Correlation of alloreactive T-cell frequencies with CMV viremia level. In patients with proven viremia, the 
correlation between alloreactive T-cell frequencies and the peak CMV-DNA copy number during viremia was 
analyzed by linear regression. The CMV-DNA copy number was log10-transformed.
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Supplemental	Figure	7.
Comparison of CD8+ T-cell subsets in explant allografts with or without acute rejection activity. Five explant al-
lografts presented acute rejection activity (AR, versus no-AR). (A) Percentages of intragraft CD8+ TEM, TEMRA, 
and (B) the subsequent ratio were compared (Mann-Whitney U test). Horizontal lines indicate median values.
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SuPPLEMENTAL MATERIAL AND METhODS
Immunosuppression
The standard immunosuppressive therapy in our center consisted of prednisone, cyclo-
sporine or tacrolimus, with or without azathioprine or mycophenolate mofetil (MMF). 
Since 1998, basiliximab was introduced as induction immunosuppression and was used 
in 58.7% of all patients in the retrospective cohort (Table 1), and meanwhile the use of 
cyclosporine was gradually replaced by tacrolimus. Tacrolimus was initiated within the 
first 5 days after transplantation in a dose of 1-2 mg/kg body weight/day. The target 
trough level was 10-15 ng/ml in the first month, 8-12 ng/ml between 1 to 6 months, 5-10 
ng/ml between 6 to 12 months, and 4-8 ng/ml after 1 year. Cyclosporine was initiated 
within 24 hours post-reperfusion in a dose of 10-15 mg/kg body weight/day, and the 
dosage was adjusted to trough levels according to a range from 200-400 ng/mL during 
the first 3 months and thereafter 100-200 ng/mL. Acute rejection episodes were treated 
with high dose of methylprednisolone intravenously, and standard levels of immunosup-
pression were applied again after the rejection resolved. Immunosuppressive regimens 
were similar in patients from whom blood samples were collected, consisting of cortico-
steroids, MMF, tacrolimus and induction with basiliximab (Supplemental Table 1).
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated by standard Ficoll gradient 
centrifugation, and were cryopreserved for phenotyping and functional experiments. To 
isolate intrahepatic lymphocytes (IHLs), biopsies of explant allografts and pre-LT healthy 
donor livers were collected in University of Wisconsin (UW) preservation solution. Fresh 
tissue was cut into small pieces and digested with 0.5 mg/mL collagenase IV (Sigma-
Aldrich, St. Louis, MO) and 0.1 mg/mL DNase I (Roche, Indianapolis, IN) for 30 minutes at 
37°C. Cell suspensions were filtered through 70 µm cell strainers and IHLs were obtained 
by Ficoll density gradient centrifugation. Phenotyping and functional experiments were 
performed immediately after IHLs isolation.
Human splenocytes were isolated from splenic tissue derived from liver donors. 
Splenic samples were cut into small pieces and forced through 74 μm netwell filters 
(Costar, Corning International, NY) to obtain single cell suspensions. Mononuclear cells 
were isolated by standard Ficoll gradient centrifugation, and were cryopreserved for 
future experiments.
Flow	cytometry	and	antibodies
The following antibodies were used: CD3-HorizonV500, CD4-APC-H7, CD8-Pacific Blue 
(BD Biosciences, San Diego, CA); TCR-Vδ1-FITC (Thermo Scientific, Waltham, MA); CD3-
Pacific Blue, TCR-Vδ2-PE (BD Pharmingen, Erembodegem, Belgium); CD45RA-PE-Vio770 
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(Miltenyi Biotec, Bergisch Gladbach, Germany); CCR7-FITC (R&D System, Minneapolis, 
MN); CD45RO-PerCP-Cy5.5, CD137-APC (Biolegend, San Diego, CA); CD3-PE-Cy7, TCR-
αβ-APC (eBioscience, San Diego, CA); CD3-FITC (Beckman Coulter, Marseille, France). 
Non-viable cells were excluded using 7-AAD (BD Biosciences, San Diego, CA) or LIVE/
DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Carlsbad, CA). Flow cytometry was 
performed on FACSCanto II flow cytometer (BD Biosciences, San Diego, CA). Data were 
analyzed with BD FACSDiva software version 6.1.1.
Quantification of alloreactive T-cell frequencies
Alloreactive T cells were analyzed by determination of activation-induced CD137 expres-
sion on T cells, as previously described with minor modifications (1). In brief: 2.5x106 
PBMCs or intra-hepatic lymphocytes (IHLs) were co-cultured with donor or third-party 
(mismatched at HLA-A, B and DR loci with both donor and recipient) splenocytes at a 1:1 
ratio in polypropylene tubes (BD Pharmingen, Erembodegem, Belgium) in duplicate, in 
1 mL IMDM (Lonza, Breda, The Netherlands) supplemented with 10% heat-inactivated 
human serum and 1% Penicilline/Streptomycine. Co-stimulaton was provided by addition 
of 1 μg/mL anti-CD49d (BD Pharmingen, Erembodegem, Belgium) and 1 μg/mL anti-CD28 
(Serotec, Kidlington, Oxford, UK). Prior to co-culture, the splenocytes were labeled with 
PKH26 (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions, to 
discriminate between stimulator splenocytes and responder PBMCs or IHLs during FACS 
analysis. As a control, cells were cultured in the presence of anti-CD49d and anti-CD28 
mAb only, without allogeneic stimulation. After 24 hours, cells were harvested for 
FACS analysis. Alloreactive CD4+ and CD8+ T cells were identified by the upregulation of 
CD137 (Supplemental Figure 1). Background expression of CD137 in conditions without 
allogeneic stimulation was subtracted during analysis. This assay has been used in the 
identification and isolation of viral, tumor, and allospecific T cells regardless of their dif-
ferentiation stage or cytokine production profile (1, 2).
CMV diagnostics and treatment strategies
CMV-DNA PCR measurements were only performed on a weekly basis in high risk patients 
(R-D+) until 90 days post-LT. For all other patients, PCR was performed in case of clinical 
suspicion of CMV infection. Due to the non-protocolized CMV-DNA PCR monitoring, the 
incidence of CMV reactivation/reinfection in R+ patients was probably underestimated. 
Low-dose (450 mg once daily) valganciclovir (valGCV) prophylaxis was administered to 
high risk patients, starting at day 7 and continuing up to day 90 post-LT. A therapeutic 
GCV-based regime, either intravenous GCV 5 mg/kg twice daily or valGCV 900 mg twice 
daily, was given to patients with positive PCR results. The regimen was given for 10 to 14 
days, and PCR results were negative before withdrawing GCV therapy. Adjustments of 
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immunosuppressive therapy were made if necessary, and normal levels of immunosup-
pression were applied again after the clearance of viremia.
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ABSTRACT
Chronic presence of viral antigens can induce T-cell exhaustion, characterized by upregu-
lation of co-inhibitory receptors and loss of T-cell function. We studied whether a similar 
phenomenon occurs after liver transplantation (LTx), when there is continuous exposure 
to allo-antigen. Expression of co-inhibitory receptors on circulating CD4+ and CD8+ T cells 
was longitudinally analyzed in 19 patients until 6 months after LTx, and cross-sectionally 
in 38 patients late (1-12 years) after LTx. Expression of the co-inhibitory receptors CD160 
and CD244 on circulating CD8+ T cells was already 6 months after LTx higher than pre-LTx, 
and the elevated expression was sustained late after LTx, with CD244 showing the most 
prominent increase. The strongest upregulation of CD244 on circulating CD8+ T cells 
was observed in patients who experienced cytomegalovirus (CMV) infection after LTx. 
CMV infection was also associated with reduced CD8+ T-cell proliferation and cytotoxic 
degranulation in response to allo-antigen late after LTx. Purified CD244+ CD8+ T cells of 
LTx patients showed lower proliferative responses to allo-antigen as well as to polyclonal 
stimulation than their CD244- counterparts. In addition, the CD244+ CD8+ T-cell popula-
tion contained the majority of CMV-peptide-loaded MHC class I tetramer-binding cells. 
In conclusion, CMV infection after LTx, rather than persistence of allo-antigen, induces 
accumulation of dysfunctional CD8+CD244+ T cells in the circulation which persist on 
long-term, resulting in reduced frequencies of circulating allo-reactive CD8+ T cells. 
These results suggest that CMV infection restrains CD8+ T-cell allo-responses after LTx.
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INTRODuCTION
After liver transplantation (LTx), most patients need lifelong immunosuppression to pre-
vent rejection of the allograft, but some patients develop spontaneously immunological 
tolerance to their liver graft and can be completely withdrawn from all immunosup-
pression (1). This phenomenon occurs more frequently after LTx than in any other organ 
transplant setting (2), suggesting that the immunological alloresponse is skewed towards 
tolerance. Allograft rejection is mainly mediated by T cells of the recipient that respond 
to allogeneic donor antigens (3). In the transplantation setting, activation of allogeneic T 
cells via their T-cell receptor (TCR) is triggered by specific recognition of donor-derived 
allo-antigenic peptides presented by recipient major histocompatibility complex (MHC) 
molecules or by direct interaction of the TCR with allogeneic MHC molecules. However, 
T cells can also express co-stimulatory and co-inhibitory receptors that affect outcome 
of T-cell responses (4). Hence, these receptors might also influence the outcome of T-cell 
responses towards the allograft.
Expression of co-inhibitory receptors is upregulated on T cells in patients with chronic 
viral infections, such as hepatitis C virus (HCV) and HIV, and in patients with cancer (5-
12). High expression of co-inhibitory receptors is associated with T-cell dysfunction, or 
“exhaustion”, and in these patients virus-specific or tumor-specific T-cell responses are 
therefore impaired. T-cell exhaustion can be defined as a state of antigen-specific T-cell 
dysfunction in response to chronic persistence of high antigenic load (5). Exhausted T 
cells have poor proliferative and effector function, show sustained expression of co-
inhibitory receptors and their transcriptional state is distinct from that of functional 
effector or memory T cells (5). Several co-inhibitory receptors have been described to 
be important in inhibiting T-cell responses, among which the most well-studied are: 
Programmed Death 1 (PD1), Lymphocyte-Activation Gene 3 (LAG3), T cell immunoglobu-
lin mucin 3 (TIM3) , CD160 and CD244 (5, 6). PD1 has two ligands: PD-L1 and PD-L2 (7, 
13). PD-L1 is expressed on both hematopoietic cells (mainly on dendritic cells (DC) and 
macrophages) and non-hematopoietic cells (parenchymal cells of many organs including 
liver; and endothelial cells) (7, 14). PD-L2 expression is restricted to DC and macrophages. 
Binding of PD1 to its ligand(s) negatively regulates T-cell responses (13, 15). LAG3 is a pro-
tein closely related to CD4, and mediates negative regulation of T-cell functions through 
interactions with its ligand MHC class II to which it binds with higher affinity than CD4 
(16, 17). TIM3 inhibits CD8+ T-cell responses by interaction with its ligand galectin-9 (8, 9). 
CD160 is a glycosylphosphatidylinositol-anchored receptor that inhibits T-cell responses 
upon binding to its ligand herpes virus entry mediator (HVEM) that is expressed on both 
hematopoietic and non-hematopoietic cells (parenchymal cells) (18). CD244, also called 
2B4, can mediate both activating and inhibitory signals upon binding with its ligand CD48. 
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High levels of CD244 expression on T cells were found to be associated with inhibitory 
receptor function (10, 14, 19).
After organ transplantation, numbers of circulating T cells that react to donor allo-anti-
gen decrease over time in a majority of patients (20-22). The mechanism underlying this 
phenomenon is as yet unclear. Whether chronic stimulation by the persistence of a high 
allo-antigenic load induces upregulation of co-inhibitory receptors and exhaustion of 
donor-specific T cells, as observed during chronic viral infections, is unknown. However, 
various experimental animal studies have shown enhanced rejection and/or decreased 
graft survival after blockade of co-inhibitory receptors in organ transplanted mice. This 
implies that co-inhibitory receptors are involved in suppressing allograft rejection in 
mice (23-26). However, the role of T-cell exhaustion and co-inhibitory receptor-ligand 
interactions in human solid organ transplantation has not yet been widely studied (25).
The aim of this study was to determine whether the expression of co-inhibitory recep-
tors on circulating T cells is upregulated after LTx in humans, to analyze which clinical 
factors influence such upregulation, and to assess whether co-inhibitory receptors 
impair allogeneic T-cell responses after LTx. We hypothesized that long-term persistence 
of a high load of allo-antigens after LTx may induce exhaustion of allogeneic T-cells, char-
acterized by upregulation of co-inhibitory receptors and hyporesponsiveness of CD8+ T 
cells to allo-antigens.
MATERIALS AND METhODS
Study design and patients
Heparinized blood was collected at 1 and 6 months after transplantation from 19 primary 
liver transplant recipients who were transplanted in the Erasmus Medical Centre Rot-
terdam (The Netherlands) (early post-LTx cohort). In addition, blood was collected during 
a single regular visit at the outpatient clinic from 38 stable primary liver transplant recipi-
ents 1 to 12 years after transplantation in the Erasmus Medical Centre Rotterdam (The 
Netherlands) (late post-LTx cohort). Multi-organ transplantation patients were excluded. 
The occurrence of CMV infection (either primary infection or reactivation) after trans-
plantation was determined either by CMV DNA polymerase chain reaction (PCR) > 50 
copies/ml or by CMV IgG seroconversion. All patients gave informed consent, and the 
study was approved by the Medical Ethics Committee of the Erasmus MC. Nineteen clini-
cally healthy blood bank donors were used as healthy controls and were age-matched 
with the late post-LTx cohort.
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Cell culture
Peripheral blood mononuclear cells (PBMC) from patients and healthy individuals were 
isolated using Ficoll Hypaque density gradient centrifugation. From the same patients, 
cryopreserved PBMC collected before LTx (pre-LTx), that were available in our bio bank, 
were used for baseline measurements. Cryopreserved splenocytes, isolated according 
to standard procedures (27) from splenic tissue of liver transplant donors, were available 
in our bio bank as well. CD40-activated B cells were expanded from donor splenocytes, 
as described previously (27), and used as stimulator cells in allogeneic T-cell stimulation 
assays. Only B cells containing <1% CD3+ T cells were used. PBMC and expanded B cells 
were cryopreserved at -135°C until further use.
Flow	cytometry
Flow cytometry was performed to determine T-cell subsets and co-inhibitory receptor 
expression. For analysis of CD4+ and CD8+ T cells, isolated PBMC were stained with anti-
CD3-horizonV500 (UCHT1, BD Biosciences, Erembodegem, Belgium), anti-CD4-APC-H7 
(SK3, BD Biosciences), and anti-CD8-efluor450 (RPA-T8, eBioscience, Vienna, Austria). 
To distinguish naive and memory T-cell subsets, cells were stained with anti-CCR7-FITC 
(150503, R&D systems, Abingdon, United Kingdom) and anti-CD45RO-PerCP-Cy5.5 
(UCHL1, Biolegend, London, United Kingdom). Naive T cells (Tn) were defined as 
CD45RO-CCR7+ T cells; central memory T cells (Tcm) as CD45RO+CCR7+; effector memory 
T cells (Tem) as CD45RO+CCR7- and terminally differentiated T cells (Temra) as CD45RO-
CCR7- (28). Surface expression of co-inhibitory receptors was determined by staining 
cells with anti-CD279(PD1)-PECy7 (J105, eBioscience), anti-CD223(LAG3)-PE (polyclonal, 
R&D systems), anti-CD160-PE (688327, R&D systems) and anti-CD244-APC (eBioDM244, 
eBioscience). Flow cytometry was performed using a FACS Canto II (BD Biosciences). 
Gates for PD1 expression were set using an isotype-matched control antibody and gates 
for LAG3, CD160 and CD244 expression were set on distinct positive populations. For 
analysis FACS Diva software was used (BD Biosciences).
Allogeneic T-cell stimulation using PBMC
To quantify allo-reactive T-cell responses, PBMC were labeled with 0.5 µM CFSE (Invit-
rogen, Paisley, United Kingdom) and 1*105 recipient PBMC were stimulated with 2*105 
irradiated (30 Gy) donor-derived or third party-derived CD40-B cells. Third party CD40-
B cells were expanded from splenocytes of an individual having the same number of 
HLA mismatches with the patient as the number of mismatches between patient and 
donor, but completely mismatched with the donor on HLA-A, B, and DR (27). Co-cultures 
were performed in 96-wells U-bottom plates in a final volume of 200 μl B-cell medium 
(IMDM + 10% human serum + 1% Penicillin/Streptomycin (Gibco) + 1% Insulin/Transferrin/
Selenium (Gibco)) (27). In addition, to determine responses to polyclonal stimulation, 
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PBMC were stimulated with PHA (5μg/ml, Murex, Paris, France). Each assay was per-
formed in duplicate. Flow cytometric analysis was performed after 5 days of culture at 
37°C and 5% CO2. Cells were washed with PBS (Lonza) and staining for cell viability was 
performed using LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen), according to the 
manufacturer’s protocol. Cells were then stained with anti-CD3-PerCP-Cy5.5 (UCHT1, 
BD Biosciences), anti-CD4-APC-H7 (SK3, BD Biosciences), anti-CD8-efluor450 (RPA-T8, 
eBioscience) to distinguish T cells, and anti-CD19-horizonV500 (HIB19, BD Biosciences) to 
exclude B cells. Cytotoxic degranulation was detected using CD107a-APC (eBioscience), 
added during the last 15 hours of the co-cultures. Cells were analyzed for proliferation 
using CFSE-dilution patterns, and for phenotype on a BD FACS Canto II Flow cytometer 
(BD Biosciences, San Jose, CA). For analysis of phenotypic markers we used FACS Diva 
software (BD Biosciences). Precursor frequencies (PF), which is the proportion of the 
cells that respond to the stimulus, of allo-reactive CD4+ and CD8+ T cells were calculated 
using ModFit LT® software (Verity Software House, USA), as previously described (27). 
From duplicate assays, average PF were calculated.
Allogeneic T-cell stimulation of sorted T cells
To compare the proliferative capacities of CD8+CD244+ and CD8+CD244- T cells, post-
LTx PBMC of patients of the late cohort were thawed and labeled with 0.5 µM CFSE. 
CFSE-labeled PBMC were stained with anti-CD3-PerCP-Cy5.5 (UCHT1, BD Biosciences), 
anti-CD4-APC-H7 (SK3, BD Biosciences), anti-CD8-efluor450 (RPA-T8, eBioscience) and 
anti-CD244-APC (eBioDM244, eBioscience), and CD8+CD244+, CD8+CD244-, and CD4+ T 
cells were purified by flowcytometric sorting, using a FacsAria Cell Sorter (BD Biosci-
ences). Only cells with purity >95% were used. Purified CD8+CD244+ or CD8+CD244- T 
cells (2*104) together with purified autologous CD4+ T cells (2*104) were stimulated with 
1.6*105 irradiated (30 Gy) donor CD40-B cells or third party CD40-B cells, as described 
above. To study the role of co-inhibitory receptor-ligand interactions in allogeneic T-cell 
responses, ligands of co-inhibitory receptors were blocked by addition of neutralizing 
anti-CD270 (HVEM/TNFRSF14) (Clone 94801, R&D systems (29)), or anti-CD48 (eBio156-
4H9, eBioscience (10, 11)) antibodies, either alone or in combination to selected alloge-
neic T-cells stimulations. After 5 days of culturing, cells were stained and ModFit analyses 
were performed as described above.
Determination of CMV-specific T cells
To determine frequencies of CMV-specific CD8+ T cells in PBMC and to assess whether 
these cells expressed CD244, 1*106 PBMC were stained with a mixture of HLA-A*01:01, 
A*02:01, A*11:01, A*24:02, B*07:02, B*08:01, and B*35:01 MHC class I tetramers loaded 
with Pp50-derived, Pp65-derived and IE-derived peptides (Department of Hematology, 
Leiden University Medical Center, The Netherlands), depending on the HLA-types of 
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the patient. The following peptides were used: Pp50: VTEHDTLLY (HLA-A0101); Pp65: 
YSEHPTFTSQY (HLA-A0101), NLVPMVATV (HLA-A0201), ATVQGQNLK (HLA-A1101), 
AYAQKIFKIL (HLA-A2402), RPHERNGFTVL (HLA-B0702), TPRVTGGGAM (HLA-B0702), and 
IPSINVHHY (HLA-B3501); IE1: QIKVRVDMV (HLA-B0801) and ELRRKMMYM (HLA-B0801). 
In addition, cells were stained with anti-CD4-PerCP (clone Leu3A SK7, BD Biosciences), 
anti-CD8-Pacific Blue (clone RPA-T8, BD Biosciences) and anti-CD244-APC (eBioDM244, 
eBioscience). Flow cytometry was performed using a LSRII (BD Bioscience) and data were 
analyzed using FACS Diva software.
Statistical analysis
All data are presented as means + SEM. All data sets were tested for normal Gaussian 
distribution using the Shapiro-Wilk normality test. Significance of differences between 
paired observations was tested using the paired t-test for normally distributed data or 
the Wilcoxon signed rank test for non-normally distributed data. Differences between 
unrelated groups were tested using the Mann-Whitney U test. Statistical analyses were 
performed using GraphPad Prism (Version 5.01, GraphPad Software Inc, San Diego, CA). 
Multivariate analysis was performed using linear regression in SPSS for Windows (ver-
sion 21.0 software package). A p-value <0.05 was considered statistically significant.
RESuLTS
Rapid	and	sustained	increase	of	CD244	and	CD160	expression	on	circulating	T	
cells after LTx
To investigate whether expression of co-inhibitory receptors on T cells changed after LTx, 
we first analyzed the longitudinal course of the expression of 5 well-known co-inhibitory 
receptors, namely PD1, LAG3, TIM3, CD160 and CD244 (5), on circulating CD4+ and CD8+ T 
cells in 19 patients during the first 6 months after LTx. Patient characteristics are depicted 
in Table I and described in Materials and Methods. Because TIM3 was hardly expressed 
on T cells in any of the individuals, we excluded TIM3 from further analyses (data not 
shown). Representative FACS plots are shown in Figure 1A.
Already 1 month after LTx a slight rise in expression of PD1 on CD4+ T cells and CD244 
on CD8+ T cells was observed (Figure 1B). At 6 months post-LTx, expression of PD1 on 
CD4+ T cells had returned to baseline level, while CD244 expression on CD8+ T cells was 
further increased. In addition, expression of CD244 on CD4+ T cells and of CD160 on CD8+ 
T cells were significantly increased at 6 months post-LTx. Longitudinal LAG3 expression 
levels tended to rise at 1 month post-LTx on both CD4+ (p=0.145) and CD8+ (p=0.138) T 
cells, but at 6 months post-LTx returned to levels similar to pre-LTx (Figure 1B).
Chapter 6
122
A
B
CD3
CD
4
CD
8
CD8
CD4
PD
1
LA
G3
CD
16
0
CD
24
4
PD
1
LA
G3
CD
16
0
CD
24
4
Is
ot
yp
e
PD
1
Is
ot
yp
e
PD
1
D E
CD160
CD
24
4
C
Figure 1
Figure	1.
Expression of co-inhibitory receptors on circulating T cells after LTx. (A) Representative FACS plots showing 
analysis of co-inhibitory receptors on CD4+ and CD8+ T cells (B) Expression of co-inhibitory receptors on circu-
lating CD4+ and CD8+ T cells of 19 liver transplant recipients before (pre-LTx) and early (1-6 months) post-LTx. 
(C) Expression of co-inhibitory receptors on circulating CD4+ and CD8+ T cells of healthy controls (HC) and 38 
liver transplant recipients before (pre-LTx) and 1-12 years post-LTx. (D) Representative FACS plot showing co-
expression of CD244 and CD160 on circulating CD8+ T cells (E) Co-expression of CD244 and CD160 on circulat-
ing CD8+ T cells in patients late after LTx (n=25). Each dot represents 1 patient, and lines indicate mean with 
standard error of the mean. *p<0.05, **p<0.005, ***p<0.0005
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To establish whether the changes observed in the first 6 months after LTx were sus-
tained later after LTx, we assessed co-inhibitory receptor expression on circulating T cells 
in blood samples collected from 38 patients 1 to 12 years after LTx and compared it with 
expression before LTx. Patient characteristics are depicted in Table I. We found no sig-
nificant differences in PD1 and LAG3 expression on both CD4+ and CD8+ T cells between 
pre-LTx and post-LTX samples. However, CD160 and CD244 expression were increased 
late after LTx on both CD4+ and CD8+ T cells (Figure 1C). In addition, we found that CD160 
and CD244 were strongly co-expressed on CD8+ T cells late after LTx: CD160 was mainly 
expressed on CD244+ CD8+ T cells and almost no CD160+CD244- T cells were observed 
(Figure 1D-E). Interestingly, expression of co-inhibitory receptors on T cells did not differ 
between patients pre-LTx and healthy age-matched controls (Figure 1C), indicating that 
liver disease had no influence on expression levels of co-inhibitory receptors.
Collectively, early after LTx a slight rise in PD1 expression on CD4+ T cells was found, 
which was not sustained, while the early increase of CD160 and CD244 expression on 
both CD4+ and CD8+ T cells was sustained late after LTx. We therefore further focused on 
these two co-inhibitory receptors.
Enhanced	expression	of	CD244	and	CD160	on	circulating	T-cell	subsets	after	LTx
Since CD244 and CD160 expression is low or absent on naive T cells and increases pro-
gressively with memory differentiation state of T cells (11, 30), we assessed whether the 
distribution of circulating naive and memory T-cell subsets changed after LTx (Figure 2A; 
Materials and Methods). After LTx, a significant reduction of CD4+ and CD8+ Tn was ob-
served, while CD4+ Tem and Temra and CD8+ Temra significantly increased (Supplemen-
tal Figure 1). Therefore, to establish whether the upregulation of CD160 and CD244 after 
LTx was due to the changes in T-cell subset distribution, we determined the expression of 
these co-inhibitory receptors on each individual T-cell subset.
In the early post-LTx cohort, we observed a significant increase in CD160 expression 
on CD8+ Tcm and Tem 6 months post-LTx (Figure 2B). In the late post-LTx cohort, CD160 
expression significantly increased after LTx on CD4+ Tem and CD8+ Tcm, Tem and Temra 
(Figure 2C).
On CD4+ Tem and Temra and on all CD8+ T-cell subsets we found increasing expression 
of CD244 during the first 6 months after LTx in the early post-LTx cohort (Figure 2B). In 
the late post-LTx cohort, CD244 expression on CD4+ and CD8+ Tem and Temra increased 
significantly after LTx (Figure 2C).
Taken together, these results show that the observed upregulation of CD160 and 
CD244 expression on circulating T cells after LTx was not only caused by a shift in T-cell 
subset distribution, but was also due to increased expression on the individual T-cell 
subsets.
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Upregulation	of	CD244	on	CD8+	T	cells	after	LTx	is	associated	with	CMV	
infection
Next, we focused on the expression of CD244 and CD160 in patients late after LTx. Since 
expression of CD244 and CD160 on T cells increases with age (31) and their expression 
can also be induced by viral infections, such as HBV, HCV and CMV (5, 10, 14, 32-34) we 
first asked whether the increasing expression of these co-inhibitory receptors after LTx 
was related to age of the patients, underlying disease (including chronic viral hepatitis), 
time after LTx, or CMV infection after LTx. Importantly, for this study CMV infection was 
only regarded as relevant when occurring between LTx and collection of the post-LTx 
blood sample. Multivariate linear regression analysis showed that the increases in CD160 
and CD244 expression (delta expression = expression post-LTx minus expression pre-LTx) 
were not significantly associated with patient age, time after LTx, or underlying disease. 
However, upregulation of CD244, but not CD160, on CD8+ T cells after LTx showed a sig-
nificant positive association with CMV infection after LTx (p=0.004) (Table II). Although 
we focused on the expression of CD244 and CD160, we also analyzed the association 
B
C
Figure 2
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Figure	2.
Expression of co-inhibitory receptors on circulating CD4+ and CD8+ T-cell subsets before and after LTx. (A) 
Representative FACS plots showing the gating strategy of naive T cells (Tn), central memory T cells (Tcm), ef-
fector memory T cells (Tem), and terminally differentiated T cells (Temra) and expression of CD160 and CD244 
on circulating CD8+ T-cell subsets. (B) Expression of CD160 and CD244 on different T-cell subsets in patients 
of the early post-LTx cohort (C) Expression of CD160 and CD244 on different T-cell subsets in patients of the 
late post-LTx cohort. Each dot represents 1 patient, and lines indicate mean with standard error of the mean. 
*p<0.05, **p<0.005, ***p<0.0005
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between CMV infection and the expression of PD1 and LAG3, but no increase in their 
expression levels was found in CMV infected patients.
Figure 3A shows that the expression of CD244 on CD8+ T cells was significantly upregu-
lated after LTx in patients with CMV infection, but not in patients without CMV infection 
after LTx. The increases in CD244 expression observed in patients without CMV infection 
were small (on the average only 7%), while a significantly higher average increase of 38% 
was observed in patients with CMV infection (Figure 3B). We therefore conclude that 
CMV infection importantly contributes to the rise in CD244 expression on CD8+ T cells 
after LTx. Together, our data suggest that strong CD244 expression is induced by CMV-
infection early after LTx and that CD244-expression remains high, even many years after 
CMV infection is cleared. To verify this, we determined CD244 expression levels on CD8+ 
T cells at 1 year post-LTx in a subgroup of CMV-infected patients (n=6) of the long-term 
cohort. As shown in Figure 3C, expression of CD244 was already increased in these pa-
tients at 1 year after LTx. Although expression levels showed a partial decrease in blood 
samples taken at 6-11 years post-LTx, they remained significantly higher than pre-LTx ex-
pression levels. These data indicate that CMV infection, which occurs predominantly in 
the first 9 months after transplantation, induces accumulation of CD8+ T cells expressing 
CD244, and after the clearance of infection (latency) these CD8+CD244+ T cells persist.
Reduced	allogeneic	CD8+	T-cell	responses	in	patients	with	CMV	infection	after	LTx
Since we found that CMV infection after LTx was associated with upregulation of 
CD244 expression on CD8+ T cells after LTx, we asked whether CMV infection also af-
fected the allo-reactivity of these cells. We therefore determined post-LTx CD8+ T-cell 
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Figure	3.
Expression of CD244 on CD8+ T cells before and after LTx in patients of the late post-LTx cohort with and with-
out CMV infection after LTx. (A) Expression of CD244 on CD8+ T cells before and after LTx in patients of the late 
post-LTx cohort with and without CMV infection after LTx. (B) Increase of CD244 expression on CD8+ T cells, 
i.e. delta CD244 (= CD244 expression post-LTx minus pre-LTx expression) in patients with and without CMV-
infection after LTx. (C) Expression of CD244 on CD8+ T cells before (pre-LTx), at 1 year, and at 6-11 years post-LTx 
in a subgroup of patients with CMV infection (n=6) of the long-term cohort. Each dot represents 1 patient, and 
lines indicate mean with standard error of the mean. *p<0.05, **p<0.005, ***p<0.0005
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allo-responses in patients of the late post-LTx cohort with and without CMV infection, 
by co-culturing CFSE-labeled patient PBMC with CD40-activated B cells from their liver 
transplant donors or from an HLA-mismatched third party. After 5 days, proliferation 
and effector function of CD8+ T cells were assessed. PF of proliferating cells were calcu-
lated using Modfit software (27), and representative examples of Modfit proliferation 
analyses are shown in Figure 4A. As depicted in Figure 4B, PF of CD8+ T cells proliferating 
in response to donor allo-antigens were significantly lower in PBMC from patients with 
Figure	4.
Allogeneic proliferative and cytotoxic degranulation responses of CD8+ T cells from patients with or without 
CMV infection after LTx. (A) Representative Modfit analysis plots showing CD8+ T-cell proliferation after 5 days 
of stimulation with donor-derived or 3rd party-derived CD40-activated B cells. (B) Precursor frequencies (PF) 
of proliferating CD8+ T cells in post-LTx PBMC of patients with or without CMV infection after LTx in response 
to donor (n=14 with CMV and n=9 without CMV) or third party (n=9 with CMV and n=8 without CMV) allo-
antigens. Blood samples were collected 1-12 years after LTx (median 7 years). (C) Representative FACS plots 
showing CD107a expression on CFSE-labeled CD8+ T cells after 5 days of stimulation with donor-derived CD40-
activated B cells. (D) CD107a expression on both proliferated and non-proliferated CD8+ T cells as percentage 
of all CD8+ T cells in post-LTx PBMC of patients with (n=8) or without (n=7) CMV infection after LTx in response 
to donor or third party allo-antigen. Each dot represents 1 patient, and lines indicate mean with standard error 
of the mean. *p<0.05
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CMV infection than from patients without CMV infection after LTx, with the same trend 
(p=0.213) in the responses to third party allo-antigens.
To assess cytotoxic effector function of CD8+ T cells in both patient categories, we 
determined their cytotoxic degranulation capacity by analyzing CD107a surface expres-
sion at the end of the co-cultures (Figure 4C). After stimulation with donor or third party 
allo-antigens, CD8+ T cells of patients with CMV infection after LTx showed significantly 
lower levels of CD107a expression than CD8+ T cells of patients without CMV infection 
(Figure 4D). More specifically, CD107a expression in non-proliferating cells was lowered 
in patients with CMV-infection, but not CD107a expression in proliferating CD8+ T cells 
(Supplemental Figure 2). These data demonstrate the existence of circulating CD8+ T cells 
that do not proliferate but are still capable of cytotoxic degranulation in response to 
allo-antigens, and show that the decreased allogeneic cytotoxic degranulation capacity 
in CMV-infected patients was confined to these non-proliferating cells.
Together, these data demonstrate a reduction of allogeneic CD8+ T-cell proliferative 
and cytotoxic degranulation responses in LTx patients with CMV infection after LTx, and 
show that CMV-infection induces accumulation of a population of dysfunctional CD8+ 
T cells which does neither proliferate, nor degranulate in response to allo-stimulation.
CD244+	CD8+	T	cells	show	impaired	proliferative	responses	to	allogeneic	
stimulation
Since we found that CMV infection was associated with a strong rise in CD244 expression 
on circulating CD8+ T cells and with hyporesponsiveness of CD8+ T cells to allo-antigens 
after LTx, we wondered whether CD244 expression hallmarks a subpopulation of CD8+ T 
cells with reduced functionality. To test this hypothesis, CFSE-labeled CD244- and CD244+ 
CD8+ T cells, as well as CD4+ T cells, were sorted from 17 LTx patients of the late post-LTx 
cohort. The sorted CD8+ T-cell subsets were co-cultured with autologous CD4+ T cells 
to provide CD4-help to the CD8+ T cells, and stimulated with allogeneic CD40-activated 
B cells either derived from the donor or from an HLA-mismatched third party. In addi-
tion, both sorted subsets were stimulated with PHA. After 5 days of culture, cells were 
harvested and proliferation was measured. Significantly lower numbers of CD244+ T 
cells than CD244- T cells proliferated in response to PHA (Figure 5A; p=0.0001). Similarly, 
significantly less CD244+ T cells than CD244- T cells proliferated in response to allogeneic 
stimulations (p=0.002 for donor and p=0.023 for third party stimulation). The impaired 
proliferative responses of CD244+ T cells were independent of the allo-antigenic source, 
as differences between CD244+ and CD244- T cells were similar in response to donor and 
third party stimulations (Figure 5B). To assess whether blocking the interaction of CD244 
with its ligand CD48 could restore the proliferative capacity of CD244+ CD8+ T cells, we 
repeated the above described experiments in a subgroup of patients in the presence of 
blocking antibodies directed against CD48. In addition, we studied the effect of blocking 
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the interaction of CD160, which is co-expressed with CD244, with its ligand HVEM dur-
ing culture. Both CD48 and HVEM were expressed on CD40-activated B cells (data not 
shown). After 5 days, we did not find any difference in allogeneic proliferation of both 
CD244+ and CD244- CD8+ T cells between conditions with and without blocking antibod-
ies (data not shown). Collectively, these data suggest that CD244 expression marks a 
subset of dysfunctional CD8+ T cells, but the receptor itself and the co-expressed CD160 
receptor do not mediate the dysfunctionality.
CD244+	CD8+ T cells contain the majority of CMV-specific cells
Since upregulation of CD244 on circulating CD8+ T cells was strongly associated with CMV 
infection after LTx and CD8+CD244+ T cells were dysfunctional, we analyzed whether 
CD244+ CD8+ T cells contained CMV-specific cells. We therefore co-stained PBMC from 
5 CMV-experienced LTx patients from our study with MHC class I tetramers loaded with 
CMV-peptides and CD244 mAb, as described in Materials and Methods. A representative 
FACS plot is shown in Figure 6A. We found that the CD244+ CD8+ T-cell population con-
tained the majority of CMV-tetramer positive cells; significantly more than the CD244- 
CD8+ T-cell population (Figure 6B, p=0.033). These data support a causal relationship 
between CMV infection and the expansion of dysfunctional CD8+ CD244+ T cells after LTx.
Figure	5.
Proliferation of CD244+ versus CD244- CD8+ T cells in response to polyclonal and allogeneic stimulation. (A) 
Precursor frequencies (PF) of sorted CD244+ versus CD244- CD8+ T cells in response to polyclonal stimulation 
(PHA). (B) Precursor frequencies of CD244+ versus CD244- CD8+ T cells of patients post-LTx in response to 
donor and third party stimulation. Cells were sorted from PBMC collected from 17 patients 2-10 years after LTx 
(median 6.2 years). Each dot represents 1 patient, and lines indicate mean with standard error of the mean. 
*p<0.05, **p<0.005, ***p<0.0005
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DISCuSSION
In this study, we showed that the co-inhibitory receptor CD160 was upregulated on cir-
culating memory CD8+ T cells, while the co-inhibitory receptor CD244 was upregulated 
on both CD4+ and CD8+ memory T cells of patients early after LTx. In addition, we found 
that the increased expression of both receptors was sustained late after LTx. In contrast, 
PD1 was transiently upregulated on CD4+ T cells 1 month after LTx, but its expression 
normalized already at 6 months after LTx. Our original hypothesis postulated that long-
term persistence of a high load of allo-antigens after LTx may induce exhaustion of al-
logeneic T-cells. In contrast to this hypothesis, impaired allogeneic CD8+ T-cell responses 
and strong upregulation of CD244 on CD8+ T cells after LTx were restricted to patients 
with CMV infection after LTx. Expression of CD244 on the majority of the CMV-specific 
CD8+ cells in patients with CMV infection after LTx suggested a causal relationship be-
tween CMV infection and the observed expansion of CD8+CD244+ T cells. The observed 
lower proliferative capacity of CD244+ CD8+ T cells than CD244-CD8+ T cells in response 
to allogeneic stimulation suggested that the allogeneic CD8+ T-cell hyporesponsiveness 
in LTx patients after CMV infection is caused by the accumulated CD8+CD244+ T cells. 
Together, these data suggest that CMV infection after LTx induces persistent accumula-
tion of CD8+CD244+ T cells in the circulation, which display features of senescence or 
exhaustion, resulting in impaired peripheral CD8+ T-cell responses to allo-antigens in 
these patients.
The observed association between accumulation of CD8+CD244+ T cells and CMV infec-
tion (11, 14, 30, 35) as well as the selective expression of CD160 and CD244 on memory T-
cell subsets is consistent with previous studies (4, 11, 30, 36). However, to our knowledge, 
this is the first study showing that CMV infection after organ transplantation induces 
Figure	6.
CMV-specific cells within CD244+ and CD244- CD8+ T-cell populations. (A) Representative FACS plots show-
ing CD244+ and CD244- CMV-tetramer positive cells CD8+ T cells. (B) Percentage CD244+ and CD244- CMV-
tetramer positive cells of CD8+ T cells of CMV-positive patients post-LTx (n=5).
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sustained CD244 expression on memory CD8+ T cells and that the resulting CD8+CD244+ 
T-cell subset is hyporesponsive to allo-antigens. It has been well-documented that CMV 
infection induces vast expansion in the circulation of a population of CMV-specific CD8+ 
T cells which are actively cycling. After establishment of CMV-latency the majority of 
CMV-specific CD8+ T cells become long-lived terminally differentiated resting T cells with 
poor proliferative capacity (37, 38). Therefore, we hypothesize that expansion of these 
cells after LTx occurs during active CMV infection, while they differentiate into long-lived 
CD244-expressing terminally differentiated T cells with poor proliferative capacity after 
establishment of CMV-latency. Expression of CD244 is also induced on CD8+ T cells by 
HIV and HCV infection, and results in impaired CD8+ T-cell responses to viral antigens. 
However, the impairment of anti-viral CD8+ T-cell responses in these patients can be 
abrogated by blocking the interaction between CD244 and its ligand CD48 (10, 11, 14). 
In contrast, our data suggest that the observed allogeneic hyporesponsiveness of CMV-
induced CD244+CD8+ T cells was not mediated by CD244-CD48 interaction, neither by 
interaction of the co-expressed inhibitory CD160 receptor with its ligand HVEM, since 
blocking CD48 or HVEM did not lead to abrogation of hyporesponsiveness of CD8+CD244+ 
T cells to allo-antigens in experiments with sorted CD244+ T cells. The impaired response 
of this subset to allo-antigens may be related to its high content of CMV-specific T cells, 
resulting in lower proportions of T cells with other specificities, including allo-reactive 
T cells (39-41). In addition, the limited TCR repertoire of CMV-specific cells (39, 42, 43) 
accumulated in this subset may result in poor cross-reactivity to directly presented allo-
antigens. However, these phenomena do not explain the impaired proliferation of the 
expanded CD8+CD244+ T cells to PHA (this study), or to CD3/CD28 stimulation in a previ-
ous study (30). Interestingly, CMV-induced expansion of CD8+ effector memory cells cor-
relates with a decrease in T-cell telomere length, indicating T-cell senescence (44), and 
T-cell senescence has particularly been related to impaired proliferative capacity (45). 
We therefore propose that the observed rise in CD244 expression in LTx patients with 
CMV infection marks expansion of a subset of highly differentiated but dysfunctional 
CD8+ T cells, which shows features of senescence or exhaustion. However, its prolifera-
tive capacity is hampered by an as yet unknown mechanism.
The observed reduction in allo-reactive CD8+ T-cell responses in LTx patients after CMV 
infection challenges the broadly accepted notion, based on experimental animal studies, 
that viral infections stimulate heterologous immunity resulting in increased frequencies 
of allo-reactive T-cells (46). Indeed, reactivation of CMV infection as well as primary 
CMV infection abrogate transplant acceptance in mice and rat (47, 48). However, several 
previously published observations in humans support our finding. First, CMV infection 
leads to T-cell senescence, and thereby impairs T-cell responses to other antigens and 
to vaccinations (34, 40, 49-51). Interestingly, CMV infection after LTx is associated with 
an increased predisposition to develop opportunistic infections (52). Secondly, immune 
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senescence has been associated with improved kidney allograft survival (53). Thirdly, the 
majority of CD8+CD244+ T cells in our patients belong to the Temra subset, and accumu-
lation of circulating CD8+ Temra has recently been shown to be associated with lower 
risk of acute rejection after kidney transplantation (41). It was not feasible to investigate 
whether CMV infection or accumulation of CD8+CD244+ cells were associated with dif-
ferences in clinical outcome such as graft or patient survival or acute rejection in our 
long-term study cohort, since all patients have stable graft function and are still alive. 
In addition, only 5 patients suffered from acute rejection. A larger prospective study is 
required to investigate associations between CMV infection or rise in CD244 and clinical 
outcomes.
The mechanism by which CMV infection induces expansion of CD244+CD8+ memory 
T cells is as yet unknown, but may be related to bystander effects of inflammatory 
responses caused by CMV or by its immune evasion strategies. A recent mouse study 
showed that CD244 is more highly upregulated during secondary than during primary 
CD8+ T-cell responses, suggesting that T-cell reactivation is required for induction of high 
CD244 expression (54). In addition, it has been shown that chronic lymphocytic chorio-
meningitis virus (LCMV) or Toxoplasm infections in mice impair memory T-cell responses 
against unrelated antigens due to generation of CD8+ Temra. This was caused by increased 
IFN-type signalling due to chronic inflammation caused by the persistent infections 
(55). A similar mechanism may be driven by CMV infection after LTx, which also causes 
inflammation in the graft and in other organs (52), while CMV is able to induce IFN-α 
production (56). A possible relation between inflammation and reduced allo-responses 
after LTx is supported by a recent study that showed that chronic HCV patients who 
are operationally tolerant after LTx over-express type I IFN and Interferon-Stimulated 
Genes in the liver graft (57). A second explanation for the association between CMV 
infection and CD8+ T-cell hyporesponsiveness may be that CMV produces viral IL-10 (58), 
which inhibits expansion of allo-reactive CD8+ T cells. A third explanation may be that 
the immunological space of the recipient is occupied by large quantities of CMV-specific 
CD8+ Temra that compete with and thus hamper the expansion of T cells with other 
specificities (59). However, these explanations remain speculative, and further research 
is needed to decipher the mechanisms by which CMV infection induces expansion of 
CD8+CD244+ memory T cells, which is beyond the scope of the present study.
In contrast to the sustained increase in CD244 and CD160 expression on circulating 
T cells after LTx, we found that PD1 was only transiently upregulated following LTx. As 
PD1 can be upregulated by TCR-activation, this finding may be explained by the early 
and transient activation of donor-specific T cells after LTx that we observed previously 
(27). However, the use of calcineurin inhibitors (CNI) by the majority of our patients may 
prevent sustained upregulation of PD1, since PD1 induction by TCR-ligation involves 
NFAT-signaling, which is inhibited by CNI (32). PD1 upregulation is also prevented by 
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mTOR inhibitors (60), immunosuppressive drugs used by a small group of patients in our 
cohorts. LAG3 and TIM3 expression did not show an increase after LTx, but we do not 
know whether this is related to the use of immunosuppressive drugs since no evidence 
exists on the effect of immunosuppressive drugs on the expression of these receptors.
A limitation of our study is that we were not able to link the CD8+ T-cell hyporesponsive-
ness to an immunologically tolerant state towards the liver allograft. To investigate the 
clinical impact of the findings presented in our study, it will be interesting to determine 
the implications of CMV infection in LTx patients on the success rate of withdrawal of 
immunosuppressive drugs. A prospective study in which immunosuppressive drugs are 
weaned off is needed to investigate this.
In conclusion, in this study we showed that CMV infection after LTx was associated with 
the expansion of CD8+CD244+ T-cells with impaired proliferative capacity in response to 
allo-antigen, causing allogeneic CD8+ T-cell hyporesponsiveness. These results suggest 
that CMV infection may hamper T-cell immunity and thereby promote immunological 
graft acceptance after LTx.
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Table	I.	Demographic and clinical characteristics of patients included in the early post-LTx and late post-LTx 
cohorts
Early post-LTx cohort Total:	19	patients
Recipient age (median, range), years 43 (25-63)
Recipient gender, female (no, %) 10 (53)
Underlying disease (no, %)
AHF 4 (21)
HCC 0 (0)
PBC/PSC/AIH/SBC 6 (32)
HBV/HCV 4 (21)
Alcoholic cirrhosis 2 (10)
Others 3 (16)
Donor age (median, range), years 44 (15-77)
Donor gender, female (no, %) 10 (53)
Basiliximab as induction immunosuppression (no, %) 10 (53)
Immunosuppressive treatment (no, %, trough level at 6 months (median, 
range) µg/l)
Cyclosporin A 7 (37) 175 (25-300)
133
CMV-induced CD244 leads to T-cell hyporesponsiveness after LTx
6
Table	I.	Demographic and clinical characteristics of patients included in the early post-LTx and late post-LTx 
cohorts (continued)
Early post-LTx cohort Total:	19	patients
Tacrolimus 11 (58) 9.1 (4.5-25)
Everolimus 2* (10) 11.7 (6.6-16.8)
Mycophenolate mofetil 1‡ (5) 2.96
No immunosuppression 0 (0)
Late post-LTx cohort Total:	38	patients
Recipient age (median, range), years 46 (20-64)
Recipient gender, female (no, %) 16 (42)
Underlying disease (no, %)
AHF 1 (3)
HCC 1 (3)
PBC/PSC/AIH 17 (45)
HBV/HCV 1 (3)
Alcoholic cirrhosis 8 (21)
Others 10 (26)
Donor age (median, range), years 43 (12-77)
Time after LTx (median, range), years 7 (1-12)
Donor gender, female (no, %) 18 (47)
Basiliximab as induction immunosuppression (no, %) 27 (71)
Immunosuppressive treatment (no, %, trough level at time of post-LTx blood 
collection (median, range) µg/l)
Cyclosporin A 2 (5) levels unknown
Tacrolimus 28 (4) 4.4 (0-9.8)
Everolimus 5† (13) 12.6 (10-15.7)
Rapamycin 1§ (3) 1.14
Mycophenolate mofetil 4‡ (11) levels unknown
No immunosuppression 3 (8)
CMV infection/no infection between LTx and collection of post-LTx blood 
sample (no, %)
Infection 20 (53)
No infection 18 (47)
AHF Acute Hepatic Failure; HCC Hepatocellular carcinoma; PBC Primary Biliary Cirrhosis; PSC Primary Scle-
rosing Cholangitis; AIH Auto-immune hepatitis; SBC Secondary Biliary Cirrhosis; HBV Hepatitis B virus; HCV 
Hepatitis C virus.
* one patient in the early post-LTx cohort received combination of tacrolimus and everolimus.
‡ one patient in the early post-LTx cohort received combination of tacrolimus and mycophenolate mofetil; 4 
patients in the late post-LTx cohort received mycophenolate mofetil of which 2 in combination with tacroli-
mus.
† 5 patients in the late post-LTx cohort received everolimus of which 2 in combination with tacrolimus.
§ 1 patient in the late post-LTx cohort received rapamycin in combination with tacrolimus.
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Table	II.	Associations of independent covariates with increasing (delta) CD160 and CD244 expression on CD4+ 
and CD8+T cells in multivariate linear regression analysis
Variable Beta p-value
Delta* CD160 on CD4+ T cells
Age recipient 0.336 0.199
Time after LTx (years) 0.171 0.492
Underlying disease 0.047 0.842
CMV infection after LTx 0.357 0.165
Delta CD160 on CD8+ T cells
Age recipient 0.239 0.368
Time after LTx (years) -0.287 0.269
Underlying disease -0.048 0.843
CMV infection after LTx 0.434 0.106
Delta CD244 on CD4+ T cells
Age recipient 0.469 0.069
Time after LTx (years) 0.180 0.450
Underlying disease -0.066 0.769
CMV infection after LTx 0.232 0.337
Delta CD244 on CD8+ T cells
Age recipient -0.223 0.251
Time after LTx (years) 0.161 0.388
Underlying disease -0.147 0.410
CMV infection after LTx 0.631 0.004
*Delta expression = expression post-LTx minus expression pre-LTx.
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Supplemental	Figure	1.
Subset distribution of circulating CD4+ and CD8+ T cells of healthy controls and patients before and late after 
LTx. Differentiation stages of T cells in LTx patients of the late post-LTx cohort (n=38) before and after LTx, and 
in healthy control subjects (HC) (n=18).
CD107a on CD8+ T cells to donor and third party
no
 C
MV
 in
fec
tio
n
CM
V i
nfe
cti
on
no
 C
MV
 in
fec
tio
n
CM
V i
nfe
cti
on
0
50
100
150
Donor Third party
p=0.23 p=0.54
%
C
D
10
7a
+  o
f p
ro
lif
 C
D
8+
 T
 c
el
ls
CD107a on CD8+ T cells to donor and third party
no
 C
MV
 in
fec
tio
n
CM
V i
nfe
cti
on
no
 C
MV
 in
fec
tio
n
CM
V i
nfe
cti
on
0
10
20
30
40
50
Donor Third party
p=0.04 p=0.07
%
C
D
10
7a
+  n
on
-p
ro
lif
 o
f a
ll 
no
n-
pr
ol
if 
C
D
8+
 T
 c
el
ls
Supplemental Figure 2
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Supplemental	Figure	2.
Allogeneic cytotoxic degranulation responses of CD8+ T cells from patients with or without CMV infection af-
ter LTx (A) CD107a expression on proliferated CD8+ T cells as percentage of all proliferated CD8+ T cells in post-
LTx PBMC of patients with (n=8) or without (n=7) CMV infection after LTx in response to donor or third party 
allo-antigen. (B) CD107a expression on non-proliferated CD8+ T cells as percentage of all non-proliferated 
CD8+ T cells in post-LTx PBMC of patients with (n=8) or without (n=7) CMV infection after LTx in response to 
donor or third party allo-antigen. Each dot represents 1 patient, and lines indicate mean with standard error 
of the mean.
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ABSTRACT
Calcineurin inhibitors (CNIs), such as cyclosporin A and tacrolimus, are the cornerstone 
of maintenance immunosuppressive regimens in liver transplantation. CNIs prevent 
rejection by inhibition of calcineurin, via which lymphocyte proliferation and interleukin 
(IL)-2 production is prevented. Tacrolimus is now the first-choice immunosuppressant 
after liver transplantation, since it is associated with fewer episodes of rejection than 
cyclosporin A. In this review we will discuss interindividual differences, which influence 
tacrolimus metabolism. Because of these factors and the narrow therapeutic index of 
tacrolimus, monitoring of drug trough levels is necessary. Furthermore, we will discuss 
studies concerning conversion from the tacrolimus twice daily to tacrolimus once daily 
formulation in stable LT patients. Due to adverse effects of CNIs, such as chronic renal 
failure, hypertension, de novo malignancy and new-onset diabetes mellitus, CNI minimi-
zation strategies have been developed, which will be discussed too.
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Calcineurin inhibitors – history
Calcineurin inhibitors (CNIs), since their introduction in the 1980s, have been the cor-
nerstone of maintenance immunosuppressive regimens in liver transplantation. The use 
of CNIs has substantially decreased the risk of acute rejection and improved short-term 
outcomes. Cyclosporin A (CsA) was introduced in 1983 as a therapeutic agent for renal 
allograft rejection andrevolutionized the field of clinical transplantation due to the im-
proved organ transplant survival rate (1). Since that time, its use has expanded to cardiac, 
liver, heart-lung, and multiple organ transplants as well as to the treatment of certain 
autoimmune diseases such as psoriasis and insulin-dependent type I diabetes. Use of CsA 
is limited by its side-effect profile, particularly its chronic nephrotoxicity, and so safer im-
munosuppressive agents have been investigated. Tacrolimus (FK-506, TAC), a compound 
of about 100-fold more potency than CsA, was developed and tested in the late eighties 
for the prevention of liver transplant rejection (2) and (3). In 1994, the US Multicenter 
FK506 Liver Study Group published a paper comparing CsA and TAC for immunosup-
pression after liver transplantation (4). The study was important for the development of 
immunosuppression after liver transplantation. First, the introduction stated that rejec-
tion remained an important cause of graft loss and death. Second, the paper reported 
that graft and patient survival with CsA and TAC was similar, but that TAC was associated 
with fewer episodes of rejection. Third, it reported that TAC was associated with less 
adverse events, such as nephrotoxicity and neurotoxicity. From the mid-1990s in more 
and more centers tacrolimus became the first-choice immunosuppressant after liver 
transplantation. In 2006, a systematic review of randomized clinical trials (RCT) evalu-
ated the beneficial and harmful effects of immunosuppression with cyclosporin versus 
tacrolimus for liver transplanted patients (5). This reported that mortality and graft loss 
at one year were significantly reduced in tacrolimus-treated recipients (Death: RR 0.85, 
95% CI 0.73–0.99; graft loss: RR 0.73, 95% CI 0.61–0.86). Tacrolimus reduced the num-
ber of recipients with acute rejection (RR 0.81, 95% CI 0.75–0.88) and steroid-resistant 
rejection (RR 0.54, 95% CI 0.47–0.74) in the first year. Lymphoproliferative disorder or 
dialysis rates were not different between tacrolimus- and cyclosporin-treated patients. 
More de novo diabetes (RR 1.38, 95% CI 1.01–1.86) occurred with tacrolimus. The current 
most used combination is tacrolimus, prednisolone andmycophenolate mofetil with in 
some centers an induction therapy with IL-2 antagonists basiliximab or dacluzimab. With 
the use of these immunosuppressants, the incidence of biopsy-proven acute rejection 
within the first year after transplantation ranges between 19 and 30% (6,7).
Calcineurin inhibitors – mechanisms of action
For understanding the mechanism via which CNIs prevent rejection, it is necessary to 
understand the mechanism of allograft rejection. T cell recognition of alloantigen is the 
primary and central event that leads to the cascade of events that result in rejection of 
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a transplanted organ. Individual T cells (or colonies of identical T cell clones) are mono-
specific as they recognize only a single peptide antigen presented in the context of Major 
Histocompatibility Complex (MHC). MHC molecules are peptide complexes, expressed 
on the surface of a variety of immune cells. T cells recognize portions of protein antigens 
that have been fragmented into peptides bound to MHC molecules. There are at least 
two distinct, but not necessarily mutually exclusive, pathways of allorecognition, the 
direct and indirect pathways. Each leads to the generation of different sets of allospecific 
T cell clones. In the direct pathway, host T cells recognize intact allo-MHC molecules 
on the surface of the donor antigen presenting cells. In the indirect pathway, T cells 
recognize processed alloantigen presented as peptides by host antigen presenting cells 
(8). After allorecognition by T cells, T cells become activated. Following T cell activation, 
a number of biochemical events occur within the cytoplasm of the T cell. These pathways 
ultimately lead to a marked and sustained elevation in intracellular calcium. This eleva-
tion in calcium promotes the formation of calcium-calmodulin complexes that activate a 
number of kinases including the phosphatase calcineurin. Calcineurin dephosphorylates 
cytoplasmic NFAT (nuclear factor of activated T cells), permitting its translocation to the 
nucleus, where it binds to the interleukin (IL)-2 promoter sequence and then stimulates 
transcription of IL-2 mRNA. IL-2 is a Proinflammatory cytokine (9,10). Calcineurin is the 
ultimate target of both cyclosporin and tacrolimus (11). Cyclosporin is a lipophilic cyclic 
peptide of 11 amino acids while tacrolimus is a macrolide antibiotic. Both drugs have 
been isolated from fungi and possess similar suppressive effects on cell mediated and 
humoural immune responses. CNIs bind with high affinity to a family of cytoplasmic 
proteins present in most cells: cyclophilins for cyclosporin; and FK binding proteins for 
tacrolimus (because tacrolimus was initially called FK506). The drug-receptor complex 
specifically and competitively binds to and inhibits calcineurin. This process inhibits 
the translocation of a family of transcription factors, leading to reduced transcriptional 
activation of early cytokine genes for IL-2, tumor necrosis factor alpha (TNF- Alpha), IL-3, 
IL-4, CD40L, granulocyte-macrophage colony-stimulating factor, and interferon-gamma 
(12). Ultimately, proliferation of lymphocytes and production of the proinflammatory 
cytokine IL-2 are reduced. Due to the inhibition of these proinflammatory actions, rejec-
tion is prevented.
Tacrolimus metabolism and individual dosing
The therapeutic use of tacrolimus is complicated by its variable oral pharmacokinetic 
profile. The interindividual variability and a narrow therapeutic index, makes therapeutic 
drug monitoring of tacrolimus levels very important (13). Tacrolimus is metabolized by 
cytochrome P450 3A (CYP3A) enzymes in the liver and small intestine – in particular, 
CYP3A4 and CYP3A5 – and are transported out of cells via P-glycoprotein (ABCB1) 
(14–16). The main reactions tacrolimus undergoes during metabolism are demethylation 
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and/or hydroxylation (17). Several individual factors may influence the metabolism. 
These factors will be discussed here. Gonschior et al studied the influence of kidney 
and liver function on tacrolimus metabolite patterns in blood in kidney and liver trans-
plant recipients (18). Gonschior et al showed that tacrolimus metabolite concentrations 
and the metabolite patterns depend on the type of graft (kidney vs liver), time after 
transplantation and cholestasis. The doses required to obtain tacrolimus blood trough 
concentrations in the therapeutic range were significantly higher in kidney than in liver 
graft patients. In liver transplant patients, all detected metabolites were higher during 
the late postoperative period (‘day > 14’) compared to earlier. More than 90% of an 
absorbed tacrolimus dose is eliminated in bile as metabolites. Gonschior et al found that 
cholestasis leaded to increased trough blood concentrations of tacrolimus metabolites 
as well as to an alteration of the metabolite pattern, which is caused by an overpropor-
tional increase of metabolites such as dideinethyl and didemethylhydroxy tacrolimus. 
This result indicates that the formation of tacrolimus during cholestasiswas impaired 
to a lesser extent than excretion of the metabolites into the bile duct. When passage 
through the biliary membrane is hampered, the metabolites usually excreted into bile 
accumulate in the hepatocyte and enter the blood. Another factor influencing the 
metabolism of tacrolimus may be interindividual differences in CYP3A enzymes. Several 
single nucleotide polymorphisms (SNPs) have been identified in the genes encoding for 
CYP3A4, CYP3A5 and P-glycoprotein. Based on literature review, Staatz et al (19) stated 
that variability in CYP3A4 expression due to environmental factors is likely to be more 
important than patient genotype. Furthermore, The CYP3A5 6986A > G SNP has a well 
established influence on the pharmacokinetics of tacrolimus. Several studies in kidney, 
heart and liver transplant recipients have reported an approximate halving of tacrolimus 
dose-adjusted trough concentrations and doubling of tacrolimus dose requirements 
in heterozygous or homozygous carriers of aCYP3A5*1 wild-type allele compared to 
homozygous carriers of a CYP3A5*3 variant allele. Influence of ABCB1 SNPs on the phar-
macokinetics of cyclosporin and tacrolimus remains uncertain, with inconsistent results. 
The majority of studies have only evaluated the effects of individual SNPs; however, 
multiple polymorphisms may interact to produce a combined effect. Differences in 
ethnic background may also influence the pharmacokinetics of tacrolimus. Mancinelli et 
al (20) investigated pharmacokinetics of tacrolimus in African Americans, white and Latin 
Americans. No significant differences among these groups were found after intravenous 
administration of the drugs. However, after oral administration the tacrolimus maximum 
concentration was significantly lower in the African Americans than in the other groups. 
This finding confirmed what has been shown in other studies; although in these studies 
the investigated drug was cyclosporin and not tacrolimus (21–26). It is unclear whether 
these differences are due to differences in CYP3A enzymes or that other factors con-
tribute to the different pharmacokinetics among different ethnic groups. To summarize, 
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in individual tacrolimus dosing, it is important to take into account that interindividual 
differences, such as time after liver transplantation, cholestasis, genetic differences in 
CYP3A enzymes and ethnic background could influence the tacrolimus metabolism. All 
these factors make therapeutic drug monitoring of tacrolimus levels necessary.
CNIs and hepatitis C (hCV)
The use of CNIs in HCV-positive patients deserves special attention. A major problem in 
HCVpositive patients undergoing liver transplantation is re-infection of the graft, with 
HCV. The current standard therapy of HCV, pegylated interferon-α (IFN- α) in combina-
tion with ribavirin, has achieved substantial success in primary HCV patients, with half 
of the patients overall developing a sustained virological response (27). Nevertheless, 
treatment of HCV recurrence after liver transplantation is much less effective, with 
approximate sustained virological response rates of only 20% (28,29). Recent studies 
showed that cyclosporin, but not tacrolimus, could inhibit HCV replication in vitro (30,31). 
Moreover, several in vitro studies have shown that cotreatment with CsA and IFN-α 
results in greater, synergistic inhibition of HCV replication (32–34). Furthermore, other 
studies have suggested that tacrolimus interferes with the antiviral activity of IFN-α in 
vitro (35,36). Pan et al more extensively investigated the effects of calcineurin inhibitors 
on IFN-α signalling and antiviral activity in subgenomic and infectious HCV models (37). 
They found no evidence that either CsA or tacrolimus interferes with IFN-α–induced 
gene expression or IFN-α–mediated antiviral activity against HCV. Their study confirmed 
results from earlier studies (30–34) showing that cyclosporin has antiviral activity alone 
and in combination with IFN-α treatment. Furthermore, treatment with tacrolimus alone 
showed limited antiviral activity, as shown earlier (30,33,38). Pan et al did not observe 
any inhibitory effect of tacrolimus on IFN-α signalling or its antiviral activity, in contrast 
to previous reports (35,36). In conclusion, cyclosporin has antiviral activity alone and 
in combination with IFN-α treatment. Treatment with tacrolimus has limited antiviral 
activity, but –according to Pan et al– does not interfere with IFN-α treatment against 
HCV. In clinical practice, tacrolimus still remains the first-choice immunosuppressant in 
liver transplant recipients, also in HCV-infected patients.
CNIs	and	interactions	with	concomitant	medication
As described above, CNIs are metabolized by cytochrome P450 3A enzymes. Because 
some other drugs affect or are metabolized by these enzymes, important interactions 
between CNIs and these drugs can occur.We will not discuss all these specific drugs 
separately, but it is important to know that interactions can occur. This indicates that 
higher or lower tacrolimus levels may be the result. In clinical practice, always consider 
possible interactions to prevent unwanted effects.
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Tacrolimus	twice	daily	versus	once	daily
In clinical practice, tacrolimus (Prograf®; Astellas Pharma Europe, Staines, UK) is usually 
administered twice daily (BID). Extended-release or QD tacrolimus (Advagraf®; Astellas 
Pharma Europe, Staines, UK) is a prolonged-release formulation that was developed to 
enable a QD dosing alternative and to have similar safety and efficacy profiles to tacroli-
mus BID with the potential to improve patient adherence and quality of life. Beckebaum 
et al studied the adherence in 125 stable LT-recipients who have been converted from a 
twice daily tacrolimus to a once daily prolonged-release formulation (39). They used a 
four-item validated questionnaire and a Visual Analog Scale. Patient’s preference with 
the treatment regimen was also assessed by a self-report at the end of the observational 
period (one year after conversion). Overall nonadherence, reported on at least one of 
the four queried items decreased from 66.4% at baseline (conversion) to 30.9% one 
year post conversion (p < 0.0001). Timing nonadherence (taking the dose with a delay 
of >2 h) decreased significantly from baseline (63.6%) to one year (27.3%), p < 0.0001. 
Taking nonadherence decreased from 20% to 8.2% (p < 0.005). Drug holidays and dose 
reduction were not reported frequently and differed not significantly from baseline to 
one year reports. Furthermore, of the 110 patients who maintained on tacrolimus QD 
medication throughout the study, 94 reported one or more advantages to conversion 
to the new formulation. No patients reported preference of reconversion to tacrolimus 
BID formulation at study completion. Tacrolimus has a narrow therapeutic index (40,41) 
and its oral bioavailability is highly variable between individuals (42). Systemic exposure 
to tacrolimus (area under the curve, AUC) is a significant efficacy variable and, therefore, 
therapy is optimized on an individual patient basis by monitoring trough levels as sur-
rogate markers of exposure. Tacrolimus pharmacokinetics (PK) have been compared 
between tacrolimus QD and tacrolimus BID in de novo and stable kidney, liver and heart 
patients (43–45). Mean AUC0-24 of tacrolimus on day 1 after transplantation was approxi-
mately 30% lower for tacrolimus QD than tacrolimus BID, but was comparable by day 
4. There was a good correlation and a similar relationship between AUC0-24 and Cmin for 
both formulations. Efficacy and safety data were also comparable. Recently, Fischer et 
al performed a randomized, phase 2, multicenter prospective trial in primary liver trans-
plant recipients. In this study they investigated and compared the pharmacokinetics of 
tacrolimus BID (n=62) and tacrolimus QD (n=67) formulations, given within 6–12 hours 
after transplantation (46). Mean AUC0-24 of tacrolimus on day 1 after transplantation was 
approximately 50% lower for tacrolimus QD than tacrolimus BID at equivalent doses, but 
was comparable by day 14 and week 6, although the mean daily doses of tacrolimus QD 
doses were higher after day 1. In practice, to achieve similar tacrolimus exposure, the 
initial dose of tacrolimus QD would need to be higher than the total tacrolimus BID dose. 
Tmax occurred later for tacrolimus QD compared with tacrolimus BID: day 1: 5.0 versus 2.9 
hours; day 14: 2.6 versus 1.9 hours; week 6: 2.8 versus 1.8 hours, respectively. This reflects 
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the prolonged-release characteristics of the tacrolimus QD formulation. The reasons for 
the differences in the extent of absorption between the QD and BID formulations in the 
immediate post transplant period are not fully understood. Fischer et al demonstrated 
a good correlation between whole-blood tacrolimus trough levels and AUC0-24 for both 
tacrolimus formulations. In clinical practice, for drug-level monitoring, the same recom-
mended target levels can be applied for both formulations to ensure similar exposure. 
Close monitoring in the early post conversion period is recommended, because of the 
differences in the extent of absorption between the QD and BID formulations. Fischer 
et al also studied acute rejection, graft and patient survival (1-year follow-up) as second-
ary endpoint. They found no significant differences in these parameters between the 
tacrolimus BID and QD treated patients. Frequently reported adverse events during the 
study were renal impairment, diabetes mellitus, vascular hypertensive disorders, hy-
perglycaemic conditions. There were no differences between the two groups for these 
adverse effects. Some studies that investigated tacrolimus BID versus Tacrolimus QD, 
but not in liver transplant recipients, suggest that tacrolimus QD is associated with lower 
peak levels than tacrolimus BID. These lower peak levels may lead to a better control of 
glycaemic metabolism (47). However, these studies found no reduction of cardiovascular 
adverse events, insulin-dependent diabetes, lipid-lowering agents and antihypertensive 
drugs per patient. In conclusion, the tacrolimus QD formulation has several advantages 
compared to the BID formulation. A once daily regimen may increase patient adherence 
and quality of life. Mean AUC of tacrolimus was different for the two formulations early 
after transplantation, but were comparable from day 14 and later on. Since no differ-
ences in adverse effects between the two formulations were found in previous studies, 
we recommend conversion from the tacrolimus BID to tacrolimus QD formulation in 
stable LT patients, to increase adherence and quality of life.
Adverse effects of CNIs
The use of CNIs may have a negative influence on kidney function; induce diabetes 
mellitus and hypertension, however depending on type of CNI, dosing regimens and 
concomitant immunosuppressive medication. Nephrotoxicity is one of the most serious 
complications of CNIs (48). Apart from intestinal transplants, liver transplant recipients 
have the highest five-year incidence of chronic renal failure (CRF) of any non-renal solid 
organ transplant recipient; additionally, the risk of death is at least fourfold higher in 
patients who develop CRF (49). Five years after liver transplantation up to 18% of the 
patients have chronic renal failure. Diabetes mellitus, hypertension and hepatitis C 
virus infection are independent risk factors for renal failure (50). A recent study in 405 
patients, who underwent a liver transplantation between 1986 and 2008 at the Erasmus 
Medical center (EMC) and were alive at one year showed that stage 3 chronic kidney 
disease (CKD-III; GFR < 60 ml/min) developed in 168 patients (43%). The one- and five 
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year cumulative incidence of CKD-III was 29.7 ± 2.3% and 41.1 ± 2.6% respectively. End-
stage kidney disease (ESKD) requiring either dialysis or kidney transplantation developed 
in 11 patients. The cumulative incidence of ESKD at ten years was 4.3 ± 1.7%. The one-, 
two- and three year cumulative incidence of CKD-III in the 194 patients using tacrolimus 
was 21.0 ± 0.03, 24.5 ± 0.03 and 26.4 ± 0.03 respectively (unpublished data, Azimpour, 
Metselaar et al., 2009). The recent introduction of the Model for endstage liver disease 
(MELD) to allocate donor livers in the Netherlands increases the probability that recipi-
ents have pre-transplant renal dysfunction that can further deteriorate with the use of 
CNIs after transplantation. Moreover, the long-term use of immunosuppressive agents 
has been associated with an increased risk of developing de novo cancer. A recent study 
in 385 patients transplanted at the Erasmus MC, Rotterdam demonstrated a 2.2-fold 
higher incidence of de novo cancer as compared to the general population. The cumula-
tive incidences at 1, 5, 10 and 15 years after liver transplantation were 2.9%, 10.5%, 19.4% 
and 33.6% respectively (51). These data are in line with a population-based study from 
Groningen with an overall relative risk as compared with the general population of 4.3 
(95% confidence interval 2.4–7.1). Multivariate analysis showed that an age > 40 year 
and pre-transplant use of immunosuppression were significant risk factors (52). Further-
more, CNIs are related with new-onset diabetes mellitus after transplantation (NODAT). 
NODAT has been reported to occur in 2.5% to 25% of liver transplant recipients, and 2% to 
53% of all solid organ transplants (53,54). The variation in the reported incidence may be 
due in part to the lack of a universal agreement on the definition of NODAT, the duration 
of follow-up, and the presence of modifiable and non-modifiable risks factors. Current 
WHO and American Diabetes Association (ADA) guidelines for the diagnosis of pre-
diabetic states (IFG and IGT) and diabetes mellitus are outlined by Pham et al (55). The 
incidence of NODAT after liver transplantation has also been found to be higher in tacro-
limus-treated versus cyclosporin-treated patients at one year post transplant. In a large 
randomized trial involving more than 500 liver transplant recipients, NODAT occurred in 
26.6% versus 16.1% of patients receiving tacrolimus and cyclosporin immunosuppressive 
therapy, respectively (56). Other risk factors for NODAT reported in literature are age, 
weight, ethnicity, family history and hepatitis C (57). In HCV-infected liver recipients, the 
prevalence of post-transplant diabetes ranges between 40% and 60% (58–60). Despite 
of the incidence of adverse effects such as chronic renal failure, hypertension, de novo 
malignancy and new-onset diabetes mellitus, tacrolimus still remains the cornerstone of 
preventing rejection after liver transplantation. The occurrence of these adverse effects, 
has led to a focus shift from acute cellular rejection and short-term post transplant sur-
vival to long-term management of complications. Furthermore, strategies to minimize 
CNI exposure have been developed.
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CNI optimization strategies
Switch to CNI-free regimen when CNI-toxicity has evolved.
The impact of CNIs on renal function after liver transplantation has led to a number 
of strategies to minimize CNI exposure (61). One approach is to switch to a calcineurin 
inhibitor-free regimen when CNI toxicity, such as renal dysfunction, has evolved. Several 
studies have evaluated CNI conversion to the Mammalian target of rapamycin (mTOR) 
inhibitors, such as sirolimus and everolimus. All these studies show that switching to 
sirolimus or everolimus improved to some extent renal function, especially early after 
conversion. However, accumulated literature shows that late mTOR conversion does not 
improve long-term renal outcome in liver transplantation. Moreover, conversion to a 
calcineurin inhibitor-free regimen was associated with rejections up to 35%. Because of 
serious side-effects a return to the calcineurin inhibitor occurred in up to 30% of the 
patients on mTOR inhibitors (62–69).
Start with mTOR inhibitor in combination with other IS drugs directly post-LT
Another approach to tackle the calcineurin inhibitor-associated problems after liver 
transplantation might be to completely avoid these drugs and start from the time of 
transplantation with mTOR inhibitors in combination with other immunosuppressive 
drugs. However, this approach will lead to a higher rate of rejection and major concerns 
consist about hepatic artery thrombosis, delayed wound healing, thrombocytopenia 
and proteinuria in the mTOR treated patients (70–73). De novo sirolimus is therefore not 
recommended in liver transplantation in the USA due to this supposed increased risk of 
hepatic artery and portal vein thrombosis and increased mortality. In Europe, sirolimus 
is approved to be used in renal transplant recipients.
Delayed introduction of reduced-dose tacrolimus under protection of MMF and 
dacluzimab
A third approach is delayed introduction of reduced-dose tacrolimus under the protec-
tion of mycophenolate mofetil (MMF) and dacluzimab. A recent study demonstrated 
that postponing introduction of tacrolimus was associated with less impairment of 
renal function without an increased frequency of rejection or graft loss. However, mean 
change from baseline in calculated creatinine clearance was still 13.6 ml/min 52 weeks 
after transplantation. Moreover, the CNI exposure in the control group was rather high 
as compared to current practice in liver transplantation, overestimating the protective 
effect of delayed introduction of tacrolimus (7). Another randomized controlled trial 
comparing dacluzimab, delayed low-dose tacrolimus (target trough level 4–8 ng/ml) 
to standard dose tacrolimus (trough level 10–15 ng/ml) and MMF showed comparable 
results (6). Delayed low-dose tacrolimus preserved early renal function without the cost 
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of increased rejection. At six months after transplantation the difference in cGFR (MDRD) 
was small, but statistically significant (75.4 vs 69.5 ml/min/1.73 m2). However, the long-
term benefits of this approach remain to be established.
Switch to CNI-free regimen early after LT
A fourth approach is to switch to a calcineurin inhibitor-free regimen early after trans-
plantation. This approach has three potential advantages. It prevents the supposed risk 
of hepatic artery thrombosis and impaired wound healing of mTOR inhibitors. Moreover, 
conversion is initiated before unrecoverable renal injury of calcineurin inhibitors has 
occurred. Currently, several international studies are running evaluating the efficacy 
and safety of mTOR inhibitors with corticosteroids in combination with elimination of 
calcineurin inhibitor in de novo liver transplant recipients compared to standard im-
munosuppressive therapy. Most of these studies focus on renal function one year after 
liver transplantation. One multicenter study has recurrence of hepatocellular carcinoma 
as primary endpoint. The complete withdrawal of CNIs in these studies warrants higher 
levels of mTOR inhibitors to avoid under-immunosuppression with an increased risk of 
allograft rejection. As a consequence of this approach a higher discontinuation rate due 
to side-effects can be expected, as is demonstrated in the late conversion studies. More-
over, a recent FDA alert notified healthcare professionals of clinical data that suggest 
increased mortality in stable liver transplant patients after conversion from a CNI-based 
immunosuppressive regimen to sirolimus. Moreover, the overall treatment failure rate at 
one year, defined as the occurrence of acute rejection or premature discontinuation for 
any reason, for the intent-to-treat population was significantly higher for the cohort of 
stable liver transplant patients converted to sirolimus compared to the cohort that con-
tinued CNI. (http://www.fda.gov/drugs/DrugSafety/default.htm). All these data support 
a different approach, namely to combine tacrolimus and sirolimus at low dosages in the 
early phase after liver transplantation and use their potential synergism, as is suggested 
in several preclinical studies (74,75). It is expected that this approach, combining both 
drugs at lower dosages, equals the protective capacity of tacrolimus against allograft 
rejection, preserve renal function in a significant way and has an acceptable tolerability 
profile. Moreover, it can be postulated that the incidence of de novo malignancy after 
transplantation will be reduced as the use of mTOR inhibitors is associated with a lower 
risk of developing cancer (76–78). These anti-neoplastic properties of mTOR inhibitors 
are further supported in experimental studies (79–81). An uncontrolled study using 
low-dose tacrolimus and sirolimus in 56 liver transplant recipients showed an excellent 
efficacy with a rejection rate of 14%. The target trough levels of tacrolimus were 5 ng/
ml and of sirolimus 7 ng/ml. Corticosteroids were weaned off at 3–6 months. Renal 
function in these patients represented a 30% improvement as compared to historical 
controls with normal dose tacrolimus (82). However, the potential benefit of combining 
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low-dose tacrolimus and sirolimus must be verified in randomized controlled trials. In 
conclusion, the impact of CNIs on renal function after liver transplantation has led to a 
number of strategies to minimize CNI exposure. A first approach is to switch to CNI-free 
regimen when CNI-toxicity has evolved. Another approach is to start with mTOR inhibitor 
in combination with other IS drugs directly post-LT. A third approach is delayed introduc-
tion of reduced-dose tacrolimus under the protection of mycophenolate mofetil (MMF) 
and dacluzimab. A fourth approach is to switch to a calcineurin inhibitor-free regimen 
early after transplantation. However, long term benefits of these approaches have to be 
established.
Practice points
• CNIs are still the cornerstone of immunosuppresion after liver transplantation.
• Tacrolimus still remains the first-choice immunosuppressant in liver transplant recipi-
ents, also in HCV-infected patients.
• CNIs have a narrow therapeutic window necessitating close drug monitoring.
• Conversion from the tacrolimus BID to tacrolimus QD formulation in stable LT pa-
tients is safe and will increase adherence and quality of life.
• Strategies to minimize CNI exposure will improve outcome after liver transplantation.
Research agenda
• Because of adverse effects of tacrolimus, CNI minimization strategies need further 
exploration to improve long term outcome after liver transplantation.
• Whether the use of mTOR inhibitors will reduce the incidence of malignancy after 
liver transplantation needs to be studied.
• Genetic differences in CYP3A enzymes and ethnic background could influence the 
tacrolimus metabolism. Whether these differences have clinical implications needs 
to be studied in larger cohorts.
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ABSTRACT
After organ transplantation, recipient T cells contribute to graft rejection. Mesenchymal 
stromal cells from the bone marrow (BM-MSCs) are known to suppress allogeneic T-cell 
responses, suggesting a possible clinical application of MSCs in organ transplantation. 
Human liver grafts harbor resident populations of MSCs (L-MSCs). We aimed to deter-
mine the immunosuppressive effects of these graft-derived MSCs on allogeneic T-cell 
responses and to compare these with the effects of BM-MSCs. BM-MSCs were harvested 
from aspirates and L-MSCs from liver graft perfusates. We cultured them for 21 days and 
compared their suppressive effects with the effects of BM-MSCs on allogeneic T-cell 
responses. Proliferation, cytotoxic degranulation and IFN-γ production of allo-reactive T 
cells were more potently suppressed by L-MSCs than BM-MSCs. Suppression was medi-
ated by both cell-cell contact and secreted factors. In addition, L-MSCs showed ex vivo 
a higher expression of PD-L1 than BM-MSCs, which was associated with inhibition of 
T-cell proliferation and cytotoxic degranulation in vitro. Blocking PD-L1 partly abrogated 
the inhibition of cytotoxic degranulation by L-MSCs. In addition, blocking IDO partly 
abrogated the inhibitive effects of L-MSCs, but not BM-MSCs, on T-cell proliferation. 
In conclusion, liver graft-derived MSCs suppress allogeneic T-cell responses stronger 
than BM-MSCs, which may be related to in situ priming and mobilization from the graft. 
These graft-derived MSCs may therefore be relevant in transplantation by promoting 
allo-hyporesponsiveness.
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INTRODuCTION
Mesenchymal stromal cells (MSCs) are rare, non-hematopoietic cells and reside in the 
bone marrow (BM) cavity. They are characterized by their ability to produce colony form-
ing unit-fibroblast (CFU-F); support of the hematopoietic microenvironment; promotion 
of bone formation and adherence to plastic in vitro (1-3). Besides their presence in the 
BM, MSC-like cells are present throughout the body, occupying a perivascular location 
[4, 5] and are critically involved in maintaining tissue homeostasis via anti-apoptotic and 
tissue-supporting properties (6-8).
It has been demonstrated that resting or naive MSCs are inherently capable of sup-
pressing T-cell responses (9-11). Bone marrow MSCs (BM-MSCs) can suppress recipient 
allo-reactive T-cell responses and thereby prevent graft rejection (12), suggesting a 
possible clinical application of MSCs in organ transplantation. Human liver grafts also 
contain MSCs (L-MSCs) [13, 14] and these are mobilized from the liver graft during the 
transplantation procedure. MSCs express several cell surface receptors that enable 
them to sense the microenvironment and alter their phenotype accordingly [6, 15]. Many 
studies have shown that it is the nature of the environmental cues that dictates the 
plasticity and - in the end - immunosuppressive capacity of MSCs (14-27). Most of the 
data that support this concept of MSC ‘mobilization’ and immune ‘priming’ are based on 
experimental mouse studies. But because humans and mice differ in immunomodula-
tory pathways used by MSCs, there is an urgent need to assess the immunosuppressive 
function of human MSCs in the clinical setting of liver transplantation (16).
In addition, it is still unknown whether human graft-derived MSCs are able to suppress 
allo-reactive T-cell responses as potently as their BM counterparts. Although the liver 
is an immunologically tolerogenic organ (17-19), it is unknown whether MSCs in healthy 
liver contribute to this tolerogenicity. The organ donation process is associated with a 
wide range of hemodynamic and inflammatory changes throughout the body [20, 21] 
that may well affect the inherent immunosuppressive properties of MSCs in the liver 
graft. Inflammation affects pathways that can inhibit T-cell responses, such as the PD-L1/
PD-1 pathway. PD-1 is an inhibitory receptor expressed on T cells, which inhibits T-cell 
responses after interaction with its ligand PD-L1 [22, 23], which is expressed on antigen 
presenting cells and MSCs. PD-L1 is known to be up-regulated after exposure to inflam-
matory cytokines, such as IFN-γ (24). Another factor that is up-regulated in MSCs in re-
sponse to IFN-γ is indoleamine 2,3-dioxygenase (IDO) [25, 26], which has been associated 
with the immunosuppressive capacity of MSCs. Therefore, these mechanisms may well 
contribute to the inhibition of allo-reactive T cells by MSCs after liver transplantation. 
In addition, soluble factors secreted by MSCs, such as transforming growth factor-beta 
(TGF-β), hepatocyte growth factor (HGF) (27) and prostaglandin E2 (PGE2) (9) may con-
tribute to their capacity to inhibit allo-reactive T-cell responses as well.
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In the present study, we aimed to assess whether graft-derived MSCs can suppress 
allo-reactive T-cell responses and if so, whether they suppress more potently than their 
BM counterparts. To assess this, we isolated L-MSCs from liver perfusates obtained from 
donor livers and added these cells to mixed lymphocyte reactions. We measured prolif-
eration and effector function of allo-reactive T cells in these co-cultures in the presence 
or absence of L-MSCs. These outcomes were compared with those of co-cultures with 
BM-MSCs.
MATERIALS AND METhODS
Ethics Statement
Liver perfusates and splenocytes were obtained from deceased donors following organ 
donation. The use of all human materials was approved by the Medical Ethical Committee 
of the Erasmus MC-University Medical Center Rotterdam and the study was performed 
in accordance with the amended Declaration of Helsinki.
Isolation and culture of MSCs
BM-MSCs were harvested from aspirated bone marrow as previously described (28). 
L-MSCs were isolated from perfusates of human liver grafts. Liver perfusates were 
collected from liver graft donors during organ donation procedure, by flushing the 
transplant liver with 1 liter of University of Wisconsin (UW) preservation solution 
followed by a second flush with 400 ml human albumin during the back table bench 
procedure, prior to implantation, as previously described (14). Liver perfusates were 
collected and centrifuged (1500 rpm, 4°C; 10 minutes) to pellet cells. The cell pellet was 
resuspended in PBS and mononuclear cells (MNCs) were isolated using Ficoll Hypaque 
density gradient separation. MNCs were counted and resuspended in culture medium 
consisting of alpha-MEM/GLUTAMAX (Gibco), 2% FBS, 1% antibiotic-antimycotic (Gibco) 
supplemented with 20 ng/ml of recombinant human (rh)EGF (eBioscience) and 10 ng/
ml of rhFGF2 (eBioscience), plated at 1.0x105 cells/cm2 in 10 cm dishes and cultured at 
37°C, 5% CO2. After 3 days, the nonadherent fraction was removed and medium was 
replaced by fresh medium. Cells were cultured until colonies became confluent and were 
harvested using a nonenzymatic solution (TrypLE, Gibco) and further expanded for later 
use. Early passage cells from bone marrow were cultured and expanded in the same 
culture conditions as described for L-MSCs.
Immunophenotypic profile of MSCs in liver perfusates and BM-MSCs
To detect the presence of mobilized MSCs and hematopoietic stem/progenitor cells (HSCs) 
in liver perfusates from deceased donors, MNCs collected from the liver perfusates, as 
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described above, were counted for viability and stained to detect and quantify MSCs. For 
HSCs, MNCs were stained with the following antibodies: lineage-FITC (BD Pharmingen), 
CD34-PE (BD Pharmingen), CD38-APC-Cy7 (eBioscience), CD45RA-PB (eBioscience), and 
CD90-APC (eBioscience). For MSCs, MNCs were stained with the following antibodies: 
CD45-PB (eBioscience), CD146-PE (eBioscience), CD44-APC-Cy7 (eBioscience), CD73-APC 
(eBioscience), CD105-PE (eBioscience), CD90-FITC (eBioscience), CD14-PB (eBioscience), 
CD19-APC-Cy7 (eBioscience), HLA-ABC-FITC (eBioscience), and HLA-DR-APC (eBiosci-
ence). The same antibodies were used to stain BM-MSCs to compare the immunophe-
notypic profile of L-MSCs and BM-MSCs. The immunophenotypic profile of L-MSCs and 
BM-MSCs was carried out on early passage (P3) cells. Prior to addition of antibodies, cells 
were treated with Fc block (Miltenyi). Cells were stained at 4°C in the dark for 30 min-
utes. Afterwards, cells were washed, centrifuged and resuspended in PBS prior to flow 
cytometric analysis. All cells were incubated with 7-AAD (eBioscience) to discriminate 
dead/dying cells and debris. Samples were collected and a minimum of 1 million cells 
were measured on a BD FACS Canto II and analyzed using FlowJo software (Tree Star). In 
the analyses, gates were based on fluorescence-minus-one controls.
Differentiation Assays
Early passage (P3) L-MSCs were placed in defined culture conditions and compared 
with early passage (P3) BM-MSCs. For osteogenic differentiation, cells were plated at 
4000 cells/cm2 per well in a 6-well dish (Corning) in regular culture medium as described 
above, and placed in a humidified chamber with 5% CO2 at 37°C. After 24 hours, me-
dium was changed to osteogenic induction medium (alpha-MEM/GLUTAMAX, 10% FBS, 
1% Penicillin-streptomycin, 50 µM ascorbic acid (Sigma), 10 mM β-glycerophosphate 
(Sigma), 100 nM dexamethasone (Calbiochem)). To induce differentiation, half of the 
medium was replaced by fresh medium every 3 days for a total of 21 days. After 21 days, 
cell cultures were fixed with 4% paraformaldehyde (Sigma) for 15 minutes, washed twice 
with PBS and stained with 40 mM Alizarin Red S stain at pH = 4.1 (Sigma) for 30 minutes 
to detect mineralization.
For adipogenic induction, 1x105 cells were plated per well in a 6-well dish in regular 
culture medium and placed in a humidified chamber with 5% CO2 at 37°C. After 24 hours, 
the wells were washed with PBS and fresh adipogenic maintenance medium (DMEM/
Low glucose (Gibco), 10 µg/mL human insulin (Invitrogen), 10% FBS, 1% Penicillin/Strep-
tomycin) was added. After 3 days, the medium was changed to adipogenic induction 
medium (DMEM/Low glucose, 10 µg/mL human insulin, 100 µM indomethacin (Sigma), 
0.5 mM IBMX (Sigma), and 1 µM dexamethasone). After 3 days, medium was changed 
back to adipogenic maintenance medium. After an additional 2 rounds of maintenance-
induction media changes, cells were incubated for an additional 7 days in adipogenic 
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maintenance medium. After this, cells were fixed with 4% paraformaldehyde and stained 
with Oil Red O (Sigma) to detect formation of lipid droplets.
Immune	priming	of	MSCs	with	IFN-γ	plus	TNF-α
Passage 3 culture expanded L-MSCs and BM-MSCs were plated at 1.0x105 cells per well 
in a 6-well dish in regular culture medium. Cells were grown for 48 hours and afterwards 
were growth arrested in serum-free media (RPMI 1640, Gibco) for 24 hours. Following 
this, cells were treated with 10 ng/mL of rhTNF-α and 10 ng/ml of rhIFN-γ. After 24 hours, 
the cell media were collected, frozen down and stored at -80°C until further use. The cells 
were stained with the following primary fluorescently conjugated antibodies: PD-L1-APC 
(eBioscience), CD73-FITC (eBioscience), CD45-PB (eBioscience), HLA-DR-PE (eBioscience) 
in the presence of Fc blocking reagent (Miltenyi) at 4°C in the dark for 30 minutes. Cells 
were analyzed using a BD FACS Canto II Flow cytometer (BD Biosciences, San Jose, CA). 
7-AAD was included to discriminate dead/dying cells and debris. A minimum of 10,000 
events were collected and analyzed using FlowJo software (Tree Star).
Mixed lymphocyte reactions (MLR) in the presence or absence of MSCs
To test the suppressive capacity of MSCs on allogeneic T-cell responses, we performed 
mixed lymphocyte reactions (MLRs), in which we stimulated CFSE-labeled peripheral 
blood mononuclear cells (PBMCs) with allogeneic CD40-ligand stimulated (CD40)-B cells 
in the presence or absence of L-MSCs or BM-MSCs. PBMCs were isolated from blood 
of healthy blood bank donors using Ficoll Hypaque density gradient centrifugation and 
cryopreserved at -135°C until further use. CD40-B cells, which were used as allogeneic 
stimulator cells, were expanded from organ donor splenocytes, as previously described 
(29). For different experiments different responder and stimulator combinations were 
used. Both PBMCs and CD40-B cells were thawed and recuperated overnight in B-cell 
medium (IMDM + 10% human serum + 1% Penicillin/Streptomycin (Gibco) + 1% Insulin/
Transferrin/Selenium (Gibco)) at 37°C and 5% CO2. PBMCs were labeled with 0.5 µM CFSE 
(Invitrogen, Paisley, UK) according to the manufacturer’s instructions and CFSE-labeled 
PBMCs (1x105) were stimulated with 2x105 irradiated (30 Gy) donor CD40-B cells in 
96-wells U-bottom plates in a final volume of 250 µl B-cell medium. In separate wells, 
1x104 or 2x104 irradiated (30 Gy) liver graft-derived L-MSCs or BM-MSCs were added 
to the co-cultures. PBMCs stimulated with 5 μg/ml Phytohemagglutinin (PHA) (Murex) 
were included as positive controls to assess their proliferative capacity. Each culture 
condition was performed in duplicate.
In separate experiments, we studied the role of PD-L1, IDO and PGE2 in inhibition of 
allogeneic T-cell responses by MSCs by adding anti-PD-L1 mAb (10 µg/ml; eBioscience) to 
block PD-L1; 1Methyl-DL-tryptophan (1MT; 250 µM; Sigma-Aldrich) to block IDO; EP1-3 
receptor blockers (10 µM; AH6809, ITK Diagnostics) and EP4 receptor blocker (20 µM; 
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AH23848, Sigma-Aldrich) to block PGE2. In addition, to test the role of PGE2, L-MSCs and 
BM-MSCs were pre-treated overnight with 5 µM of Indomethacin (I7378, Sigma Aldrich). 
Indomethacin (5 µM) was also present during the 5 days of co-culturing.
After 5 days of culture at 37°C and 5% CO2, cell-free supernatant was collected, frozen 
and stored at -20°C for later analysis, and cells were stained for cell viability, using the 
LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen), according to the manufacturer’s 
protocol. Cells were then stained with anti-CD3-PerCP-Cy5.5 (BD Biosciences), anti-CD4-
APC-H7 (BD Biosciences), anti-CD8-efluor450 (eBioscience) to distinguish T-cell subsets 
and anti-CD19-horizonV500 (BD Biosciences) to exclude B cells from analysis. Cytotoxic 
degranulation was detected by addition of CD107a-APC (eBioscience) during the last 15 
hours of the co-cultures. Cells were analyzed for proliferation, using CFSE-dilution pat-
terns, and for phenotype on a BD FACS Canto II Flow cytometer (BD Biosciences, San Jose, 
CA). For analysis of phenotypic markers we used FACS Diva software (Becton Dickinson) 
and precursor frequencies (PF) of allo-reactive CD4+ and CD8+ T cells were calculated 
using ModFit LT® software (Verity Software House, USA), as previously described (29). 
From duplicate assays, average precursor frequencies were calculated.
IFN-γ production was measured in the culture supernatants by standard enzyme-
linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (Hu-
man IFNγ CytoSetTM, Invitrogen). TNF-α production was also measured in the culture 
supernatants by ELISA (human TNF-α Ready-Set-Go!, eBioscience)
Polymerase Chain Reaction (PCR)
Early passage (P3) liver perfusate-derived and bone marrow-derived MSCs were plated 
at 1.0 x 105 cells per well in a 6-well dish (Corning) in full growth medium. After 24 hours 
cells were growth arrested in serum free media (RPMI) for 24 hours. Following this, 
700 µl of Qiazol lysis buffer (Qiagen) was added to each well and cells were harvested. 
RNA was isolated using a Qiagen miRNeasy mini kit (Qiagen, Venlo, the Netherlands) 
and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). A total of 300 ng 
was used to make cDNA using an iScript cDNA synthesis kit from Bio-Rad (Bio-Rad 
Laboratories, Stanford, CA, USA) and 15 ng cDNA was used per real-time quantitative 
PCR (RT-qPCR) reaction. The expression of prostaglandin-endoperoxide synthase 1 and 2 
(PTGS1 and PTGS2) was quantified using RT-qPCR with a SensiMix Plus SYBR Kit (BioLine, 
London, UK) according to the manufacturer’s instructions. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as a household gene for normalization of gene 
expression. RT-qPCR was performed using the following primers; PTGS1-forward CGC-
CAGTGAATCCCTGTTGTT; PTGS1-reverse AAGGTGGCATTGACAAACTCC; PTGS2-forward 
CTGGCGCTCAGCCATACAG, PTGS2-reverse CGCACTTATACTGGTCAAATCCC. GAPDH-for-
ward: AAGGTCGGAGTCAACGGATTT, GAPDH-reverse: ACCAGAGTTAAAAGCAGCCCTG. 
The fold change in mRNA was determined using the ΔCt method.
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Statistics
Data were analyzed with GraphPad Prism 5.0 software and expressed as mean ± SEM. 
To test whether data were normally distributed the Kolmogorov-Smirnov test was used. 
Differences between groups were analyzed using the paired t-test (normally distributed 
paired data), Wilcoxon signed rank test (non-normally distributed paired data) or Mann 
Whitney test (unpaired data). One-sample t-test was performed to test differences 
between experimental conditions and control conditions consisting of one sample. P-
values < 0.05 were considered significant.
RESuLTS
Immunophenotypic and differentiation potential of MSC-like cells mobilized 
from liver grafts are similar to those of BM-MSCs
To explore whether MSCs mobilize from human liver grafts after tissue injury in vivo we 
collected liver graft perfusates during flushing of liver grafts at time of transplantation. 
These livers have been exposed to hemodynamic, ischemic and inflammatory changes 
during the donation process. From these liver perfusates, we recovered a population of 
cells that adhered to plastic and were amenable to expansion, like BM-MSCs (Figure 1A 
and B). In addition, these graft-derived cells could well differentiate into adipocytes and 
osteocytes (Supplemental Figure 1). Likely these cells originate from the graft paren-
chyma and not from residual donor blood, as MSCs could not be recovered from donor 
blood cells [14, 30]. To confirm whether these graft-derived cells were of mesenchymal 
origin we compared their phenotype with that of BM-MSCs. This analysis revealed that 
liver perfusate-derived cells lacked the hematopoietic markers CD45, HLA-DR, CD14 
and CD19 (representative flow cytometric plots in Figure 1C) while they expressed the 
common mesenchymal markers CD146, CD44, CD73, CD90 and CD105 (Figure 1D). This 
phenotype was similar to that of BM-MSCs (Figure 1C and D). Combined, these data sug-
gest that MSC-like cells in perfusates represent genuine graft-derived liver MSCs.
L-MSCs suppress allo-reactive T cells better than BM-MSCs
Previously, it has been shown that BM-MSCs can suppress proliferation of allo-primed T 
cells (9). We compared the suppressive capacity of L-MSCs with that of BM-MSCs in mixed 
lymphocyte reactions (MLRs) in which CFSE-labeled PBMCs were stimulated with alloge-
neic splenocyte-derived CD40-B cells as strong antigen presenting cells, as described 
previously (29). The level of T-cell proliferation was determined using CFSE-dilution 
patterns, from which we calculated precursor frequencies (PF) of responding T cells, as 
shown in Figure 2A. We found that both CD4+ and CD8+ T cells proliferated in response 
to stimulation with allogeneic CD40-B cells over a 5-day period. Precursor frequencies in 
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the control conditions varied from ~2-10%, because different responder and stimulator 
cells combinations were used for different experiments. To test the suppressive capacity 
of L-MSCs and BM-MSCs, we added L-MSCs or BM-MSCs to the co-cultures at an MSC/
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Figure	1.
Detecti on of mesenchymal stromal (MSC)-like cells in the perfusates from human liver graft s. (A) Representa-
ti ve phase contrast images of plasti c adherent cells recovered from the mononuclear cell fracti on of liver per-
fusates from liver graft s and from bone marrow (BM). (B) Expansion of plasti c adherent cells obtained from 
the perfusates of liver graft s over the course of 21 days. P1-3: passage 1-3. (C) Representati ve multi colour fl ow 
cytometric plots demonstrati ng that culture expanded plasti c adherent cells recovered from liver perfusates 
lacked the hematopoieti c markers CD45, HLA-DR, CD14 and CD19. (D) Representati ve multi colour fl ow cyto-
metric plots demonstrati ng that the immunophenotypic profi le of culture expanded plasti c adherent cells 
recovered from liver perfusates was similar to that of BM-MSCs, based on CD45-CD146+CD44+CD73+CD90+. 
Gates are based on fl uorescence minus one in control conditi ons.
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Figure	2.
Graft -derived L-MSCs suppress allo-reacti ve T-cell responses stronger than BM-MSCs. CFSE-labeled PBMCs 
were cultured for 5 days with allogeneic splenocyte-derived CD40-ligand sti mulated B cells (CD40-B cells). 
Mixed lymphocyte reacti ons (MLR) were performed in the presence and absence of either L-MSCs (n = 12) 
or BM-MSCs (n=6). CFSE-diluti on patt erns of CD4+ and CD8+ T cells were analyzed and precursor frequen-
cies (PF) were calculated with ModFit® soft ware. (A) Representati ve ModFit-derived CFSE-diluti on patt erns 
of CD4+ (left  panel) and CD8+ (right panel) T cells aft er 5 days sti mulati on with allogeneic CD40-B cells with 
and without MSCs. (B) Scatt er dot plots showing precursor frequencies of allo-reacti ve CD4+ and CD8+ T cells 
in the MLR without MSCs (control MLR, dott ed line) and in the MLRs with L-MSCs versus BM-MSCs. Data 
depicted as mean ± SEM. (C) In parallel, fl ow cytometric analysis of CD107a (y-axis) on CD4+ (upper panel) 
and CD8+ (lower panel) T cells in the MLRs was performed. Representati ve fl ow cytometric plots are shown 
from control MLR, MLRs with L-MSCs and MLRs with BM-MSCs. (D) Scatt er dot plots showing % proliferated 
CD107a+ CD4+ and CD8+ T cells in the control MLR (dott ed line) and in the MLRs with L-MSCs versus BM-MSCs. 
Data depicted as mean ± SEM. (E) In parallel, samples of the same PBMCs were analyzed for IFN-γ producti on 
upon sti mulati on with CD40-B cells. Five days aft er beginning the MLR, supernatants were harvested and 
IFN-γ levels were measured using ELISA. Scatt er dot plots showing IFN-γ producti on in MLR (dott ed line) and 
in MLRs with L-MSCs versus BM-MSCs. Diff erences between suppressive eff ects of L-MSCs versus BM-MSCs 
were tested using Mann Whitney test. * p<0.05 ** p<0.01 *** p<0.001
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PBMC ratio of 1:10 or 1:5. With addition of L- MSCs (n =12, different donors) at ratio 1:5 
proliferation of allo-reactive CD4+ T cells was nine-fold lower and of CD8+ T cells ten-fold 
lower than in control culture without L-MSCs. This difference was significantly different 
(p<0.0001). The anti-proliferative effect of BM-MSCs (n=6, different donors) was also 
evident, causing a four-fold lower proliferation of both CD4+ and CD8+ T cells than in 
control cultures without BM-MSCs (p<0.0001). Interestingly, L-MSCs suppressed CD8+ 
T cell proliferation significantly better than BM-MSCs (Figure 2B; p<0.05). This superior 
suppressive effect of L-MSCs was also observed for CD4+ T cells, although not statistically 
significantly (Figure 2B, p=0.068). With the addition of MSCs at MSC/PBMC ratio 1:10 
we found the same trend towards a stronger anti-proliferative effect of L-MSCs than 
BM-MSCs, although the suppression was less strong and differences between L-MSCs 
and BM-MSCs were stronger at ratio 1:5. Apparently there is a dose-dependent inhibitive 
effect of MSCs on T-cell proliferation. In addition, L-MSCs inhibited cytotoxic degranula-
tion, as measured with surface expression of CD107a on proliferated T cells, of both allo-
reactive CD4+ and CD8+ T cells significantly better than BM-MSCs (p<0.01, Figure 2C, D). 
Finally, L-MSCs reduced IFN-γ production significantly (p<0.01) while BM-MSCs did not. 
This difference between BM-MSCs and L-MSCs was statistically significant (figure 2E, 
p<0.05). TNF-α production was strongly inhibited by both L-MSCs and BM-MSCs with no 
significant difference between L-MSCs and BM-MSCs (data not shown).
Soluble	factors	secreted	by	L-MSCs	suppress	CD4+,	but	not	CD8+, T-cell 
proliferation	and	CD4+	and	CD8+ cytotoxic degranulation
To assess whether the inhibition of L-MSCs on T-cell responses were cell-cell contact-in-
dependent, MLRs were performed in the presence of conditioned medium (CM) derived 
from MSC-cultures. We found that the CM from L-MSCs suppressed the proliferation 
of allo-reactive CD4+ T cells, while CM from BM-MSCs did not (Figure 3A, p<0.001). CM 
from L-MSCs also suppressed proliferation of CD8+ T cells significantly (p<0.01), but this 
effect was not significantly different from the suppressive effects of CM from BM-MSCs 
(Figure 3A). In addition, CM from L-MSCs suppressed the cytotoxic degranulation ca-
pacity of allo-reactive CD4+ T cells and CD8+ T cells significantly better than CM from 
BM-MSCs (Figure 3B, p<0.001 and p<0.01 respectively). CM from L-MSCs was not able 
to suppress IFN-γ production or TNF-α production (data not shown). Taken together, 
these data suggest that the immunomodulatory potential of L-MSCs is at least partially 
mediated by secreted factors.
L-MSCs	express	higher	levels	of	PD-L1	than	BM-MSCs,	which	is	associated	with	
suppression of allo-reactive T-cell responses
We wondered which mechanism could cause the superior immunosuppressive capacity 
of L-MSCs in comparison with their BM-MSCs counterparts. An important co-inhibitory 
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pathway in (allo-reactive) T-cell responses is the PD-1/PD-L1 pathway (31). We found 
that L-MSCs have higher baseline expression levels of PD-L1 than BM-MSCs (Figure 4A,C, 
p<0.05), which could be a reason for the higher suppressive capacity of L-MSCs. Pro-
inflammatory cytokines have been described to up-regulate PD-L1. Since pro-inflam-
matory cytokines increase during the organ donation process, it is possible that during 
donation, MSCs in the liver become primed and thereby up-regulate PD-L1. To assess the 
effect of pro-inflammatory cytokine priming on PD-L1 expression and suppressive ca-
Figure	3.
Graft-derived L-MSCs suppress allo-reactive T-cell responses stronger by soluble factors than BM-MSCs. Su-
pernatants from MSCs (conditioned medium (CM)) were added to the MLR and at the end of 5 days allo-
reactive T-cell responses were measured. (A) Scatter dot plots showing precursor frequencies of allo-reactive 
CD4+ and CD8+ T cells in the MLR without CM (control MLR, dotted line) and in the MLRs with CM from L-MSCs 
versus CM from BM-MSCs. Data depicted as mean ± SEM. (B) Scatter dot plots showing % proliferated CD107a+ 
CD4+ and CD8+ T cells in the control MLR (dotted line) and in the MLRs with CM L-MSCs versus CM BM-MSCs. 
Data depicted as mean ± SEM. * p<0.05 ** p<0.01 *** p<0.001
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pacity, we exposed L-MSCs and BM-MSCs to TNF-α and IFN-γ ex vivo and measured their 
PD-L1 expression and suppressive function. After priming, we indeed found a strongly 
up-regulated PD-L1 expression on both L-MSCs and BM-MSCs (Figure 4B,C).
We wondered whether the superior suppressive effects of L-MSCs were mediated by 
their higher level of PD-L1 expression. We first looked at the correlation between PD-L1 
expression on MSCs and the corresponding T-cell responses in the MLRs and found that 
Figure	4.
Graft-derived L-MSCs express higher levels of PD-L1 than BM-MSCs; PD-L1 is up-regulated after ex vivo priming 
with pro-inflammatory cytokines and associated with suppression of allo-reactive T-cell responses. (A) Repre-
sentative flow cytometric plots demonstrating baseline expression of PD-L1 on L-MSCs and BM-MSCs. (B) Rep-
resentative flow cytometric plots demonstrating induced expression of PD-L1 following ex vivo priming with 
pro-inflammatory cytokines rh-IFN-γ/TNF-α at 10 ng/mL for 24 hours. (C) Scatter dot plot showing percent-
ages of live CD45- cells expressing PD-L1 at baseline or following stimulation with rh-IFN-γ/TNFα, quantified 
using flow cytometry (L-MSCs, n=16; BM-MSCs, n=6). (D) Correlation between baseline PD-L1 expression on 
the MSCs added to the MLRs and precursor frequencies of CD4+ and CD8+ T cells in the MLRs and correlation 
between PD-L1 and cytotoxic degranulation in the MLRs. Correlation was tested using Spearman’s rank cor-
relation coefficient. To test whether the suppressive effects of L-MSCs and BM-MSCs could be abrogated by 
blocking PD-L1, a PD-L1 blocking antibody was added to the MLRs. (E) Scatter dot plots showing % proliferated 
CD107a+ CD4+ and CD8+ T cells in the control MLR (dotted line); in the MLRs with L-MSCs versus L-MSCs+anti-
PD-L1 and in the MLRs with BM-MSCs versus BM-MSCs+anti-PD-L1. Data depicted as mean ± SEM. Differences 
between MLRs with and without anti-PD-L1 were tested using paired t-test. * p<0.05 ** p<0.01 *** p<0.001
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a higher PD-L1 expression on MSCs was strongly correlated with lower proliferation of 
both CD4+ and CD8+ T cells in the MLRs. In addition, higher PD-L1 expression levels were 
also strongly correlated with lower cytotoxic degranulation capacity of both CD4+ and 
CD8+ T cells in the MLRs (Figure 4D). We then added an anti-PD-L1 antibody to the MLRs 
to test whether blockade of the PD-1/PD-L1 interaction abrogated the suppressive ef-
fects of the L-MSCs. We found that anti-PD-L1 did not abrogate the suppressive effects 
of L-MSCs on proliferation and IFN-γ production or TNF-α production of T cells (data 
not shown), but significantly abrogated the effects on CD4+ and CD8+ T-cell cytotoxic 
degranulation (Figure 4E, p<0.05 and p<0.01 respectively).
Immunosuppressive effects of MSCs partly involves IDO, but not prostaglandin 
E2
In a previous study of our research group (14) we performed a gene expression profiling 
to compare the molecular phenotypes of L-MSCs and BM-MSCs. These data showed 
that L-MSCs and BM-MSCs were very similar, but a small number of genes was differ-
entially expressed between L-MSCs and BM-MSCs. In the present study, we focused on 
the genes that were differentially expressed, to investigate whether these could provide 
insight into the differences in immunomodulatory effects of L-MSCs and BM-MSCs. One 
of the genes that were significantly differentially expressed was PTGS1, which encodes 
for Cyclooxygenase-1 (COX-1). COX-1 is the key enzyme in prostaglandin biosynthesis 
(32). Prostaglandins are produced by MSCs and have previously been described to inhibit 
T-cell responses (9). Since PTGS1 was 20-fold higher expressed in L-MSCs than BM-MSCs, 
differences in prostaglandin production between the two types of MSCs could well 
explain the immunomodulatory differences that we found. We first confirmed the dif-
ference in PTGS1 gene expression between L-MSCs and BM-MSCs using PCR (Figure 5A, 
p<0.001). We then investigated whether culturing MSCs in the presence of COX-1 inhibi-
tor Indomethacin affected the immunomodulatory function of L-MSCs or BM-MSCs in 
the co-cultures with PBMCs. However, we found no effects of this (Figure 5B). In ad-
dition, we determined whether blockers of the prostaglandin receptors EP1,2,3 and 4 
abrogated the inhibitive effects of CM from L-MSCs or BM-MSCs. However, we were not 
able to show higher rates of T-cell proliferation after addition of the blockers (Figure 5C).
Another suppressive mechanism described for MSCs is the production and activity of 
indoleamine 2,3-dioxygenase (IDO) [25, 26]. After addition of 1MT to block IDO we found 
significant abrogation of the immunosuppressive effects of L-MSCs, but not BM-MSCs, 
on T-cell proliferation (Figure 6, p<0.001). No effect on cytotoxic degranulation was 
observed (data not shown). In conclusion, L-MSCs inhibit CD4+ and CD8+ T-cell degranula-
tion partly by PD-L1/PD-1 interaction and inhibit T-cell proliferation partly by IDO.  
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DISCuSSION
In this study we showed that graft-derived L-MSCs which are released during trans-
plantation suppress proliferation, cytotoxic degranulation and IFN-γ production of 
allo-reactive T cells. This suppressive capacity of L-MSCs was significantly better than 
that of BM-MSCs, even though the phenotype and differentiation potential of L-MSCs 
and BM-MSCs were very similar. However, L-MSCs expressed higher levels of PD-L1 than 
BM-MSCs. PD-L1 is the ligand for the co-inhibitory receptor PD-1 on T cells. On L-MSCs, 
expression of PD-L1 was associated with inhibition of T-cell proliferation and cytotoxic 
Figure	5.
Effects of blocking PGE2 on the inhibition of T-cell responses by L-MSCs and BM-MSCs. (A) Relative expres-
sion of PTGS1 in L-MSCs (n=10) versus BM-MSCs (n=5). B) Scatter dot plots showing precursor frequencies of 
allo-reactive CD4+ and CD8+ T cells in the MLR without MSCs (control MLR, dotted line) and in the presence 
and absence of L-MSCs (n=3) versus BM-MSCs (n=2) pre-treated with and in the presence of COX-1 inhibitor 
Indomethacin. Data depicted as mean ± SEM. C) Scatter dot plots showing precursor frequencies of allo-
reactive CD4+ and CD8+ T cells in MLRs with CM from L-MSCs (n=6) versus CM from BM-MSCs (n=3), in the 
presence and absence of blockers of PGE2 receptors EP1-4. Data depicted as mean ± SEM. * p<0.05 ** p<0.01 
*** p<0.001
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degranulation in vitro. There was a strong correlation between levels of PD-L1 expression 
on MSCs and corresponding proliferation and cytotoxic degranulation of T cells in the 
co-cultures. The up-regulation of PD-L1 on graft-derived MSCs may be a consequence of 
in vivo priming by pro-inflammatory cytokines, which are elevated during the donation 
process [33, 34]. Blocking of PD-L1 in vitro partly abrogated the suppressive effects of 
L-MSCs on CD4+ and CD8+ T-cell cytotoxic degranulation. However, blocking of PD-L1 did 
not abrogate the effects on proliferation and IFN-γ and TNF-α production. Apparently, 
the PD-L1 expression represents a surrogate marker of inhibition, but the higher PD-L1 
expression on L-MSCs only partly explains that suppressive effects of L-MSCs on T-cell 
responses were superior to those of BM-MSCs. Likely other mechanisms are involved in 
this.
We showed that, besides cell-cell contact-dependent mechanisms, soluble factors 
produced by L-MSCs contribute to the superior suppression of allo-reactive T-cell 
responses as well. Since soluble factors have been described to contribute to the immu-
nosuppressive properties of MSCs (35) we further investigated the suppressive function 
of secreted factors of MSCs present in conditioned culture media on allo-reactive T-cell 
responses. Our finding that CM from L-MSCs suppressed T-cell proliferation, but not T-
cell degranulation and IFN-γ and TNF-α production, whereas CM from BM-MSCs exerted 
no suppressive effects, suggests that L-MSCs produce T-cell suppressive soluble factors 
Figure	6.
Effects of blocking IDO on the inhibition of T-cell responses by L-MSCs and BM-MSCs. Scatter dot plots show-
ing precursor frequencies of allo-reactive CD4+ and CD8+ T cells in the MLR without MSCs (control MLR, 
dotted line) and in the presence of L-MSCs (n=12) versus BM-MSCs (n=6), in the presence and absence of 
IDO-blocker 1MT. Data depicted as mean ± SEM. Differences between MLRs with and without 1MT were 
tested using Wilcoxon signed rank test. * p<0.05 ** p<0.01 *** p<0.001
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that BM-MSCs do not produce. These soluble factors released by graft-derived L-MSCs 
may directly affect T cells or indirectly via their effect on antigen presenting cells [12, 
36]. Soluble factors secreted by L-MSCs could inhibit the stimulator CD40-B cells in the 
co-cultures, which thereby causes inhibition of the T-cell responses.
An interesting finding was that L-MSCs showed higher expression of PTGS1, a key en-
zyme involved in prostaglandin production, than BM-MSCs. Although prostaglandins are 
produced by MSCs and are able to inhibit T-cell responses (9), we did not find abrogative 
effects of blocking prostaglandins, either by Indomethacin or by prostaglandin receptor 
inhibitors. Clearly these results show no role for PGE2 in the inhibition by MSCs.
More importantly, we found that blocking IDO partly restored T-cell proliferation that 
was inhibited by L-MSCs, while this had no effect on the conditions with BM-MSCs. IDO 
has previously been shown to inhibit T-cell responses by MSCs [25, 26, 37]. Our finding 
that blocking IDO only abrogated the inhibition by L-MSCs and not BM-MSCs supports the 
hypothesis that the immunomodulatory function of MSCs is highly plastic, as published 
previously (38), since L-MSCs have been exposed to an inflammatory environment.
One of the limitations of comparative studies of MSC populations is the lack of consen-
sus to immunophenotypically define these cells (6). The current study compared MSC 
populations from liver grafts and bone marrow. MSCs found in liver graft perfusates 
adhered to plastic, were amenable to expansion and expressed cell surface markers 
that are described to identify MSCs, similar to BM-MSCs (6). The superior suppressive 
capacity of L-MSCs may be related to the tissue source. The phenotype of MSCs in the 
liver may reflect the hypo-responsiveness of the hepatic immune system. Another dif-
ference is that L-MSCs have been exposed to extensive ischemia, whereas cells from 
bone marrow were not exposed to substantial ischemia. Lastly, a difference between 
BM-MSCs and L-MSCs is their mobilization. L-MSCs were mobilized and released from 
the liver parenchyma during the donation process, whereas BM-MSCs were obtained 
from the stroma, without mobilization and release. Which of these differences is most 
likely to attribute to the T-cell suppressive capacity of MSCs needs further evaluation.
For future clinical applications, our study provides insights in the superior immuno-
suppressive capacity of L-MSCs, which may lead to cell-based immunosuppressive 
therapies using liver graft-derived MSCs. For this therapeutic application, L-MSCs need 
to be isolated from the donor liver and expanded in vitro, as described previously (39), 
since L-MSCs are present in low numbers. After expansion, L-MSCs should be infused in 
patients and may have an important function in the setting after liver transplantation 
(39) or may be used as bridging therapy before transplantation in patients with acute 
liver failure [40, 41].
In conclusion, we showed that MSCs mobilized from livers grafts strongly suppress 
allo-reactive T-cell responses. This suppression was stronger than non-mobilized and 
non-primed MSCs derived from BM stroma. These differences may not only be related 
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to the intragraft immune priming of L-MSCs in the organ donor or due to mobilization of 
MSCs from the graft, but may also be related to the inherent immunological tolerogenic-
ity of the liver. In the setting of liver transplantation, resident and/or mobilized L-MSCs 
may therefore regulate immune-mediated liver damage by suppressing pathogenic allo-
reactive T-cell responses, leading to better acceptance of liver grafts.
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Supplemental	Figure	1.
Differentiation potential of the plastic adherent MSC-like cells recovered from liver perfusates and from BM. 
Representative image of adipogenic differentiation depicted by uptake of Oil Red O (upper panels). Osteo-
genic differentiation potential depicted by Alizarin Red S staining (lower panels).
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Liver transplant patients are susceptible to severe complications that strongly affect 
their survival and quality of life (1). The aims of this thesis were to identify risk factors 
for the occurrence of complications in patients with end-stage liver disease (ESLD), both 
before and after liver transplantation (LTx), and to develop strategies to optimize immu-
nosuppression after LTx in order to reduce immunosuppression-related complications. 
Important complications in LTx patients are acute rejection and side effects of immuno-
suppressive drugs, such as infections. For example, up to 80% of LTx patients develop 
at least one episode of infection during the first year after transplantation, which is the 
leading cause of death early post-LTx (2, 3), and about 30% of LTx patients experience 
one or more episodes of acute rejection. Other factors that influence the occurrence 
and severity of these complications can be subdivided into different categories, amongst 
which genetic factors and viral factors. How these factors may affect complications in 
LTx patients, and which strategies may be used to reduce complications of the use of 
immunosuppression after LTx has been investigated in this thesis and our findings will be 
summarized and discussed in this chapter. We will also discuss which issues need to be 
addressed in future studies.
I.	 Genetic	factors	affecting	susceptibility	to	infections	and	rejection	in	liver	
transplant patients
Summary
In part I (Chapters	2-4) of this thesis we focused on genetic factors in innate immunity 
receptors and their downstream inflammatory response genes that may affect suscepti-
bility to infections in patients before and after LTx and to acute rejection after LTx.
In Chapter	2 we investigated the allelic variants in the gene encoding the pro-inflam-
matory cytokine Tumor Necrosis Factor (TNF)-α. We showed that presence of the variant 
allele TNFA c.238A (rs361525) in ESLD patients almost completely protects from develop-
ing severe bacterial infections (SBIs) and SBI-related death in two independent cohorts 
of patients awaiting LTx. In addition, the A allele was associated with lower serum levels 
of TNF-α than the GG genotype. Although one could speculate that lower levels of the 
pro-inflammatory cytokine TNF-α may be associated with higher risk of infections, the 
strong protective effect of this allele supports the biological concept that TNF-mediated 
desensitization of innate immune cells drives increased susceptibility to bacterial infec-
tions in patients with ESLD (4-6). TNFA rs361525 genotyping in patients waiting for LTx 
may help to determine the individual risk of SBIs, which is helpful to decide on the use of 
prophylactic antibiotics in these patients.
In Chapter	3 we studied the predictive value of donor mannose-binding lectin (MBL) 
genotyping for bacterial infections in patients after LTx in our own center, since three 
previous studies showed that patients transplanted with genetically MBL-insufficient 
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donor livers experienced more bacterial infections after LTx (7-9), while a fourth study 
found no association between donor MBL genotype and post-transplant infections (10). 
We noted that each of these studies categorized the donor livers differently with regard 
to MBL-sufficiency. We therefore categorized the donor livers in our study similar to the 
stratification systems that were used in the cited studies. Importantly, none of the three 
stratifications resulted in a statistically significant association between the donor MBL 
genotype and clinically significant infections in our patient cohort.
In Chapter	4 we studied associations between genetic variants in various innate immu-
nity receptors and the risk of bacterial and fungal infections as well as acute rejection in 
two cohorts of patients after LTx. Our data show that neither risk of bacterial and fungal 
infections nor risk of acute rejection after LTx is significantly influenced by 50 common 
genetic polymorphisms in innate immunity receptors. Since some of the investigated 
genetic variants in innate immunity receptors were found to be associated with risk of 
infections in critically ill non-transplanted patients (11-19), our findings suggest that the 
influence of these genetic variants is less prominent in transplanted patients. We believe 
that transplant-related variables therefore are superior to the tested genetic polymor-
phisms as risk factors for bacterial and fungal infections and acute rejection.
Discussion and future perspectives
Since up to 80% of LTx patients develop at least one episode of infection during the first 
year after transplantation (2, 3), and about 40% of patients waitlisted for LTx suffer from 
severe infections (Chapter	2), it is important to identify risk factors for infections in these 
patients. In this part we studied whether genetic variants in the innate system and their 
downstream inflammatory response genes affect the risk of infections in LTx patients, 
since innate immunity receptors trigger innate immune responses against microbial 
components and are also critically involved in shaping adaptive anti-microbial immune 
responses (11, 20, 21), and it has been described that genetic variants in these receptors 
are associated with the risk of infections in critically ill non-transplantation patients (11-
19). In addition, since immunosuppressive drugs suppress the adaptive immune system 
of patients after LTx, the role of the innate immune system may become more important 
in combating infections. Although we also investigated associations between genetic 
variants and acute rejection and fungal infections after LTx, in this discussion we will 
focus on the effect of genetic variants on the risk of bacterial infections pre-LTx and 
post-LTx.
Interestingly, we found that a genetic variant in a cytokine gene of the Toll-like receptor 
(TLR) 4 signaling pathway, namely TNFA c.238A encoding the pro-inflammatory cytokine 
TNF-α, was significantly associated with the risk of bacterial infections in patients before 
LTx (Chapter	2), while in patients after LTx none of the studied genetic variants in innate 
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immune receptors were associated with bacterial infections (Chapter	3-4), although the 
TNFAc.238A polymorphism that we tested pre-LTx was not examined in our cohorts post-
LTx. An important question that arises is: why did we not find associations between the 
genetic variants and infections after LTx while the study described in Chapter	2 as well as 
other studies showed significant associations with infections in both immunocompetent 
and immunocompromised patients?
First, we showed in Chapter	3 that previous studies that found an association between 
donor MBL2 variants and infections post-LTx used different ways to stratify donor livers 
into MBL-sufficient and MBL-insufficient on basis of genetic MBL polymorphisms (7-9). 
We have concerns about the validity of the results of these studies, because it is arbitrary 
which stratification method should be used, and the associations may have become 
insignificant when other stratification methods would have been used. However, none 
of the stratification methods resulted in significant associations between donor MBL2 
variants and infections post-LTx in our study. This may be related to the time of follow-
up, which was shorter in our study than in the other studies. This issue will be discussed 
below in more detail.
Second, in Chapter	 4	we showed that genetic variants in various innate immunity 
receptors in recipients as well in donors were not associated with the risk of infections 
after LTx, while in other studies significant associations were shown between some 
of these genetic variants and infections in critically ill non-LTx patients. These studies 
showed that genetic variants in TLR2, TLR4 and CD14, which were also studied in our 
study, were significantly associated with infections, specifically bacteremia and sepsis. 
TLR2 recognizes microbial membrane constituents such as lipoteichoic acid, peptidogly-
can, and lipoproteins of gram-positive bacteria; and variants in this receptor may there-
fore mainly affect the risk of gram-positive infections (17). TLR4 binds gram-negative 
bacterial lipopolysaccharide (LPS). First, LPS is bound by circulating LPS-binding protein 
(LBP), which functions as an opsonin for CD14, which in turn acts as a catalyst for the 
binding of LPS to MD2, a co-receptor that is physically associated with TLR4. Genetic 
variants in TLR4, CD14 and/or LBP may therefore mainly affect the risk of gram-negative 
infections (13-16). For this reason, we analyzed associations between genetic variants 
and gram-positive or gram-negative infections also separately. Nevertheless, in contrast 
to the cited studies (11-19), we did not find any association between genetic variants 
in these receptors and clinically serious infections (CSI) in patients after LTx. A clinical 
factor that influences the risk of gram-negative or gram-positive infections is the use of 
selective bowel/digestive decontamination (SDD). Although SDD does not significantly 
increase the risk of CSI in general, it may cause a decrease in gram-negative bacterial 
infections, with an increased risk for gram-positive infections (22). In Chapter	 4 we 
described that patients from our study transplanted before the year 2000 received SDD, 
while patients transplanted after 2000 did not. In our study, patients with and without 
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SDD were not analyzed separately because the groups became too small; and thereby 
associations between variants in the TLR4 pathway and gram-negative infections and 
between TLR2 variants and gram-positive infections may have been missed. In addition, 
the lack of confirmation of associations between these variants and either gram-positive 
or gram-negative infections in our validation cohort may be explained by differences in 
SDD treatment as well, since patients in the validation cohort were transplanted in later 
years than patients in the identification cohort.
In addition, an important difference between critically ill non-transplant patients and 
post-LTx patients is that post-LTx patients use immunosuppressive drugs. As described in 
Chapter	4, not much is known about the influence of type and intensity of immunosup-
pression on expression of pattern recognition receptors (PRRs), although it has been 
shown that high dose steroid pulse therapy to treat acute rejection after LTx reduced 
expression of TLR2 and TLR4 on circulating monocytes (23). If immunosuppressive drugs 
affect the expression of PRRs in patients after LTx, this may explain that genetic vari-
ants in these receptors become less important in patients after LTx than in the general 
population.
Not many previous studies have investigated associations between genetic variants in 
receptors of the innate immune system and CSI in patients after LTx. Lee et al (24) showed 
that a polymorphism in TLR2 affected the recurrence rate of gram-positive infections and 
gram-positive septic shock in patients after LTx, but not the incidence of gram-positive 
infections. De Rooij et al showed that mutation of donor ficolin was associated with CSI 
and that the wild-type allele of donor mannan-binding lectin serine peptidase (MASP)2 
was associated with CSI in two independent cohorts (8). A polymorphism in nucleotide-
binding oligomerization domain (NOD)2 was associated with CSI in another study from 
the same research group (25). Interestingly, we did not find these associations in our 
cohorts, although the same polymorphisms were studied. An explanation for this differ-
ence may be that the studies used other follow-up times. We considered CSI only in the 
first three months after LTx, while the authors who found associations between variants 
in the lectin pathway and CSI (8, 25) studied infections within the first year after LTx. In 
Figure 1 of the study of de Rooij et al (8) it is shown that variants in different components 
of the lectin pathway have a cumulative effect on the risk of CSI, and this risk increases 
over time after LTx. Importantly, 3 months after LTx the difference in infection rate be-
tween patients with wild-type versus one variant in the lectin pathway is relatively small, 
but increases one year after LTx. In our study (Chapter	4) we may therefore have missed 
a significant influence of the genetic variants due to a shorter follow-up time and due to 
looking at the variants independently of each other, instead of combining them in order 
to find a cumulative effect.
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In addition, it is known that infections at different time periods after LTx are influenced 
by different risk factors. As reviewed by Van Hoek et al (26), infections in the first month 
post-LTx are largely influenced by surgical risk factors and other transplant-related 
factors, while infections between one and six months post-LTx are more related to im-
munosuppression; and late infections (after six months post-LTx) may be influenced by 
co-morbidities such as hepatitis C, diabetes, and graft dysfunction. Due to the shorter 
follow-up time in our study, the influence of transplant-related factors on the incidence 
of CSI may be more prominent than in the other cited studies, and due to this, effects of 
genetic variants may have been missed in our study. In addition, although we included 
clinical variables in our multivariate analyses, unfortunately we did not include some 
of the risk factors that are known to contribute to CSI after LTx (26), such as prolonged 
ICU-stay, amount of intra-operative blood transfusion, and MELD-scores.
To further establish whether genetic variants in innate immunity receptors affect the 
risk of CSI after LTx, we suggest first to take into account the timing of infections, thereby 
studying infections in the first month post-LTx separately from infections between one 
and six months post-LTx. The effect of genetic variants in the innate immune system 
may be the strongest in the second time-frame, since this is the time-frame in which 
infections are most strongly affected by immunosuppression and less by surgical and 
transplant factors. Second, we suggest to include important transplant-related factors 
in the analyses, as mentioned above. Third, larger patient cohorts are needed, in order 
to enable stratification of patients into groups with different prophylactic antibiotic 
therapies, which also has been shown to influence the risk of CSI (26), and with and 
without SDD, which may influence the incidence of post-transplant gram-positive versus 
gram-negative infections, thereby affecting the relative influences of genetic variants in 
TLR2 and TLR4 pathways.
Importantly, the TNFA polymorphism that we showed to protect patients against infec-
tions pre-LTx (Chapter	2) was not determined in our patients post-LTx (Chapter	4). For 
future study, it would be very interesting to follow-up those of the patients studied in 
Chapter 2 who were transplanted, in order to determine whether the TNFA c.238 A allele 
also protects patients against infections and infection-related death after LTx. In addi-
tion, it is also interesting to retrospectively investigate whether the polymorphisms that 
we studied in Chapter 4 are associated with infections in these patients before they were 
transplanted.
For clinical practice, although we did not find significant effects of the other genetic 
variants in the TLR4 pathway that we tested in Chapter 2, it is interesting to investigate 
whether different combinations of genetic variants in this pathway or in other pathways 
are associated with the risk of infections in LTx patients, in order to establish a “genetic 
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risk profile” either with or without combination with clinical risk factors. This will increase 
the predictive value of these risk factors and contribute to identifying different patient 
categories who need less or more prophylactic antibiotic treatment and microbial moni-
toring.
II.	 Viral	factors	affecting	anti-donor	T-cell	reactivity	after	liver	transplantation
Summary
In Part II (Chapter	5-6) we described the influence of viral factors, especially cytomega-
lovirus (CMV) infection, on the T-cell alloresponse after LTx.
In Chapter	5 we showed that patients with CMV primary infection after LTx show ex 
vivo donor-specific CD8+ T-cell hyporesponsiveness. Moreover, in a large retrospective 
cohort study of LTx patients from our center we showed that patients with primary CMV 
infections are protected from the occurrence of late acute rejection (LAR). In addition, we 
determined circulating Vδ1 and Vδ2 γδ T-cell subsets and calculated the ratios between 
these two subsets. We found that CMV primary infection patients had higher Vδ1/Vδ2 T-
cell ratios in peripheral blood than patients with other CMV serostatus. Higher Vδ1/Vδ2 
T-cell ratios have been associated with operational tolerance in previous studies (27-29). 
We therefore conclude that CMV primary infection may promote tolerance towards the 
allograft in LTx patients.
In Chapter	6 we investigated whether allogeneic T-cell responses after LTx are regu-
lated by co-inhibitory receptors. It is known that persistent viral infections can induce the 
expression of these receptors on T cells, thereby enabling suppression by co-inhibitory 
ligands expressed in infected tissues (30-36). We hypothesized that persistent presence 
of alloantigens after LTx might induce co-inhibitory receptor expression on T cells and 
thereby suppression of donor-specific T-cell responses. Although experimental animal 
studies have shown involvement of co-inhibitory receptor-ligand interactions in liver 
allograft tolerance, the role of these receptors in T-cell alloresponses after LTx in humans 
has not been established yet. We showed that, already six months after LTx, expression 
of the co-inhibitory receptors CD160 and CD244 on circulating CD8+ T cells of LTx patients 
was higher than before LTx, and the elevated expression was sustained late after LTx, 
with CD244 showing the most prominent increase. Interestingly, significant upregulation 
of CD244 on circulating CD8+ T cells was restricted to patients who experienced CMV 
infection after LTx. CMV infection was also associated with reduced ex vivo CD8+ T-cell 
proliferation and cytotoxic degranulation in response to allo-antigens late after LTx. 
Purified CD244+ CD8+ T cells of LTx patients showed lower proliferative responses than 
their CD244- counterparts to alloantigens as well as in response to polyclonal stimuli. In 
addition, the CD244+ CD8+ T-cell population contained the majority of CMV-MHC class I 
tetramer positive cells. In conclusion, CMV infection after LTx, rather than persistence of 
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alloantigen, is associated with the expansion of a dysfunctional CD8+CD244+ T-cell subset 
and development of systemic allogeneic CD8+ T-cell hyporesponsiveness. These results 
suggest that CMV infection restrains CD8+ T-cell alloresponses after LTx.
Discussion and future perspectives
As discussed in Chapter	1, T-cell responses to viruses, including CMV, have been pro-
posed as one of the main barriers to achieve transplant tolerance (37), as shown in 
experimental animal models (38-40). As reviewed by D’Orsogna et al (41), this is probably 
caused by virus-specific memory T cells that cross-react against allogeneic HLA, resulting 
in increased T-cell responses against allogeneic organ grafts. In contrast to this, in both 
Chapter	5 and Chapter	6 we showed that CMV infection after LTx was associated with 
ex vivo allogeneic hyporesponsiveness of circulating CD8+ T cells, which possibly favors 
tolerance towards the liver graft rather than rejection. Although there were some dif-
ferences between the two studies, which will be discussed below, each of these studies 
has its own strengths. Chapter	5 showed, besides the association between primary CMV 
infection and ex vivo allogeneic CD8+ T-cell hyporesponsiveness, a clinical confirmation 
of this association, namely a significantly reduced incidence of late acute rejection epi-
sodes in LTx patients with primary CMV infection. In addition, we found an association 
between primary CMV infection and an increased ratio of circulating Vδ1/Vδ2 T cells, a 
marker that was found to be associated with operational tolerance after LTx in previ-
ous studies. Chapter	6 provides a more mechanistic view on the association between 
CMV infection and T-cell hyporesponsiveness after LTx. This chapter adds to the study 
presented in Chapter 5 as it shows that CMV infection induces sustained expression of 
the co-inhibitory receptor CD244 on circulating CD8+ T cells of patients after LTx. These 
CD244+ T cells showed generalized hyporesponsiveness, both towards allo-antigens 
and a polyclonal stimulus, and this population contained the majority of CMV-specific 
CD8+ T cells in CMV-infected LTx patients. These data suggested that CD244-induction 
is one of the mechanisms by which CMV infection induces CD8+ T-cell hyporesponsive-
ness. However, we showed that blocking CD244 interaction with its ligand CD48 did not 
enhance responsiveness of CD244+ CD8+ T-cells to alloantigens. We therefore conclude 
that CD244 expression on CD8+ T cells in CMV-infected LTx patients is rather a surrogate 
marker for the expansion of differentiated T cells with limited proliferative potential, 
than a mechanism that leads to hyporesponsiveness or tolerance.
There are several differences between these two chapters. First, in Chapter	5 we deter-
mined circulating T-cell responses in patients early after LTx, while in Chapter	6 patients 
late after LTx were studied. It is therefore not allowed to compare the results of the two 
studies one-to-one.
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A second difference is that we used different assays to determine alloreactive CD8+ T-
cell responses: in Chapter	5 we determined expression of the activation marker CD137 
after 24 hours of allogeneic stimulation, while in Chapter	6 CD8+ T-cell proliferation and 
cytotoxic degranulation were measured after 5 days of allogeneic stimulation. Interest-
ingly, we found in Chapter	5 that early activation of alloreactive CD8+ T cells was reduced 
donor-specifically in CMV-infected patients, and Chapter	6 added to this that prolifera-
tion of alloreactive CD8+ T cells was donor-specifically reduced as well in CMV-infected 
patients. In addition, Chapter	6 showed impaired cytotoxic degranulation of alloreactive 
CD8+ T cells in these patients, which was however observed for the response to both 
donor and third party allo-antigens. Apparently, in CMV-infected patients late after LTx 
CD8+ T cells become generally exhausted and not only in response to donor alloantigens. 
The reason for this is unknown. It would be interesting to investigate this by perform-
ing a microarray experiment on CD244+ versus CD244- CD8+ T cells, since we showed 
that CD244+ CD8+ T cells are induced in CMV-infected patients, and are hyporesponsive 
in response to stimulation with both donor and third party allo-antigens. In addition, 
this experiment should be performed for patients early and late after LTx, to determine 
whether early after LTx these cells are donor-specifically hyporesponsive while they may 
become generally hyporesponsive late after LTx.
A third difference between the two studies is that in Chapter	5 the association between 
CMV infection and CD8+ T-cell hyporesponsiveness was only observed in CMV primary 
infection patients, but not CMV reactivation patients (therefore reactivation patients 
were taken as one category together with IgG+ CMV non-reactivation patients), while in 
Chapter	6 the association was found for both primary infected patients and reactivation 
patients (therefore primary infection and reactivation patients were combined into one 
category: CMV infection patients). An explanation for this difference may be related to 
the method of categorizing patients into four groups of CMV status: 1) CMV naïve (CMV 
IgG- recipient transplanted with a liver from a CMV IgG- donor, (R-/D-)); 2) CMV primary 
infections (CMV IgG- recipient who gets a first CMV infection after LTx due to transplan-
tation of a liver from a CMV IgG+ donor (R-/D+), and infection is determined either by 
positive PCR > 50 DNA copies/mL or CMV IgG seroconversion; 3) CMV non-reactivations 
(CMV IgG+ recipient who does not experience CMV reactivation after LTx); and 4) CMV 
reactivations (CMV IgG+ recipient who does experience CMV reactivation after LTx, 
either determined by positive PCR > 50 DNA copies/mL or positive CMV IgM). Distinction 
between patients in category 3 and 4 is however often difficult, because no protocolled 
CMV monitoring is performed in patients falling into these categories and reactivation 
could be easily missed when diagnostics are not performed, for example because clinical 
signs of CMV infection are missing or misinterpreted. This may lead to underestimation 
of the number of patients in category 4 (which are more hyporesponsive), together with 
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overestimation of the number of patients in category 3. As a consequence of this, the 
difference in CD8+ T-cell responsiveness between the two categories may be underesti-
mated, since there have probably patients been included in category 3 having CD8+ T-cell 
hyporesponsiveness that actually belong to category 4. It may therefore be a wise solu-
tion to combine patients in categories 3 and 4, which was done in Chapter	5. However, 
in Chapter	6 we observed large differences in CD8+ T-cell responses between the two 
categories, so even if the difference was underestimated the results will remain similar. 
However, to gain more insights into allogeneic T-cell responses in categories 3 and 4, a 
future study with patients in which CMV PCRs are performed by protocol in all patients 
will be needed.
Another interesting subject to investigate in future studies is the link between CMV 
infection and operational tolerance after LTx. Our findings, showing that CMV infection 
is associated with CD8+ T-cell hyporesponsiveness, induction of CD244 expression, 
fewer LAR, and higher Vδ1/Vδ2 T-cell ratios, lead to the hypothesis that CMV infection 
may result in operational tolerance in LTx patients. To investigate such association, a 
prospective trial in which immunosuppressive drugs are weaned off in LTx patients, 
combined with determination of CD8+ T-cell responses and CMV status, is required. If 
this association would be proven to exist, CMV status may easily be taken into account by 
physicians when selecting LTx patients for tapering or withdrawing immunosuppressive 
therapy, since it is easily measured without additional effects or costs. In addition, our 
current studies do not provide clues for a causal relationship between CMV infection 
and reduced systemic CD8+ T-cell alloresponsivity. In Chapter	6 we discussed that the 
T-cell hyporesponsiveness that we observed in CMV-infected patients may be related to 
several mechanisms, such as: limited T-cell receptor (TCR) repertoire of CMV-specific T 
cells; T-cell senescence and shorter telomere length of CMV-specific T cells, resulting in 
limited proliferative capacity; IFN-α production due to chronic inflammation caused by 
CMV, resulting in impaired memory T-cell responses; and finally production of viral IL-10 
by CMV. Future studies are needed to investigate which of these mechanisms cause the 
CD8+ T-cell hyporesponsiveness in CMV-infected patients after LTx. First, we suggest to 
perform immunophenotypic analysis of the TCR-Vbeta repertoire in LTx patients with 
different CMV serostatus, combined with determination of CD8+ T-cell alloresponses, to 
test the hypothesis that CMV-infected patients have a limited TCR repertoire, resulting 
in T-cell hyporesponsiveness. Second, telomere length of CD8+ T cells should be mea-
sured in LTx patients with and without CMV infection. Third, we suggest to determine 
IFN-α and IL-10 mRNA expression, preferentially in liver grafts from CMV-infected versus 
non-infected patients. A good source to study this may be liver biopsies from both CMV-
experienced and non-experienced LTx patients to compare both groups.
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III.	 Optimization	of	immunosuppression	after	liver	transplantation
Summary
After LTx, all patients are treated with immunosuppressive drugs to prevent rejection 
of the liver graft. In Chapter	7 of this thesis we described that from the 1980s calcineu-
rin inhibitors (CNIs), such as cyclosporine A (CsA) and tacrolimus (TAC), have been the 
most used immunosuppressive drugs after LTx. These drugs inhibit calcineurin, which 
via an intracellular signaling cascade leads to inhibition of a family of transcription 
factors, resulting in reduced transcriptional activation of early cytokine genes, such as 
IL-2, TNF-α, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor, and IFN-γ (42). 
Ultimately, proliferation of T cells and production of pro-inflammatory cytokines by T 
cells are reduced. Due to inhibition of T-cell reactivity, allograft rejection is prevented. 
However, due to the generalized inhibition of T-cell reactivity, which is also needed to 
combat pathogens, the use of CNIs involves a serious risk of infections. Other side effects 
of CNIs are nephrotoxicity, neurotoxicity, hypertension, de novo malignancy and new-
onset diabetes mellitus. Since studies from the 1990s onwards showed that TAC was 
associated with less nephrotoxicity and neurotoxicity than CsA, TAC has become the first 
choice maintenance immunosuppressant after LTx, often combined with prednisolone 
(43). However, as described in Chapter	7, because of the side effects that still may occur 
due to the use of TAC, several strategies have been developed to minimize the dosage of 
TAC. We described four strategies:
1. Switch to CNI-free immunosuppressive regimen when CNI-toxicity has evolved.
2. Start with mTOR inhibitor in combination with other immunosuppressive drugs directly 
post-LTx (CNI-free regimen)
3. Delayed introduction of reduced-dose tacrolimus under protection of mycophenolate 
mofetil (MMF) and dacluzimab
4. Switch to CNI-free regimen early after LTx
In Chapter	 8 we hypothesized that the immunosuppressive properties of liver graft-
derived MSCs (L-MSCs) are superior to those of bone marrow-derived MSCs (BM-MSCs). 
We investigated the immunosuppressive effects of MSCs from both sources on allogeneic 
T-cell responses. For this purpose, we isolated MSCs from liver graft perfusates. In this 
chapter we described that proliferation, cytotoxic degranulation and IFN-γ production 
of allo-reactive T cells were more potently suppressed by L-MSCs than by BM-MSCs. 
Suppression was mediated both by cell-cell contact and secreted factors. The latter 
was established by the finding that in cultures with conditioned media (culture medium 
derived from MSC cultures) (CM) from L-MSCs also suppressed T-cell responses, while 
CM from BM-MSCs were not suppressive. In addition, L-MSCs showed ex vivo a higher 
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expression of PD-L1 than BM-MSCs, which was associated with more potent inhibition of 
T-cell proliferation and cytotoxic degranulation in vitro. Blocking PD-L1 partly abrogated 
the inhibition of cytotoxic degranulation by L-MSCs. In addition, blocking IDO partly 
abrogated the inhibitory effects of L-MSCs, but not BM-MSCs, on T-cell proliferation. In 
conclusion, liver graft-derived MSCs suppress allogeneic T-cell responses stronger than 
BM-MSCs, which may be related to in situ priming and mobilization from the graft. These 
graft-derived MSCs may therefore be relevant in liver transplantation by suppressing 
recipient T-cell responses to the allogeneic liver graft.
Discussion and future perspectives
In Chapter	7 we stated that calcineurin inhibitors (CNIs) are the cornerstone of mainte-
nance immunosuppression after LTx, despite their adverse effects. To minimize these 
adverse effects, we propose to optimize the use of CNIs by developing new treatment 
strategies that minimize or even replace the use of CNIs after LTx. Whether the use of 
mammalian target of rapamycin (mTOR) inhibitors will reduce the incidence of malig-
nancy after liver transplantation needs to be studied in the future. Regarding kidney 
function after LTx, a recent 24-month prospective, randomized, multicenter, open-label 
study with de novo liver transplant patients was performed to compare kidney functions 
in patients treated with tacrolimus (TAC) versus the combination of everolimus (EVR) and 
reduced TAC (44, 45). In this study, patients were randomized at 30 days to everolimus 
(EVR) combined with reduced tacrolimus (TAC; n = 245), TAC Control (n = 243) or TAC 
Elimination (n = 231). The last group was prematurely terminated because of high rates 
of acute rejections. This study showed a significantly lower incidence of acute rejection 
episodes in the combination group than in the TAC control group, and, more importantly, 
a significantly better kidney function at 2 years after LTx in patients treated with com-
bination therapy than with TAC alone. Another study is ongoing in our center, in which 
standard dose TAC is compared with a combination of reduced dose sirolimus and re-
duced dose TAC to study the effects on kidney function, malignancy and adverse effects 
such as de novo diabetes mellitus and hypertension. Results of this study are awaited 
in the coming years. Because of the adverse effects of TAC, CNI minimization strategies 
need further exploration to improve long-term outcome after liver transplantation.
Besides studies to develop clinical CNI minimization strategies, basic research should 
focus on finding alternative treatment strategies in order to replace or minimize immu-
nosuppressive drugs that are used nowadays. For that purpose, as mentioned in Chapter 
1, cell-based treatment strategies are under investigation, of which MSC-therapy is of 
special interest because of the immunosuppressive capacities of these cells. In previ-
ous studies, it has been shown that MSCs may have the following immunosuppressive 
properties: 1) inhibition of T-cell proliferation (46-50); 2) induction of regulatory T cells 
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(Tregs) (51); 3) inhibition of T-cell stimulatory capacity of DCs (52); and 4) differentia-
tion of macrophages towards a regulatory phenotype and function (53). MSCs can be 
isolated from various tissues, such as bone marrow, adipose tissue, and many organs 
including liver (54-57). The cited studies showed that MSCs from all these locations 
have immunosuppressive properties, as these studies used MSCs isolated from various 
tissues and anatomical compartments of the human body. In a previous study from 
our research group, it was shown that L-MSCs are immunosuppressive as well (57). In 
Chapter	8 we compared for the first time the immunosuppressive effects of L-MSCs and 
BM-MSCs on allogeneic T-cell responses. Although MSCs from both sources suppressed 
T-cell responses strongly in vitro, we interestingly found that L-MSCs were significantly 
more suppressive than BM-MSCs. We also showed that PD-L1 and IDO were involved in 
suppression of T-cell responses by L-MSCs. We hypothesized that these differences are 
not only related to the intragraft immune priming of L-MSCs in the organ donor or due 
to mobilization of MSCs from the graft, but also to the inherent immunological tolero-
genicity of the liver. Although future studies are needed to provide more insight into 
the mechanisms that render L-MSCs superior to BM-MSCs in suppressing allo-reactive 
T-cell responses, we would like to speculate further on the possible clinical application of 
L-MSCs as alternative immunosuppressive treatment in LTx patients.
Most of the evidence regarding safety and efficacy of MSCs as a therapeutic agent in 
solid organ transplantation comes from the Expert Meetings of the Mesenchymal Stem 
Cells in Solid Organ Transplantation (MiSOT) Consortium (58). These meetings focus on 
translation of preclinical data into early clinical settings in which MSC-therapy is used 
after kidney transplantation. To our knowledge, no clinical studies have been performed 
on MSC-therapy in LTx patients yet. In patients with liver disease however, studies have 
shown that administration of MSCs reduced liver fibrosis and was beneficial in patients 
with acute liver failure as bridging therapy before LTx (59, 60).
When envisioning application of MSC-therapy after solid organ transplantation, the fol-
lowing steps need to be performed. First, MSCs need to be isolated from bone marrow, 
adipose tissue or organ tissue. Then they need to be expanded in vitro, as previously 
described (61). After expansion, the cells are intravenously (i.v.) infused into the patient. 
Although a study in mice by Eggenhofer et al demonstrated that MSCs are short-lived 
after i.v. infusion and that viable MSCs do not pass the lungs (62), to date, this strategy of 
MSC-administration in humans has been shown to be relatively safe and feasible in kid-
ney transplantation patients. Eggenhofer et al stated that long-term immunomodulatory 
and regenerative effects of infused MSC must therefore be mediated by other cell types. 
Tan et al showed that MSC-therapy prevented acute cellular rejection and reduced the 
need for induction and maintenance immunosuppression (63). In addition, a pilot study 
on safety and feasibility of MSC-therapy in two kidney transplant patients, performed 
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by Perico et al, showed that MSC-administration was safe, and both patients had long-
term stable graft function (64), and another study showed reduction of tubulitis and 
interstitial fibrosis/tubular atrophy in some patients (65). In addition, MSC-therapy after 
kidney transplantation may induce systemic alloimmune modulation: a donor-specific 
down-regulation of the allogeneic proliferation of PBMCs was reported after autologous 
BM-MSC-therapy (65) and higher ratios of circulating regulatory T cells (Tregs) to memory 
T cells were reported in another study (64).
Several issues regarding MSC-therapy need to be considered. First, the optimal timing 
of MSC-infusion in transplant patients is still a matter of debate. The most recent MiSOT 
position paper (58) advocates that the timing of MSC-administration depends on the 
therapeutic goal and on concomitant immunosuppressive drugs: to induce a tolerogenic 
state and prevent early acute rejections, MSC may be given around transplantation (64), 
while later administration after transplantation may be needed for treatment of ongoing 
(subclinical) chronic rejection. However, long-term effects of MSCs on chronic rejection 
are still awaited (58).
A second issue of discussion is the use of concomitant immunosuppressive drugs. In all 
safety trials regarding MSC-therapy in kidney transplant patients, patients used CNIs 
as maintenance immunosuppression. It was however shown in preclinical studies that 
mycophenolic acid may have a synergistic immunosuppressive effect together with 
MSCs (66), while CNIs have not (67). In future clinical studies, different combinations 
of immunosuppressive drugs together with MSCs need to be investigated. Another re-
maining question that needs to be addressed in future studies is whether MSCs may be 
used instead of induction immunosuppressive therapy with basiliximab, since previous 
studies showed conflicting results (63, 64).
Other important issues that have been investigated but still need attention in future 
studies are the potential oncogenicity of MSCs and the occurrence of opportunistic 
infections in patients undergoing MSC-therapy. Although there is currently no evidence 
that MSCs induce malignancies (68), other studies showed that MSCs during expansion 
before clinical application were at risk for genetic alterations (69, 70). Regarding the 
occurrence of infections, one study showed a higher risk of opportunistic infections in 
patients receiving MSC-therapy after kidney transplantation (65), while another study 
showed a protective effect of MSCs on the occurrence of infections (63).
The last issue regarding clinical applicability of MSC-therapy in solid organ transplanta-
tion we would like to discuss is the source of MSCs. Since Chapter	8 focused on com-
paring immunosuppressive capacities of MSCs from two different sources, this topic is 
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very much related to our study. As described above, MSCs can be isolated from various 
types of tissues (54-57) and they may be of autologous or allogeneic origin. As reviewed 
by Roemeling-Van Rhijn et al (71), for clinical application, MSCs from allogeneic origin 
have the advantage that they can be isolated from bone marrow aspirates of healthy 
individuals, culture expanded and cryopreserved, after which they are readily available 
for infusion at any moment, for example immediately during transplantation. However, 
autologous MSCs may be less immunogenic than allogeneic MSCs, with lower risk of 
induction of an immune response against MSCs. This is however still a subject for future 
study, since previous studies on the one hand showed that allogeneic MSCs do not 
provoke immune responses (46, 72), while on the other hand other studies showed that 
allogeneic MSCs may be recognized by the adaptive immune system (73-75), which may 
result in rapid clearance of MSCs (76). In the clinical trials performed so far, only autolo-
gous MSCs have been used. Using autologous MSCs from patients awaiting LTx is another 
option to consider. However, isolating MSCs from bone marrow aspirates of patients on 
the waiting list for LTx may be debilitating for those patients who are in bad condition. 
Although the immunogenicity of allogeneic MSC needs further study, a very recent pilot 
study showed that administration of donor-derived BM-MSC was safe and allowed re-
duction of conventional dose of tacrolimus in living-related kidney transplant recipients, 
at least during 12 months of follow-up (77). Since we showed in Chapter	8 that donor 
liver graft-derived MSCs suppressed allogeneic T-cell responses better than BM-MSCs 
(both of allogeneic origin), we think that perfusates from the donor liver may be a very 
good source of MSCs for immunosuppressive therapy after LTx. A disadvantage of this 
source is that MSCs are not available at time of transplantation, because they need to 
be expanded before infusion. However, it will be possible to administrate the cells a few 
weeks after LTx. In addition, it is questionable whether it is possible to expand L-MSCs 
to a sufficient number of cells in order to make them suitable for MSC-therapy. In the 
cited studies in which BM-MSCs showed to be immunosuppressive in kidney transplant 
patients 1-2*106 MSCs/kg were infused (63, 65), and according to the expansion data that 
we showed in Chapter	8 (Figure1B), this number of cells may be achievable for some, but 
not all, donor-livers. Future studies in LTx patients are needed to determine whether suf-
ficient immunosuppressive effects can be achieved by lower numbers of L-MSCs, since 
L-MSCs showed to be much more suppressive than BM-MSCs.
Overall conclusion
In this thesis we showed that genetic and viral factors importantly contribute to the 
risk of complications in liver transplant patients, although the impact of genetic factors 
showed to be more prominent before LTx than after LTx. In addition, we described clinical 
strategies to optimize the use of immunosuppressive drugs after LTx and showed basic 
findings that may lead to cell-based immunosuppressive treatment. In Table I the main 
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findings of this thesis are summarized, including strengths and limitations of our findings. 
In addition, based on the findings described in this thesis, a summary of suggestions 
for application of the findings in clinical practice (‘clinical practice points’), as well as 
suggestions for future study are provided in this table.
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Levertransplantatiepatiënten zijn vatbaar voor ernstige complicaties die hun overleving 
en kwalieit van leven sterk beïnvloeden. De doelen van dit proefschrift waren: risicofac-
toren identificeren voor het optreden van complicaties in patiënten met eindstadium 
leverziekte, zowel voor als na levertransplantatie (LTx) en strategieën ontwikkelen om 
het gebruik van afweeronderdrukkende medicijnen (immunosuppressiva) te optimali-
seren/verminderen. Dit laatste heeft als doel complicaties die gepaard gaan met het 
gebruik van deze medicijnen te voorkómen of verminderen. Belangrijke complicaties 
in LTx patiënten zijn acute afstoting van hun lever transplantaat en bijwerkingen van 
immunosuppressiva, zoals infecties. Ongeveer 80% van de LTx patiënten krijgt namelijk 
tenminste één infectie tijdens het eerste jaar na LTx en infectie is de meest voorkomende 
doodsoorzaak in patiënten vroeg na LTx. Daarnaast krijgt ongeveer 30% van de LTx pa-
tiënten één of meerdere keren te maken met afstoting van hun donor lever. Naast het 
gebruik van immunosuppressiva zijn er andere factoren die het optreden en de ernst van 
complicaties in LTx patiënten beïnvloeden en deze factoren zijn onder te verdelen in een 
aantal categorieën, waaronder genetische en virale factoren. Hoe deze factoren compli-
caties in LTx patiënten beïnvloeden en welke strategieën gebruikt kunnen worden om 
complicaties van immunosuppressiva te verminderen, is onderzocht in dit proefschrift. 
In dit hoofdstuk worden de belangrijkste resultaten samengevat en bediscussieerd. 
Verder zal hier worden besproken welke zaken er zouden moeten worden onderzocht in 
toekomstige studies.
I.	 Genetische	factoren	die	vatbaarheid	voor	infecties	en	afstoting	in	
levertransplantatiepatiënten beïnvloeden
Samenvatting
In Deel I (Hoodstukken	2-4) van dit proefschrift hebben we onderzocht of variaties in 
genen die coderen voor receptoren van het “innate immuunsysteem” (oftewel het aan-
geboren, niet-specifieke immuunsysteem) vatbaarheid voor infecties in patiënten voor 
en na LTx en voor afstoting na LTx kunnen beïnvloeden.
In Hoofdstuk	2 hebben we ingezoomd op variaties in genen die coderen voor een cyto-
kine (signaalstof) genaamd Tumor Necrosis Factor Alpha (TNF-α). In dit hoofdstuk heb-
ben we gevonden dat de aanwezigheid van een variant allel, namelijk het A-allel, in het 
gen dat codeert voor TNF-α in patiënten met eindstadium leverziekte op de wachtlijst 
voor LTx zeer sterk beschermt tegen het optreden van ernstige bactierële infecties en 
tegen overlijden ten gevolge van een ernstige infectie. Verder vonden we lagere hoe-
veelheden TNF-α in het bloed van patiënten met het A-allel dan in patiënten met twee 
G-allelen. Deze bevindingen zijn in lijn met wat eerder is aangetoond: meer TNF-α leidt 
tot uitputting van immuuncellen, waardoor de vatbaarheid voor infecties groter wordt. 
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Het bepalen van deze genetische variatie in het TNF-α gen in patiënten op de wachtlijst 
voor LTx is daarom van nut om het risico op infecties per individu in te schatten, wat kan 
helpen in de keuze voor het al dan niet preventief geven van antibiotica.
In Hoofdstuk	3 hebben we onderzocht of genetische variaties in genen die coderen 
voor mannose-bindend lectine (MBL), een eiwit van het innate immuunsysteem, van 
leverdonoren voorspellend zijn voor het optreden van infecties in patiënten na LTx. Op 
basis van deze genetische variaties zijn donorlevers in te delen in levers met voldoende 
of onvoldoende MBL. Drie eerdere onderzoeken hebben gevonden dat patiënten die 
getransplanteerd waren met een donorlever die genetisch onvoldoende MBL had meer 
bacteriële infecties na LTx doormaakten, maar een vierde onderzoek vond deze associ-
atie niet. De drie onderzoeken die de associatie wel vonden, gebruikten echter alledrie 
een verschillende methode om donorlevers in te delen in voldoende of onvoldoende 
MBL. In ons onderzoek hebben we daarom donorlevers ingedeeld op basis van deze 
drie methoden, maar met geen enkele van deze drie methoden vonden we een associ-
atie tussen genetische variatie in MBL van de donor en het optreden van infecties in LTx 
patiënten.
In Hoofdstuk	4 hebben we onderzocht of er een associatie is tussen genetische variaties 
in diverse receptoren van het innate immuunsysteem van zowel donor als ontvanger en 
het optreden van infecties en afstoting in patiënten na LTx. Onze resultaten lieten zien 
dat geen enkele van de 50 geteste variaties was geassocieerd met het optreden van 
infecties of afstoting, terwijl een aantal van deze variaties in eerdere onderzoeken wel 
een verhoogd risico op infecties gaf in niet-transplantatiepatiënten met andere aandoe-
ningen. Blijkbaar spelen na transplantatie andere dan genetische factoren een grotere 
rol in het risico op infecties en afstoting.
Discussie en handreikingen voor vervolgonderzoek
Aangezien ongeveer 80% van de LTx patiënten tenminste één episode van infectie 
doormaakt tijdens het eerste jaar na LTx en ongeveer 40% van de patiënten op de 
wachtlijst voor LTx één of meerdere infecties krijgt, is het belangrijk om risicofactoren 
voor infecties in deze patiënten te identificeren. In Deel I van dit proefschrift hebben we 
onderzocht of genetische variaties in het innate immuunsysteem risicofactoren kunnen 
zijn voor infecties in deze patiënten. Het innate immuunsysteem speelt namelijk een 
belangrijke rol bij de afweer tegen infecties en variaties in dit immuunsysteem zijn in 
andere patiëntengroepen geassocieerd met verschillen in risico’s op infecties.
Zoals hierboven beschreven, vonden we in patiënten op de wachtlijst vóór LTx een 
sterke associatie tussen een genetische variatie in het TNF-α gen en infecties (hoofdstuk 
2), terwijl we in de Hoofdstukken	3	en	4 geen associatie vonden tussen andere genetische 
variaties en infecties ná LTx. De vraag die dan rijst, is: waarom vonden we geen associatie 
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tussen diverse genetische variaties en infecties ná LTx terwijl andere onderzoeken die 
wel hebben gevonden en terwijl we ook een associatie vonden met infecties vóór LTx?
Ten eerste, in Hoofdstuk	3 hebben we laten zien dat andere studies die wel een as-
sociatie vonden tussen genetische variaties in donor MBL en de kans op infecties na 
LTx verschillende methoden hebben gebruikt om donorlevers in te delen in voldoende 
of onvoldoende MBL op basis van de genetische variaties. Het is echter arbitrair welke 
methode gebruikt dient te worden en mogelijk waren deze assocaties niet gevonden 
als de onderzoekers andere methoden hadden gebruikt. Echter, met geen van de drie 
methoden hebben wij de associatie gevonden. Dit zou kunnen liggen aan de kortere 
follow-up tijd die wij hebben gebruikt om infecties in deze patiënten in kaart te brengen, 
terwijl in de andere studies een langere follow-up tijd werd genomen. Dit geldt ook voor 
de variaties die we in Hoofdstuk	4	hebben onderzocht: in andere studies naar deze 
variaties werd vaak een follow-up van 1 jaar genomen, terwijl wij hebben gekeken in de 
eerste 3 maanden na LTx. Hiermee zouden we associaties hebben kunnen gemist.
Ten tweede, in Hoofdstuk	4 hebben we laten zien dat genetische variaties in diverse 
receptoren van het innate immuunsysteem niet geassocieerd waren met infecties na LTx, 
terwijl in andere studies een aantal van deze variaties significant geassocieerd bleken te 
zijn met infecties in ernstig zieke niet-levertransplantatiepatiënten. Een reden voor dit 
verschil zou kunnen zijn dat de associaties die eerdere studies vonden vaak gevonden 
werden in receptoren die een bepaalde groep bacteriën herkent, de zogenaamde gram-
positieve of juist gram-negatieve bacteriën. Hoewel wij in Hoofdstuk	4 infecties ook 
hebben opgesplitst in infecties met gram-positieve versus gram-negatieve bacteriën, 
vonden wij niet dezelfde associaties als de andere onderzoeken. Dit zou temaken kunnen 
hebben met het gebruik van selectieve darmdecontaminatie (SDD), een methode die in 
LTx patiënten vóór het jaar 2000 gebruikt werd om de bacteriën in het maagdarmkanaal 
te verminderen, zodat deze patiënten mogelijk minder kans op infecties hadden. Er is 
echter later aangetoond dat SDD-gebruik bij LTx patiënten het risico op infecties in het 
algemeen niet beïnvloedt, maar dat er in verhouding wel meer infecties met gram-posi-
tieve bacteriën dan gram-negatieve bacteriën optreden. Doordat wij de groep patiënten 
met en zonder SDD-gebruik als één groep hebben geanalyseerd, hebben we mogelijk 
associaties tussen genetische variaties en het optreden van infecties gemist.
Een ander verschil tussen LTx patiënten en andere ernstig zieke patiëntencategorieën 
is dat LTx patiënten immunosuppressieve medicijnen gebruiken om afstoting van de do-
norlever te voorkomen. Het is echter onbekend of deze medicijnen ook invloed hebben 
op expressie van de receptoren van het innate immuunsysteem die we hebben onder-
zocht in Hoofdstuk	4. Wanneer dit zo is, zou dit kunnen verklaren waarom genetische 
variaties in deze receptoren wel geassocieerd zijn met infecties in niet-LTx patiënten, 
terwijl ze minder belangrijk zijn in LTx patiënten.
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Verder, het is bekend dat infecties in verschillende tijdsperioden na LTx worden beïn-
vloed door verschillende klinische risicofactoren. Infecties in de eerste maand post-LTx 
worden sterk beïnvloed door chirurgische factoren en andere transplantatie-gerela-
teerde factoren, terwijl infecties tussen één en zes maanden na LTx meer gerelateerd 
zijn aan het gebruik van immunosuppressieve medicijnen en late infecties (meer dan 
zes maanden na LTx) kunnen worden beïnvloed door aanwezigheid van andere aandoe-
ningen, zoals hepatitis C, diabetes en vermindere functie van de donorlever. Door de 
kortere follow-up tijd in onze studie (zie boven) zou het zo kunnen zijn dat de invloed 
van chirurgische en andere transplantatie-gerelateerde factoren op infecties groter is 
in onze studie dan in de andere studies, waardoor een significante invloed van geneti-
sche factoren gemist is. Hoewel we een aantal belangrijke transplantatie-gerelateerde 
factoren wel hebben meegenomen in de analyses, hebben we helaas een aantal andere 
factoren die van invloed kunnen zijn niet meegenomen, zoals lang verblijf op de Intensive 
Care, hoeveelheid bloedtransfusie tijdens LTx en scores die de mate van leverziekte voor 
LTx vastleggen.
Om in vervolgonderzoek verder te onderzoeken of genetische variaties in receptoren 
van het innate immuunsysteem het risico op infecties na LTx beïnvloeden, zouden we 
allereerst aanbevelen om een langere follow-up tijd te nemen en infecties in de eerste 
maand na LTx apart te analyseren van infecties die tussen de eerste en de zesde maand 
na LTx vóórkomen. Ten tweede zouden de hierboven genoemde klinische factoren mee-
genomen moeten worden in de analyses, aangezien deze het risico op infecties ook sterk 
kunnen beïnvloeden. Ten derde, grotere patiëntencohorten zijn nodig om het mogelijk 
te maken ook in subgroepen van LTx patiënten naar de invloed van genetische variaties 
op het risico op infecties te kijken, zoals de hierboven beschreven subgroepen van LTx 
patiënten die wel of geen SDD hebben ondergaan.
Een ander interessant onderwerp voor vervolgonderzoek is om de genetische variatie 
in het TNF-α gen die in Hoofdstuk	2 in patiënten vóór LTx sterk geassocieerd was met 
infecties ook te analyseren in patiënten ná LTx. Hiervoor zouden dezelfde patiënten als 
in Hoofdstuk 2 gevolgd kunnen worden na hun LTx, waarbij in kaart gebracht wordt of de 
A-variatie in het TNF-α gen ook beschermend werkt tegen het optreden van infecties ná 
LTx. Omgekeerd zou het interessant zijn om te onderzoeken of de variaties die we in de 
Hoofdstukken	3	en	4 hebben onderzocht ná LTx, in dezelfde patiënten voordat ze hun 
LTx ondergingen geassocieerd zijn met het optreden van infecties.
Ten slotte zou het meerwaarde kunnen hebben om de verschillende genetische vari-
aties in het innate immuunsysteem te combineren met elkaar of met klinische factoren, 
om zo te onderzoeken of bepaalde combinaties een verhoogd of juist verlaagd risico 
geven op infecties. Dit zou voor de klinische praktijk een grotere voorspellende waarde 
voor het optreden van infecties kunnen hebben, waardoor patiënten kunnen worden 
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geïdentificeerd die meer of juist minder prophylactisch antibitiotica nodig hebben voor 
of na hun LTx.
II.	 Virale	factoren	die	anti-donor	T-cel	reactiviteit	beïnvloeden
Samenvatting
In Deel II (Hoofdstukken	5-6) hebben we onderzocht wat de invloed is van virale facto-
ren, voornamelijk van cytomegalovirus (CMV) infectie, op de T-cel respons na LTx.
In Hoofdstuk	5 hebben we gevonden dat CD8+ T-cellen van patiënten met een primaire 
CMV infectie na LTx een verminderde respons hadden tegen donor materiaal (donor-spe-
cifieke hyporesponsiviteit). Verder vonden we dat in een groot cohort van LTx patiënten, 
getransplanteerd in ons centrum, patiënten met een primaire CMV infectie beschermd 
waren tegen het optreden van late acute afstoting. Ook hebben we in een deel van de 
LTx patiënten de aantallen Vδ1 en Vδ2 γδ T-cellen gemeten en de ratio tussen deze twee 
celtypen berekend. We vonden dat LTx patiënten met primaire CMV infectie hogere Vδ1/
Vδ2 T-cel ratio’s hadden dan LTx patiënten met een andere CMV serostatus. In eerdere 
studies waren hogere Vδ1/Vδ2 T-cel ratio’s geassocieerd met operationele tolerantie. 
Wij concluderen daarom uit ons onderzoek dat primaire CMV infectie tolerantie voor de 
donorlever zou kunnen bevorderen.
In Hoofdstuk	6 hebben we onderzocht of allogene T-cel responsen na LTx worden ge-
reguleerd door aanwezigheid van co-inhibitoire receptoren. Het is namelijk bekend dat 
continue aanwezigheid van bijvoorbeeld virale infecties de expressie van co-inhibitoire 
receptoren op T-cellen kan verhogen en daardoor de T-cel respons tegen geïnfecteerd 
weefsel remt. Aangezien er na LTx ook continue aanwezigheid van lichaamsvreemd 
materiaal (allo-antigenen) is, was onze hypothese dat na LTx expressie van co-inhibitoire 
receptoren op T-cellen van LTx patiënten verhoogd is en dat daardoor T-cel respons 
tegen de donorlever geremd wordt. In dierexperimentele onderzoeken is aangetoond 
dat co-inhibitoire receptoren inderdaad tolerantie voor de donorlever kunnen bevor-
deren, maar of dit ook zo is in mensen is onbekend. In dit hoofdstuk hebben we laten 
zien dat, al zes maanden na LTx, de expressie van de co-inhibitoire receptoren CD160 en 
CD244 op circulerende CD8+ T-cellen van LTx patiënten hoger was dan vóór LTx. Ook in 
patiënten lang na LTx was deze verhoging zichtbaar, met vooral een grote stijging van 
CD244. Interessant genoeg vonden we de sterke CD244-verhoging vooral in patiënten 
die een CMV infectie na LTx hadden doorgemaakt. Daarnaast was CMV infectie geassoci-
eerd met verminderde deling en effector respons (cytotoxische degranulatie) van CD8+ 
T-cellen in reactie op stimulatie met allo-antigenen laat na LTx. Daarnaast deelden opge-
zuiverde CD244+CD8+ T-cellen van LTx patiënten minder goed dan CD244-CD8+ T-cellen 
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in reactie op stimulatie met allo-antigenen of een polyclonale stimulus. We zagen ook 
dat de CD244+CD8+ T-cel populatie de meerderheid van CMV-tetrameer positieve cellen 
bevatte. Concluderend hebben we gevonden dat CMV infectie na LTx is geassocieerd 
met toename van een dysfunctionerende T-cel subset, namelijk CD244+CD8+ T-cellen, en 
met allogene hyporesponsiviteit van CD8+ T-cellen. Deze resultaten suggereren dat CMV 
infectie CD8+ T-cel responsen na LTx inperken.
Discussie en handreikingen voor vervolgonderzoek
T-cel responsen tegen virussen, onder anderen tegen CMV, zijn in eerdere onderzoeken 
beschreven als één van de belangrijkste barrières voor tolerantie voor een donororgaan. 
Dit komt waarschijnlijk doordat T-cellen die tegen virussen zijn gericht kruisreageren 
tegen allogeen HLA van het donororgaan, leidend tot verhoogde T-cel reacties tegen 
het donororgaan en dus meer kans op afstoting. In tegenstelling tot deze bevindingen, 
hebben wij in de Hoofdstukken	5	en	6 laten zien dat CMV infectie na LTx juist geas-
socieerd was met lágere T-cel responsen, hetgeen eerder tot tolerantie dan tot afstoting 
zou leiden. In Hoofdstuk	5 toonden we dit aan doordat we in patiënten met primaire 
CMV infectie na LTx lagere T-cel responsen waarnamen, tezamen met de klinische be-
vestiging in een groot patiëntencohort dat LTx patiënten met een primaire CMV infectie 
minder acute afstoting hadden. Daarnaast vonden we in deze patiëntencategorie hogere 
ratio’s Vδ1/Vδ2 T-cellen, iets wat in eerdere studies geassocieerd was met tolerantie 
voor donorlevers. Hoofdstuk	 6 voegde hieraan een meer mechanistisch aspect toe, 
namelijk de bevinding dat CMV infectie een verhoogde expressie van de co-inhibitoire 
receptor CD244 induceert op CD8+ T-cellen van LTx patiënten. De cellen die CD244 tot 
expressie brengen bleken vervolgens minder sterk te reageren op stimulatie met zowel 
allo-antigenen als een polyclonale stimulus en daarnaast bleek deze celpopulatie de 
meerderheid van de CMV-specifieke T-cellen te bevatten in patiënten met CMV infectie 
na LTx. Tezamen laten deze data zien dat CD244-inductie één van de mechanismen kan 
zijn waardoor CMV infectie na LTx leidt tot lagere T-cel responsen tegen allo-antigen. 
Echter, wanneer we CD244 blokkeerden met een antistof waardoor het effect van CD244 
wordt tegengegaan, gingen de T-cellen niet sterker reageren. We concluderen daarom 
dat CD244 expressie op T cellen van CMV-geïnfecteerde LTx patiënten eerder een sur-
rogaatmarker voor expansie van gedifferentieerde cellen met verminderde functie is, 
dan het mechanisme zelf dat leidt tot tolerantie.
Hoewel de bevindingen van de Hoofdstukken	5	en	6 met elkaar in lijn zijn, is er ook 
een aantal verschillen tussen deze hoofdstukken. Ten eerste, in Hoofdstuk	5 hebben we 
T-cel responsen in patiënten vroeg na LTx bepaald, terwijl we in Hoofdstuk	6 patiënten 
laat na LTx hebben bestudeerd. Daarom kunnen de twee hoofdstukken niet één op één 
vergeleken worden.
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Een tweede verschil tussen de hoofdstukken is dat we twee verschillende assays hebben 
gebruikt om responsen van alloreactieve CD8+ T-cellen te meten: in Hoofdstuk	5	keken 
we naar de expressie van een vroege activatiemarker (na 24 uur stimulatie), terwijl we 
in Hoofdstuk	6 deling en effector functie van T-cellen maten (na 5 dagen stimulatie). 
Interessant genoeg vonden we hiermee dat de vroege activatie van alloreactieve CD8+ 
T-cellen donor-specifiek verlaagd was in CMV-geïnfecteerde patiënten (hoofdstuk 
5) en dat ook de deling van alloreactieve CD8+ T-cellen donor-specifiek verlaagd was 
(Hoofdstuk	6). Echter, de effector functie van alloreactieve CD8+ T-cellen was in CMV 
patiënten verlaagd tegen niet alleen donor allo-antigenen maar ook allo-antigenen van 
andere origine. Dit zou erop kunnen wijzen dat CD8+ T-cellen in CMV patiënten na LTx in 
het algemeen uitgeput raken en minder goed functioneren en niet alleen in reactie op 
allo-antigenen van de donor. Het is onbekend waardoor dit komt. Om dit te onderzoeken 
zou een microarray experiment gedaan kunnen worden op CD8+ T-cellen met en zonder 
CD244, om te onderzoeken of er verschillen in genexpressie zijn tussen deze twee cel-
populaties die zouden kunnen verklaren waarom de ene populatie sterker reageert dan 
de andere.
Een derde verschil tussen de twee hoofdstukken is dat in Hoofdstuk	5 de associatie 
tussen CMV infectie en lagere T-cel responsen alleen werd gevonden in LTx patiënten 
met een primaire CMV infectie, terwijl in Hoofdstuk	6 deze associatie werd gevonden in 
zowel patiënten met een primaire CMV infectie als een reactivatie van het virus na LTx. 
In Hoofdstuk	5 werden patiënten met en zonder reactivatie van het virus juist als één 
groep beschouwd. Dit heeft temaken met het feit dat in veel patiënten na LTx niet wordt 
gediagnosticeerd of er reactivatie is of niet, omdat dit vaak klinisch niet relevant lijkt te 
zijn. Om beter te onderzoeken of de beschreven associatie ook geldt voor de groep met 
CMV-reactivatie, zou in de toekomst een studie moeten worden gedaan waarbij in alle 
patiënten na LTx diagnostiek wordt verricht om te onderzoeken of er reactivatie van het 
virus is of niet. Alleen dan kan een volledig correct onderscheid gemaakt worden tussen 
patiënten met en zonder reactivatie van CMV.
Een ander interessant onderwerp voor vervolgonderzoek is de link tussen CMV infectie 
en operationele tolerantie na LTx. De hierboven beschreven bevindingen suggereren wel 
dat CMV infectie leidt tot tolerantie, maar om dit echt aan te tonen is een prospectieve 
trial met LTx patiënten nodig bij wie immunosuppressieve medicijnen worden afgebouwd 
en T-cel responsen worden gemeten op verschillende tijdstippen, tezamen met het 
bepalen van de CMV status. Wanneer inderdaad blijkt dat CMV infectie leidt tot meer 
tolerantie na LTx (geen afstoting van de donorlever terwijl de patiënt geen immunosup-
pressieve medicijnen gebruikt), dan zou CMV status door artsen als factor meegenomen 
kunnen worden om te bepalen of de immunosuppressieve medicijnen kunnen worden 
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afgebouwd of niet. Daarnaast is vervolgonderzoek in het laboratorium nodig om te 
onderzoeken wat de oorzaak is dat CMV infectie leidt tot lagere T-cel responsen.
III.	 Optimalisatie	van	immuunsuppressie	na	levertransplantatie
Samenvatting
Na LTx worden patiënten behandeld met immunosuppressiva om afstoting van het 
levertransplantaat te voorkomen. In Hoofdstuk	 7 van dit proefschrift hebben we 
beschreven dat sinds de jaren ’80 calcineurine remmers zoals cyclosporine A (CsA) en 
tacrolimus (TAC) de meest gebruikte immunosuppressiva zijn na LTx. Deze medicijnen 
remmen calcineurine, wat via een signaal in de cel leidt tot remming van allerlei trans-
criptiefactoren, resulterend in verminderde activatie van genen betrokken bij interleu-
kine (IL)-2, TNF-α, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor en IFN-γ. 
Uiteindelijk leidt dit tot verminderde deling van T-cellen en verminderde productie van 
pro-inflammatoire cytokinen. Door remming van de T-cel reactiviteit wordt afstoting van 
het transplantaat voorkomen. Echter, doordat de T-cel reactiviteit wordt geremd, die 
ook nodig is om ziekteverwekkers aan te vallen, leidt het gebruik van calcineurine rem-
mers tot een verhoogd risico op ernstige infecties. Andere bijwerkingen van calcineurine 
remmers zijn nierschade, zenuwschade, hoge bloeddruk, kanker en diabetes mellitus. 
Toen in de jaren ’90 aangetoond werd dat TAC geassocieerd was met minder nierschade 
en zenuwschade dan CsA werd TAC het eerste keus immunosuppressieve middel na LTx, 
vaak gecombineerd met prednisolon. Echter, nog steeds kunnen er allerlei bijwerkingen 
optreden van het gebruik van immunosuppressiva en daarom zijn er strategieën bedacht 
om de dosering van TAC te minimaliseren. Vier van deze strategieën zijn beschreven in 
Hoofdstuk 7:
1. Switch naar een immunosuppressief schema zonder calcineurine remmers als er 
schade door calcineurine remmers is opgetreden
2. Start direct na LTx al met een mTOR remmer in combinatie met andere immunosup-
pressiva (schema zonder calcineurine remmer)
3. Vertraagde introductie van tacrolimus in lagere dosering, gecombineerd met my-
cofenolaat mofetil en dacluzimab
4. Switch naar een immunosuppressief schema zonder calcineurine remmers vroeg na 
LTx
In Hoofdstuk	8 was onze hypothese dat de immunosuppressieve eigenschappen van 
mesenchymale stamcellen (MSCs) uit donorlevers (L-MSCs) sterker zijn dan die van 
mesenchymale stamcellen uit beenmerg (BM-MSCs). Van beide typen MSCs hebben we 
daarom onderzocht hoe sterk ze allogene T-cel responsen remmen om deze vervolgens 
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te vergelijken. Hiervoor isoleerden we allereerst MSCs uit perfusaten (spoelvloeistoffen) 
van donorlevers en kweekten deze op om ze in aantal te laten toenemen. Toen we beide 
typen MSCs aan reacties van allogene T-cellen toevoegden, zagen we dat L-MSCs de 
deling en effector functie (cytotoxische degranulatie en IFN-γ productie) van allogene 
T-cellen veel sterker remden dan BM-MSCs. Deze remming kwam tot stand door zowel 
cel-cel contact als door MSCs uitgescheiden factoren. Dit laatste concludeerden we op 
basis van de bevinding dat het kweekmedium waarin de L-MSCs gekweekt waren ook 
in staat was om T-cel repsonsen te remmen, terwijl kweekmedium van BM-MSCs geen 
remming veroorzaakte. Verder zagen we dat L-MSCs al na isolatie uit de donorlevers 
een hogere expressie van PD-L1 vertoonden dan BM-MSCs, wat geassocieerd was met 
sterkere remming van T-cel responsen. Wanneer we PD-L1 vervolgens blokkeerden, 
werd de remming van cytotoxische degranulatie die L-MSCs bewerkstelligden deels 
opgeheven. Verder zagen we dat blokkeren van de factor indolamine-2,3-dioxygenase 
(IDO) de remmende effecten van L-MSCs op T-cel deling ook deels kon opheffen, terwijl 
dit geen effect had op de condities met BM-MSCs. Concluderend, L-MSCs onderdrukken 
allogene T-cel responsen sterker dan BM-MSCs, wat gerelateerd kan zijn aan de condities 
in de donorlever tijdens de donatie. Deze L-MSCs zouden relevant kunnen zijn voor het 
onderdrukken van ontvanger T-cel responsen tegen het levertransplantaat.
Discussie en handreikingen voor vervolgonderzoek
In Hoofdstuk	7 hebben we beschreven dat calcineurine remmers nog steeds de hoek-
steen zijn van immunossuppressieve therapie na LTx, ondanks hun bijwerkingen. Om 
de bijwerkingen van deze groep medicijnen te minimaliseren, hebben we een aantal 
strategieën voorgesteld om het gebruik te reduceren of te vervangen door andere type 
medicijnen. Een mogelijke kandidaat is het gebruik van mTOR remmers, waarvan ge-
dacht wordt dat bijwerkingen als nierschade en kanker minder zijn dan met het gebruik 
van calcineurine remmers. In een groot onderzoek, waaraan ook ons centrum deelnam, 
is aangetoond dat in patiënten die een combinatie van een calcineurine remmer en 
een mTOR remmer (Everolimus genaamd) gebruikten, de nierfunctie beter was dan in 
patiënten die alleen een calcineurine remmer gebruikten. Een andere studie waarbij een 
vergelijkbaar middel wordt onderzocht is op dit moment nog gaande en de resultaten 
hiervan kunnen over een aantal jaar worden verwacht. Verder onderzoek is nog steeds 
nodig om het gebruik van calcineurine remmers en daarmee hun bijwerkingen zoveel 
mogelijk te beperken.
Naast klinische studies die erop gericht zijn om bijwerkingen van immunosuppressieve 
medicijnen te beperken, is er basaal onderzoek nodig om alternatieve behandelings-
strategieën te ontwikkelen die in de toekomst mogelijk immunosuppressieve medicijnen 
compleet kunnen vervangen. Voor dat doel wordt veel onderzoek gedaan naar behan-
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deling met cellen in plaats van medicijnen. Eén kandidaat hiervoor is behandeling met 
mesenchymale stamcellen (MSCs), een celtype dat een goede kandidaat zou zijn van-
wege zijn afweeronderdrukkende capaciteiten. MSCs komen voor in allerlei weefsels, 
waaronder beenmerg en lever. Ook uit donorlevers kunnen deze cellen worden geïso-
leerd. In Hoofdstuk	8 hebben we voor het eerst de afweeronderdrukkende capaciteiten 
vergeleken van MSCs die uit beenmerg komen versus die uit donorlevers komen. Hierbij 
toonden we aan dat MSCs uit donorlevers T-cel responsen veel sterker onderdrukken 
dan MSCs uit beenmerg. Aangezien T-cel responsen afstoting kunnen veroorzaken, zou 
deze bevinding kunnen betekenen dat MSCs uit levers afstoting tegen kunnen gaan en 
dat ze dit nog sterker kunnen dan MSCs uit beenmerg.
Om therapie met MSCs na transplantatie praktisch mogelijk te maken, moet er nog wel 
een aantal vervolgstappen gedaan worden. Allereerst moeten MSCs worden geïsoleerd 
uit weefsel, bijvoorbeeld beenmerg of lever. De cellen moeten daarna worden vermenig-
vuldigd in het laboratorium, waarna ze intraveneus kunnen worden toegediend aan de 
patiënt. Hoewel eerdere studies hebben laten zien dat na toediening de cellen maar kort 
leven en in de longen van de patiënt blijven hangen, hebben studies bij niertransplanta-
tiepatiënten laten zien dat deze methode veilig is en dat de cellen hun afweeronderdruk-
kende effect in korte tijd al hebben uitgevoerd. Waarschijnlijk doen ze dit door middel 
van een afweeronderdrukkend effect op andere celtypen die wel langer in leven blijven.
Een aantal zaken betreffende MSC-therapie na transplantatie behoeven vervolgonder-
zoek:
-  Optimale timing van MSC-infusie in de patiënt, bijvoorbeeld tijdens de transplantatie 
of enige weken erna
-  Wel of geen gebruik van andere immunosuppressieve medicijnen naast de MSCs
-  Oncogeniciteit van MSCs en het eventueel optreden van opportunistische infecties
-  Uit welk weefsel MSCs geïsoleerd dienen te worden
Dit laatste onderwerp is sterk gerelateerd is aan het onderzoek dat we in hoofdstuk 
8 hebben verricht, aangezien we in dit hoofdstuk de immunosuppressieve capaciteit 
van lever-MSCs versus beenmerg-MSCs hebben vergeleken. Enerzijds zou het gebruik 
van beenmerg-MSCs voordeel kunnen hebben ten opzichte van MSCs uit donorlevers, 
omdat beenmerg-MSCs geïsoleerd kunnen worden uit gezonde individuen (beenmerg 
donoren), waardoor een voorraad MSCs voor therapie opgeslagen kan worden die direct 
beschikbaar is op het benodigde moment (tijdens transplantatie). Gebruik van MSCs 
uit donorlevers brengt met zich mee dat deze eerst moeten worden vermenigvuldigd, 
waardoor ze pas enige tijd na LTx beschikbaar zijn voor toediening aan de patiënt. Een 
voordeel zou echter kunnen zijn dat kleinere aantallen cellen mogelijk al tot het gewenste 
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immunosuppressieve effect leiden, aangezien we in Hoofdstuk	8 hebben aangetoond 
dat lever-MSCs T-cel responsen veel sterker onderdrukten dan beenmerg-MSCs. Dit 
laatste zou echter nog verder onderzocht moeten worden.
Conclusie
In dit proefschrift hebben we beschreven dat genetische en virale factoren kunnen 
bijdragen aan het bepalen van het risico op complicaties zoals infecties en afstoting in 
LTx patiënten. De rol van genetische factoren in het ontstaan van infecties lijkt echter 
vóór LTx groter te zijn dan ná LTx. Daarnaast hebben we klinische strategieën beschre-
ven die het gebruik van immunosuppressieve medicijnen na LTx kunnen optimaliseren, 
waardoor bijwerkingen van deze medicijnen beperkt kunnen worden. Ook hebben we 
basale bevindingen gedaan die ertoe kunnen leiden dat in de toekomst het gebruik van 
de huidige immunosuppressieve medicijnen na LTx kunnen worden vervangen door the-
rapie met mesenchymale stamcellen, die afstotingsreacties sterk kunnen onderdrukken.
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hiervoor! Verder zal ik je creativiteit rondom het konijnenhok en andere acties niet snel 
vergeten…!
Rik, de normaalste Amerikaan die ik ken;) Geintje. Je bent een topper, gezellige ka-
mergenoot en dank voor je hulp bij mijn computer-troubles. Het eerste NVVI congres 
in Lunteren kwam je strak in pak, ik vind dat nog steeds terecht, maar helaas was je de 
enige. Succes bij het afmaken van je PhD! En als je teruggaat naar Amerika, wees dan het 
gezonde voorbeeld voor je landgenoten…;)
Estella, you started your PhD in the second part of mine. Thanks for being a nice group 
mate and roommate. I wish you all the best for the rest of your research period!
Wenshi, kind and quiet roommate, always willing to answer the phone when it was 
ringing a hundred times ;) Thanks for being a kind colleague!
hester, je werd onze kamergenoot toen ik in de afrondende fase zat. Hoewel je ook 
veel bij de derma te vinden was, wil ik je hierbij danken voor je gezelschap. Ik wens je veel 
succes toe bij je onderzoek!
Ook de andere labcollega’s wil ik hierbij hartelijk danken.
Leonie, zonder jou kunnen we het lab wel sluiten. Jouw daadkrachtig optreden is met 
niets te vergelijken en gaat ook nog eens gepaard met betrokkenheid op ieders werk 
en persoonlijk leven. Ik waardeer je hierom enorm en wil je hierbij bedanken voor de 
kletsmomentjes en al je oma-verhalen. Veel gelukgewenst met je leuke en lieve klein-
kinderen!
Monique, toonbeeld van toewijding, dank voor je hulp bij de MSC paper. En jouw 
labjournaal: respect, die kan in een museum!
Petra, getalenteerde analist. Bedankt voor je samenwerking in het LTx team, je inte-
resse en vragen tijdens de meetings, samenwerking aan de MSC paper en natuurlijk je 
gezelligheid tijdens werk en pauzes. Succes met je verdere werk en mocht je het zat zijn 
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in de wetenschap, laat het ff weten, dan praten we verder over die bloemenwinkel van 
ons…;)
Marieke (van der Heide), bedankt voor de gezellige uurtjes achter de sorter en voor 
je geduld als ik weer eens op mijn stepje met een bak ijs heen en weer moest crossen 
als ik een buisje vergeten was. En ook enorm bedankt voor je expertise die me door die 
ingewikkelde sortproeven heen heeft geholpen!
Raymond, dank voor je hulp bij heel veel ondersteunende zaken, computers, adminis-
tratie, declaraties, etcetera. We vergeten wel eens hoe onmisbaar dat is. Bedankt voor 
al je inzet.
Anthonie, het lab is nooit saai als jij er rondloopt. Bedankt voor je humor en je zang-
stem. En natuurlijk voor al je hulp om wegwijs te raken op het lab en je hulp als de facs 
weer eens vastliep. Facskleuring in een plaat doen heb ik van jou en dat werkt inderdaad 
verrekte snel! En nogmaals sorry voor die kromme naald van de Canto. Bewijst maar 
weer dat dokters niet op het lab horen hè;)
Kim, veel leuke en goede gesprekken hebben we gevoerd de afgelopen jaren, ik ga je 
missen! Super leuk dat we betrokken konden zijn bij elkaars zwangerschap en kraamtijd, 
dank voor je vriendschap.
Evelyn, bedankt voor al je gezelligheid op het lab en tijdens congressen en voor het 
succesvol organiseren van het (bijna gratis) labuitje. En ik bewaar erg leuke herinnerin-
gen aan het maken van het Angela-filmpje met jou!
Paula, het baken van de celkweek, de relaxedheid zelve. Ik heb genoten van het uitwis-
selen van reisfoto’s en verhalen. Veel reisplezier gewenst in de toekomst en hopelijk kan 
het kweeklab op jou blijven leunen!
Aniek, bedankt voor je gezelligheid en je praktische hulp op het lab als ik iets zocht 
(vaak). Top dat je weer terugkwam op het lab!
Wouter, afscheidsborrel-genoot. Dank voor de goede gesprekken en je gezelschap op 
het lab.
Martijn, altijd relaxed en toch hardwerkend, dank voor je bijdrage aan het groepsge-
voel en voor je gezelschap op het lab.
Vincent, organisator van de MDL-dag, in een pinguinpak of was het een ander dier? 
Dank voor je gezelschap en je inzet voor het lab.
Kostas, groepsgenoot met de klinische ervaring en kennis en pfff, die statistiek cursus 
die we samen volgden was een zware dobber. Dank voor de samenwerking in de afgelo-
pen jaren.
Gertine, dank voor al je praktische adviezen op het lab en je gezelschap tijdens de vele 
uurtjes dat ik zat te Modfitten op jullie kamer.
Greta, wat moesten we zonder jou? Als je er niet was, stapelden de lege doosjes zich 
op en werd weer duidelijk hoe nodig je bent. Bedankt voor al je ondersteunende werk!
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Frances, no-nonsense, altijd hardwerkend maar toch altijd bereid tot een praatje en 
interesse in anderen. Bedankt voor je collegialiteit in de afgelopen jaren.
Auke, leuk dat je naar Rotterdam bent gekomen, een aanwinst voor het lab. Bedankt 
voor je gezelschap tijdens werk en pauzes.
Gwenny, bedankt voor je goede vragen en analytische opmerkingen tijdens seminars 
en in de wandelgangen en daarnaast bedankt voor al je gezelligheid!
Nadine, je bent altijd erg lief en geïnteresseerd in anderen, dank voor je betrokkenheid 
en praktische hulp bij diverse dingen op het lab.
henk, LTx-teamgenoot, dank voor je bijdrage aan de werkbesprekingen, het rector-
spelen, en je bereidheid om te helpen bij het opwerken van LTx-materialen.
Alle andere collega’s van het lab die ik hier niet persoonlijk noem, heel hartelijk dank 
voor het bijdragen aan een prettige werkomgeving en fijne groep collega’s!
To all the Chinese colleagues: thank you especially for organizing the Chinese New Year 
party, it was great!
Het was een komen en gaan van collega’s en ook aan mensen die al weg zijn, wil ik hierbij 
een woord van dank richten.
Özlem, van jou mocht ik de belangrijke assays leren en het project van de indirecte 
assay overnemen, jouw kindje. Bedankt dat je me hebt ingewerkt, terwijl je zelf op dat 
moment gigantisch druk was en bijna naar Ethiopië ging.
Sean, thanks for working together on the MSC-project! I am very happy that we could 
continue this cooperation, and that this resulted in a very nice publication. Thanks for all 
the work.
Alexander, very relaxed and kind colleague. Thank you for sharing your experience in 
the group.
Viviana, we worked together during my graduation research and your kindness helped 
me significantly to find my way in the lab. Thanks!
Veda, thank you for the moments of reflection on research and on combining research 
with mothership. Thanks for being such as kind colleague!
Suomi, baken van enthousiasme en ambitie. Jouw werkhouding strekt velen tot voor-
beeld. Dank voor de gezelligheid op het lab.
Jasper, jammer dat je weg bent, je hoort echt op ons lab. Bedankt voor je gezelligheid 
en nuchterheid!
Arjan, van jou herinner ik me in de eerste plaats je broodbeleg en taartrecepten. 
Daarnaast ook bedankt voor de leuke momenten op het lab en voor het creëren van het 
‘groepsgevoel’.
Susanne, warm persoon. Na een praatje met jou kon ik altijd weer met hernieuwde 
frisse moed door. Top dat je MDL-arts wordt, ik weet zeker: een hele goede!
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Werner, de sportman met altijd mooie sportverhalen en (voedings)tips. Hoewel we 
vrijwel niet samen hebben gewerkt, vind ik het erg jammer dat je weg ging. Mocht ik ooit 
de hele marathon gaan doen, dan bel ik je ff voor advies OK?
Dowty, I still remember the delicious duck from the restaurant in Ubud that you ad-
vised me to go to! Good luck in the future.
Pratika, thanks for assisting me with some antibodies and thanks for your kindness.
Sarwa, kamergenoot in het Hs gebouw en hardwerkend intelligent voorbeeld. Mooi om 
jou te hebben leren kennen en jouw toewijding te zien. Heel veel succes in je verdere 
carrière en ook veel geluk voor je toekomst samen met Kostas, Erin en Alexander.
Marieke (Roemeling-van Rhijn), we leerden elkaar kennen tijdens de immunologie 
cursus, maar het voelde alsof we elkaar al jaren kenden. We bleken veel gemeenschap-
pelijk te hebben, niet alleen het hebben van Herold als baas. Dank voor je steun en fijne 
gesprekken! Heel veel succes als MDL-arts in spé en voor je privé-leven samen met Stijn 
en de boys.
Lisette Elzinga-Tinke, van eerstejaars geneeskunde studenten in de collegebanken 
(we hebben zelfs nog Sinterklaas gevierd) naar nu, een lange tijd van vriendschap en 
ervaringen delen. Dank voor wie je bent en voor alle fijne gesprekken. Heel veel succes 
met het afronden van je PhD en in de toekomst, om een goede dokter te zijn.
Op de polikliniek mocht ik samenwerken met en leren van de hepatologen.
Dr.	De	Man, bedankt voor de samenwerking op de polikliniek, rondom patiëntenzorg 
en LOL III patiënten.
Dr.	De	knegt, beste Rob, zowel in het opzetten van BIOTOL als rondom patiënten voor 
de LOL III en biopten hebben we samengewerkt. Bedankt voor de samenwerking, de 
gezellige momenten en je humor. Succes met het vervolg van BTIOTOL!
Dr.	Taimr, beste Pavel, man van de vriendelijke blik en weinig woorden. Bedankt voor 
je samenwerking op de poli en voor het initiëren van de samenwerking met de collega’s 
in Praag. Ik hoop dat deze vruchtbare samenwerking mooi vervolg mag krijgen!
Prof.	Janssen, Bedankt voor het kritisch reviewen van de SNP paper en uw interesse 
voor mijn onderzoek.
Dr.	Tjwa, beste Eric, inmiddels niet meer in het Erasmus MC, maar jouw supervisie 
tijdens mijn oudste co-schap blijft me bij als een inspirerende en leerzame tijd. Bedankt 
ook voor je interesse in mijn onderzoek.
Dr.	Schouten, beste Jeoffrey, dank voor je samenwerking op de poli.
Dr.	Vanwolleghem, Thomas, mooi hoe je patiëntenwerk en labwerk combineert! Veel 
succes verder gewenst hierbij.
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Dr.	Sprengers, beste Dave, dank voor je betrokkenheid bij onderzoek en de samen-
werking hier en daar, op de poli en tijdens labmeetings. Ik wens je veel succes om in de 
toekomst research en patiëntenzorg zo goed te blijven combineren.
Verder mag niet ongenoemd blijven onze hepatologie statistica, Bettina, al tijdens mijn 
afstudeeronderzoek leerde ik je kennen. Dank dat je me wegwijs hebt gemaakt in de 
wondere wereld van de multivariate analyses!
Mijn dank gaat verder uit naar stafleden van het lab.
Andrea, bewonderenswaardig hoe je onderzoek en onderwijs combineert. Dank voor 
je analytische vragen tijdens seminars en dank voor je gezelschap.
André, toegewijd en altijd relaxed, hiermee een voorbeeld voor velen. Dank voor het 
meedenken, met name op het “exhaustion” project.
Ron, als één van de weinige stafleden was je veel op het lab te vinden, met je wakend 
oog voor veiligheid en mycoplasma-vrij werken. Dank voor je inzet hiervoor en dank voor 
je interesse en betrokkenheid bij mijn onderzoek.
hanneke, dank voor je gezelschap tijdens pauzes, je betrokkenheid en adviezen op 
gebied van zowel onderzoek als moederschap.
hugo, het is benijdenswaardig hoeveel kennis je uit je middelbare schooltijd nog pa-
raat hebt. Dank voor het delen van deze kennis, o.a. tijdens seminars, en het overdragen 
hiervan aan de jongere generatie.
Collega’s van het interne lab, Karin, Anne, Ruud, Martin, bedankt voor de gezelligheid 
tijdens de ATC in Seattle en Bootcongressen. En alle andere collega’s die bij de journal 
club aanwezig waren, bedankt voor de leerzame uurtjes!
Nicolle Litjens en Michiel Betjes, jullie beide bedankt voor de inspirerende discussies 
en het inhoudelijk meedenken op mijn labproject!
Met veel plezier kijk ik terug op de uren die ik doorbracht op het LTx secretariaat. Wat zal 
ik jullie missen, dames!
Lara, met zo’n capabele en toegewijde verpleegkundig specialist als jij mag het team 
in haar handjes knijpen. Ik dank je voor de gezelligheid en de prettige samenwerking in 
patiëntenzorg en research.
Miranda, jij had aan een half woord genoeg en je regelde het allemaal wel weer. Top-
per! Dank voor je hulp bij duizend en één dingen en dank ook voor je betrokkenheid bij 
mijn persoonlijk leven.
Elly, de liefde voor Zeeland en de fruitteelt hadden we alvast gemeenschappelijk. Dank 
voor de kersen en voor al je hulp bij het verzamelen van bloed en formuliertjes, ook al 
vroeg ik soms het onmogelijke…Ik heb het enorm gewaardeerd!
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Fatma, vooral in de eerste jaren werkten we samen, dank voor je gezelligheid en je 
altijd lieve woorden.
Sylvia, je was altijd oprecht geïnteresseerd en ik kon steeds weer bij je terecht voor 
database vragen, waarna er weer een mooie lijst in mijn mail belandde. Dank voor je vele 
hulp en je warme betrokkenheid.
Catelijne, hardwerkend en nuchter en in de samenwerking had je altijd aan een half 
woord genoeg. Dank voor de fijne samenwerking en voor je hulp bij de LOL III.
De secretaresses, Marjolein, Mirjam en Sandra, dank alledrie voor jullie ondersteu-
ning, oplettendheid en samenbindend werken.
Marion, heel erg bedankt voor jouw hulp in met name de afrondende fase van mijn 
promotie. Het is ongelooflijk prettig hoe snel en goed jij dingen regelt en hoeveel dingen 
je me uit handen hebt genomen. Dank hiervoor!
Alle collega’s van de dakpoli, bedankt voor het vormen van een leuke groep MDL arts-
onderzoekers en voor de leerzame PhD-dagen.
Vele ondersteunde collega’s hebben bijgedragen aan het succesvol doen van patiënten-
onderzoek:
Mensen van de poli MDL, jullie wil ik hierbij ook hartelijk danken voor de afgelopen 
jaren, jullie praktische ondersteuning maakte het mogelijk én prettig om patiëntenon-
derzoek te kunnen doen.
Personeel van de dagbehandeling op 3 noord, jullie heel erg bedankt voor het afne-
men van bloed voor onderzoek en de prettige samenwerking hierbij.
Edith en collega’s van het CRB, bedankt voor de prettige samenwerking bij het opzet-
ten en uitvoeren van de LOL III studie. Edith, dank dat je altijd bereid was me wegwijs te 
maken in de administratie van de studie en dat je veel taken hiervan op je nam.
Thijmen, wat had ik zonder jou gemoeten? Betrouwbare en capabele student, je kwam 
als geroepen in een tijd waarin ik busy busy was. Zowel je hulp bij de ‘administratie’ van 
de LOL III als het scoren van infecties voor “Praag” waren onontbeerlijk voor mij. Dank 
hiervoor! Fijn om te weten dat jij mijn opvolger bent op de LOL. Succes in de toekomst 
om een goede dokter te zijn.
Hierbij wil ik danken de collega’s “uit het land” met wie ik samen mocht werken op de 
LOL III studie of andere studies:
Lida Beneken Kolmer en Prof.	Bart	van	Hoek en de rest van het LTx team uit Leiden, 
dank voor de samenwerking op de LOL III studie. De Groningse collega’s Jan Bottema, 
Aad van den Berg en Koert de Jong voor het mede-opzetten van de studie. Jammer 
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dat dit minder liep dan gehoopt, ik hoop dat dit in de toekomst een mooier vervolg zal 
krijgen.
Liesbeth de Boer, dank voor je betrokkenheid bij het onderzoek en voor het mede 
mogelijk maken van de studie.
Marcel hofstra, je hebt me soms aardig tot wanhoop gedreven met die queries, maar 
persoonlijk mocht ik je graag;) Dank voor je gezelligheid en voor het oplossen van voor 
mij veelal onmogelijke database handelingen.
Cynthia Konijn, dank voor je hulp bij het opzetten van de LOL-III database en voor de 
prettige samenwerking.
Renate de Boer, dank voor je snelle en accurate labwerk in het project met de CMV-
specifieke T-cellen!
Dave Roelen, dank voor je hulp bij het project dat we gezamenlijk met Praag deden, 
waarmee je het mogelijk maakte een mooi validatiecohort te vormen!
I would like to thank all the colleagues from Prague for the wonderful cooperation, which 
resulted in a nice publication. Renata, thank you for all the work you did and for your 
enormous commitment. Dr.	Sperl, thank you for the initiation of the project and for 
giving me the opportunity to work together with your team.
Mijn familie, zowel die met de bloedband als de schone, wil ik danken voor de interesse 
in mijn werk en de steun die van jullie uit ging, maar vooral voor het zijn van een warm 
en liefdevol nest. De familieband die we hebben, koester ik en stijgt ver uit boven de 
blijdschap die het afronden van deze promotie met zich mee brengt! In het bijzonder 
dank ik jullie, paps en memmy, voor het in veel opzichten mogelijk maken van mijn studie 
en het betrokken zijn bij dit vervolg daarop!
Dan ten slotte mijn thuis, mijn lieve Rutger, het geluk dat jij me geeft maakt het bijna 
ongepast je in dit dankwoord te bedanken. Soms leek je nog beter te snappen wat ik 
deed dan ik zelf;) Je was mijn eerste hulp bij statistiek, maar vooral mijn eerste hulp bij 
(het voorkómen van) frustratie en stress. Dank je wel voor het smeren van mijn brood 
en voor het koken. En vooral dank dat thuiskomen bij jou elke dag een feest is. Lieve 
Felix, je had het voorrecht negen maanden op stage mee te mogen op het lab en dat 
deed je fantastisch. Tijdens presentaties op congressen gaf je me op het juiste moment 
nog even een extra ondersteunende por: “zet ‘em op mamma”! En ook na je geboorte 
heb je me behalve wat energievretende nachten vooral zoveel geluk gegeven dat je mijn 
energieboost was om dit boekje te schrijven.
Lieve Victor, ook jij mocht negen maanden meedoen, vooral tijdens de afronding van 
dit boekje. Het uitzien naar jouw komst gaf me vleugels om dit af te maken voordat jij 
geboren werd. Nu kan ik volop van je genieten.
Chapter 11
244
Rutger, Felix en Victor, het is lekker af! Wat is het heerlijk om in de nieuwe fase die 
aanbreekt, jullie altijd bij me te hebben!
Emmeloes
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is associated with CD8+ T-cell hyporesponsiveness to allo-antigen. Accepted for 
publication in The Journal of Immunology
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PhD PORTFOLIO
Name PhD student Emmy Louise Dorothea (Emmeloes) de Mare-Bredemeijer
Erasmus MC Department Gastroenterology and Hepatology
PhD period January 2011 – December 2014
Promotor Prof. dr. H.J. Metselaar
Co-promotor Dr. J. Kwekkeboom
General courses
Februari 2014 Biomedical English writing and Communication
Maart 2013 Biostatistical Methods I: Basic Principles (CC02a), NIHES, Rotterdam
Maart 2012 The advanced Course “Molecular Immunology”, Rotterdam
Oktober 2010  Good Clinical Practice / Basiscursus regelgeving en organisatie voor 
klinisch onderzoekers, Rotterdam
September 2010  Short Introductory Course on Statistics & Survival Analysis for MD’s, 
Rotterdam
National conferences – Presentations
2014  NVVI 50th Anniversary Congress 2014, Efteling, Kaatsheuvel, The 
Netherlands (poster presentation)
2013 Bootcongres, NTV, Duiven, The Netherlands (oral presentation)
2013  Voorjaarscongres 2013 NVGE, Veldhoven, The Netherlands (poster 
presentation)
International conferences – Presentations
2014  World Transplant Congress 2014, San Francisco, USA (poster presenta-
tion)
2013 American Transplantation Congress, Seattle, USA (oral presentation)
2013  International Liver Congress 2013, EASL, Amsterdam, The Netherlands 
(oral presentation)
2013  ILTS 2013, 19th Annual International Congress, Sydney, Australia 
(poster presentation)
2012  ILTS 2012, 18th Annual International Congress, San Francisco, USA 
(poster presentation)
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National conferences – Participation
2012  APC’s revisited, the function of antigen presenting cells in health and 
disease, NVVI, Lunteren, The Netherlands
2012 Bootcongres, NTV, Maastricht, The Netherlands
2011 Bootcongres, NTV, Amsterdam, The Netherlands
2011  Time for high T: Features and functions of T-cells in health and disease, 
NVVI, Lunteren, The Netherlands
International conferences – Participation
2011 The 2nd International Conference on Transplantomics and Biomakers
 in Organ Transplantation, Barcelona, Spain
Scientific	Awards	and	Grants
2013  Registration Bursary EASL International Liver Congress 2013 and free 
membership EASL
2013 Travel grant Astellas Pharma B.V.
2013 Travel grant Dutch Society of Hepatology (NVH)
2013 Travel Grant Trustfonds Erasmus MC (for ATC 2013, Seattle)
Teaching activities
2012 Lecture Minor Transplantatiegeneeskunde 2012
2011-2012 Supervising students Master of Science Infection and Immunity
Other activities
2011-2014  Local study coordinator and co-investigator of “A multi-center ran-
domized, open label, controlled study in primary liver transplantation 
comparing long term renal function in recipients treated with standard 
dose extended-release tacrolimus alone and recipients treated with a 
combination of low dose extended-release tacrolimus and low dose 
sirolimus”
2011-2013  Co-investigator of “Extension study to the multicenter, open-label, 
randomized, controlled study CRAD001H2304 to evaluate the long-
term efficacy and safety of concentration controlled everolimus in 
liver transplant recipients”
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ABOuT ThE AuThOR
Emmeloes de Mare-Bredemeijer was born as Emmy Louise Dorothea 
Bredemeijer on April 7th 1986 in Harderwijk, The Netherlands. She 
was raised by her beloved parents Ferdi Bredemeijer and Emmy 
Cnossen, and grew up together with her 4 sisters and 3 brothers. 
In 2004 she completed secondary school and started her medical 
school at the Erasmus University Rotterdam, The Netherlands. In 
2008, she performed her graduation research in the Laboratory of 
Gastroenterology and Hepatology, under supervision of Dr. Jaap 
Kwekkeboom and Prof. Dr. Herold Metselaar. Her research was entitled “Genetic poly-
morphisms in innate immune receptors as a risk factor for rejection and infection after 
liver transplantation”. After two years of clinical internships, she obtained her medical 
degree in 2010, and started her PhD project. During this project, she combined clinical 
research on immunosuppression in liver transplantation patients with basic research in 
the laboratory at the Department of Gastroenterology and Hepatology of the Erasmus 
University Medical Center Rotterdam, again under supervision of Dr. Jaap Kwekkeboom 
and Prof. Dr. Herold Metselaar. In 2013, Emmeloes and her husband Rutger de Mare 
received a son: Felix. In May 2015 their second son was born: Victor. After finishing her 
PhD, Emmeloes is going to work as fertility doctor at Sint Franciscus Gasthuis Rotterdam.
